NZ792477A - Aav capsid designs - Google Patents
Aav capsid designsInfo
- Publication number
- NZ792477A NZ792477A NZ792477A NZ79247717A NZ792477A NZ 792477 A NZ792477 A NZ 792477A NZ 792477 A NZ792477 A NZ 792477A NZ 79247717 A NZ79247717 A NZ 79247717A NZ 792477 A NZ792477 A NZ 792477A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hsa
- mir
- aav
- promoter
- raav
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title claims description 62
- 238000013461 design Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 168
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 137
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 120
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 120
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 91
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 90
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 59
- 108700019146 Transgenes Proteins 0.000 claims description 123
- 239000002679 microRNA Substances 0.000 claims description 83
- 108091070501 miRNA Proteins 0.000 claims description 81
- 150000001413 amino acids Chemical group 0.000 claims description 71
- 239000013598 vector Substances 0.000 claims description 61
- 235000018102 proteins Nutrition 0.000 claims description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 38
- 210000003169 central nervous system Anatomy 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 210000004185 liver Anatomy 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 230000000392 somatic effect Effects 0.000 claims description 26
- 239000013607 AAV vector Substances 0.000 claims description 20
- 230000002452 interceptive effect Effects 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 15
- 238000009739 binding Methods 0.000 claims description 15
- 238000011820 transgenic animal model Methods 0.000 claims description 15
- 210000000481 breast Anatomy 0.000 claims description 13
- 210000000496 pancreas Anatomy 0.000 claims description 13
- 230000001939 inductive effect Effects 0.000 claims description 12
- 230000000241 respiratory effect Effects 0.000 claims description 12
- 210000001635 urinary tract Anatomy 0.000 claims description 11
- 108091026890 Coding region Proteins 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 10
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 8
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 8
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 claims description 7
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims description 7
- 102100028709 Thyroxine-binding globulin Human genes 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- GWNUTBHQOQVVDA-UHFFFAOYSA-N CClO Chemical compound CClO GWNUTBHQOQVVDA-UHFFFAOYSA-N 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 108010063045 Lactoferrin Proteins 0.000 claims description 4
- 102100034263 Mucin-2 Human genes 0.000 claims description 4
- 108010008705 Mucin-2 Proteins 0.000 claims description 4
- 102100039507 Retinoschisin Human genes 0.000 claims description 4
- 101710111169 Retinoschisin Proteins 0.000 claims description 4
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 claims description 4
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 102000013532 Uroplakin II Human genes 0.000 claims description 4
- 108010065940 Uroplakin II Proteins 0.000 claims description 4
- 102100038851 Uroplakin-2 Human genes 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 4
- 229940078795 lactoferrin Drugs 0.000 claims description 4
- 235000021242 lactoferrin Nutrition 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- 102400000321 Glucagon Human genes 0.000 claims description 3
- 108060003199 Glucagon Proteins 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
- 229960004666 glucagon Drugs 0.000 claims description 3
- 230000002338 cryopreservative effect Effects 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims 3
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 claims 1
- 102000010445 Lactoferrin Human genes 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims 1
- 102400000827 Saposin-D Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 101710173761 Uroplakin-2 Proteins 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 abstract description 60
- 230000008685 targeting Effects 0.000 abstract description 15
- 238000012546 transfer Methods 0.000 abstract description 10
- -1 S—fluorouracil Chemical compound 0.000 description 155
- 210000001519 tissue Anatomy 0.000 description 150
- 210000004027 cell Anatomy 0.000 description 112
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 79
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 64
- 230000014509 gene expression Effects 0.000 description 62
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 52
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 51
- 201000010099 disease Diseases 0.000 description 49
- 206010028980 Neoplasm Diseases 0.000 description 40
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- 208000035475 disorder Diseases 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 29
- 230000006870 function Effects 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 25
- 238000001415 gene therapy Methods 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 19
- 208000017169 kidney disease Diseases 0.000 description 18
- 238000004806 packaging method and process Methods 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 16
- 101150044789 Cap gene Proteins 0.000 description 16
- 241000700605 Viruses Species 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 16
- 239000013608 rAAV vector Substances 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 11
- 239000002502 liposome Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 230000026683 transduction Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 210000002845 virion Anatomy 0.000 description 10
- 208000022873 Ocular disease Diseases 0.000 description 9
- 241000243142 Porifera Species 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000010415 tropism Effects 0.000 description 9
- 206010069754 Acquired gene mutation Diseases 0.000 description 8
- 102100032435 BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2 Human genes 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000798415 Homo sapiens BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2 Proteins 0.000 description 8
- 208000019693 Lung disease Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 230000037439 somatic mutation Effects 0.000 description 8
- 230000005100 tissue tropism Effects 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 208000030270 breast disease Diseases 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 208000016222 Pancreatic disease Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001566 pro-viral effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 208000022461 Glomerular disease Diseases 0.000 description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
- 102100032241 Lactotransferrin Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 4
- 208000016599 Uterine disease Diseases 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 208000014001 urinary system disease Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 102100034452 Alternative prion protein Human genes 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 description 3
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 3
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 108091008065 MIR21 Proteins 0.000 description 3
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 208000026723 Urinary tract disease Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108010022687 fumarylacetoacetase Proteins 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002088 nanocapsule Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 210000004923 pancreatic tissue Anatomy 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 101150066583 rep gene Proteins 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 description 2
- 102000007371 Ataxin-3 Human genes 0.000 description 2
- 108010032947 Ataxin-3 Proteins 0.000 description 2
- 102000007370 Ataxin2 Human genes 0.000 description 2
- 108010032951 Ataxin2 Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 102000052609 BRCA2 Human genes 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 208000026292 Cystic Kidney disease Diseases 0.000 description 2
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 2
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 2
- 208000024940 Dent disease Diseases 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 102100024108 Dystrophin Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 208000007522 Fused Kidney Diseases 0.000 description 2
- 208000027472 Galactosemias Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 2
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 2
- 102100030651 Glutamate receptor 2 Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 2
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 2
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 2
- 101001010449 Homo sapiens Glutamate receptor 2 Proteins 0.000 description 2
- 101000614618 Homo sapiens Junctophilin-3 Proteins 0.000 description 2
- 101000822103 Homo sapiens Neuronal acetylcholine receptor subunit alpha-7 Proteins 0.000 description 2
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 2
- 108091070514 Homo sapiens let-7b stem-loop Proteins 0.000 description 2
- 108091070512 Homo sapiens let-7d stem-loop Proteins 0.000 description 2
- 108091069047 Homo sapiens let-7i stem-loop Proteins 0.000 description 2
- 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 description 2
- 108091069016 Homo sapiens miR-122 stem-loop Proteins 0.000 description 2
- 108091060466 Homo sapiens miR-1224 stem-loop Proteins 0.000 description 2
- 108091044921 Homo sapiens miR-1225 stem-loop Proteins 0.000 description 2
- 108091044923 Homo sapiens miR-1226 stem-loop Proteins 0.000 description 2
- 108091044953 Homo sapiens miR-1228 stem-loop Proteins 0.000 description 2
- 108091069004 Homo sapiens miR-125a stem-loop Proteins 0.000 description 2
- 108091069085 Homo sapiens miR-126 stem-loop Proteins 0.000 description 2
- 108091069086 Homo sapiens miR-127 stem-loop Proteins 0.000 description 2
- 108091069024 Homo sapiens miR-132 stem-loop Proteins 0.000 description 2
- 108091069102 Homo sapiens miR-136 stem-loop Proteins 0.000 description 2
- 108091067617 Homo sapiens miR-139 stem-loop Proteins 0.000 description 2
- 108091069017 Homo sapiens miR-140 stem-loop Proteins 0.000 description 2
- 108091068991 Homo sapiens miR-141 stem-loop Proteins 0.000 description 2
- 108091068993 Homo sapiens miR-142 stem-loop Proteins 0.000 description 2
- 108091068992 Homo sapiens miR-143 stem-loop Proteins 0.000 description 2
- 108091068999 Homo sapiens miR-144 stem-loop Proteins 0.000 description 2
- 108091069002 Homo sapiens miR-145 stem-loop Proteins 0.000 description 2
- 108091092238 Homo sapiens miR-146b stem-loop Proteins 0.000 description 2
- 108091069088 Homo sapiens miR-150 stem-loop Proteins 0.000 description 2
- 108091068955 Homo sapiens miR-154 stem-loop Proteins 0.000 description 2
- 108091065981 Homo sapiens miR-155 stem-loop Proteins 0.000 description 2
- 108091067605 Homo sapiens miR-183 stem-loop Proteins 0.000 description 2
- 108091067635 Homo sapiens miR-187 stem-loop Proteins 0.000 description 2
- 108091068998 Homo sapiens miR-191 stem-loop Proteins 0.000 description 2
- 108091067995 Homo sapiens miR-192 stem-loop Proteins 0.000 description 2
- 108091069034 Homo sapiens miR-193a stem-loop Proteins 0.000 description 2
- 108091068960 Homo sapiens miR-195 stem-loop Proteins 0.000 description 2
- 108091067692 Homo sapiens miR-199a-1 stem-loop Proteins 0.000 description 2
- 108091067467 Homo sapiens miR-199a-2 stem-loop Proteins 0.000 description 2
- 108091092296 Homo sapiens miR-202 stem-loop Proteins 0.000 description 2
- 108091067580 Homo sapiens miR-214 stem-loop Proteins 0.000 description 2
- 108091067572 Homo sapiens miR-221 stem-loop Proteins 0.000 description 2
- 108091067573 Homo sapiens miR-222 stem-loop Proteins 0.000 description 2
- 108091069527 Homo sapiens miR-223 stem-loop Proteins 0.000 description 2
- 108091070371 Homo sapiens miR-25 stem-loop Proteins 0.000 description 2
- 108091070397 Homo sapiens miR-28 stem-loop Proteins 0.000 description 2
- 108091065453 Homo sapiens miR-296 stem-loop Proteins 0.000 description 2
- 108091070383 Homo sapiens miR-32 stem-loop Proteins 0.000 description 2
- 108091066902 Homo sapiens miR-330 stem-loop Proteins 0.000 description 2
- 108091066896 Homo sapiens miR-331 stem-loop Proteins 0.000 description 2
- 108091066985 Homo sapiens miR-335 stem-loop Proteins 0.000 description 2
- 108091067013 Homo sapiens miR-337 stem-loop Proteins 0.000 description 2
- 108091067010 Homo sapiens miR-338 stem-loop Proteins 0.000 description 2
- 108091066899 Homo sapiens miR-340 stem-loop Proteins 0.000 description 2
- 108091067008 Homo sapiens miR-342 stem-loop Proteins 0.000 description 2
- 108091065456 Homo sapiens miR-34c stem-loop Proteins 0.000 description 2
- 108091067258 Homo sapiens miR-361 stem-loop Proteins 0.000 description 2
- 108091067259 Homo sapiens miR-362 stem-loop Proteins 0.000 description 2
- 108091067286 Homo sapiens miR-363 stem-loop Proteins 0.000 description 2
- 108091067254 Homo sapiens miR-367 stem-loop Proteins 0.000 description 2
- 108091067253 Homo sapiens miR-369 stem-loop Proteins 0.000 description 2
- 108091067564 Homo sapiens miR-373 stem-loop Proteins 0.000 description 2
- 108091067243 Homo sapiens miR-377 stem-loop Proteins 0.000 description 2
- 108091067552 Homo sapiens miR-379 stem-loop Proteins 0.000 description 2
- 108091067557 Homo sapiens miR-380 stem-loop Proteins 0.000 description 2
- 108091032537 Homo sapiens miR-409 stem-loop Proteins 0.000 description 2
- 108091032108 Homo sapiens miR-424 stem-loop Proteins 0.000 description 2
- 108091032103 Homo sapiens miR-425 stem-loop Proteins 0.000 description 2
- 108091092306 Homo sapiens miR-432 stem-loop Proteins 0.000 description 2
- 108091086503 Homo sapiens miR-450b stem-loop Proteins 0.000 description 2
- 108091032542 Homo sapiens miR-452 stem-loop Proteins 0.000 description 2
- 108091062137 Homo sapiens miR-454 stem-loop Proteins 0.000 description 2
- 108091063813 Homo sapiens miR-455 stem-loop Proteins 0.000 description 2
- 108091053841 Homo sapiens miR-483 stem-loop Proteins 0.000 description 2
- 108091053855 Homo sapiens miR-485 stem-loop Proteins 0.000 description 2
- 108091053840 Homo sapiens miR-486 stem-loop Proteins 0.000 description 2
- 108091059229 Homo sapiens miR-486-2 stem-loop Proteins 0.000 description 2
- 108091092228 Homo sapiens miR-490 stem-loop Proteins 0.000 description 2
- 108091092229 Homo sapiens miR-491 stem-loop Proteins 0.000 description 2
- 108091092303 Homo sapiens miR-497 stem-loop Proteins 0.000 description 2
- 108091064508 Homo sapiens miR-501 stem-loop Proteins 0.000 description 2
- 108091064362 Homo sapiens miR-508 stem-loop Proteins 0.000 description 2
- 108091064367 Homo sapiens miR-509-1 stem-loop Proteins 0.000 description 2
- 108091086508 Homo sapiens miR-509-2 stem-loop Proteins 0.000 description 2
- 108091087072 Homo sapiens miR-509-3 stem-loop Proteins 0.000 description 2
- 108091064366 Homo sapiens miR-513a-1 stem-loop Proteins 0.000 description 2
- 108091064370 Homo sapiens miR-513a-2 stem-loop Proteins 0.000 description 2
- 108091092284 Homo sapiens miR-515-1 stem-loop Proteins 0.000 description 2
- 108091092278 Homo sapiens miR-515-2 stem-loop Proteins 0.000 description 2
- 108091064420 Homo sapiens miR-518a-1 stem-loop Proteins 0.000 description 2
- 108091064422 Homo sapiens miR-518a-2 stem-loop Proteins 0.000 description 2
- 108091064446 Homo sapiens miR-520d stem-loop Proteins 0.000 description 2
- 108091064441 Homo sapiens miR-524 stem-loop Proteins 0.000 description 2
- 108091064471 Homo sapiens miR-525 stem-loop Proteins 0.000 description 2
- 108091063565 Homo sapiens miR-532 stem-loop Proteins 0.000 description 2
- 108091086504 Homo sapiens miR-541 stem-loop Proteins 0.000 description 2
- 108091061666 Homo sapiens miR-542 stem-loop Proteins 0.000 description 2
- 108091063807 Homo sapiens miR-545 stem-loop Proteins 0.000 description 2
- 108091061687 Homo sapiens miR-548a-3 stem-loop Proteins 0.000 description 2
- 108091063777 Homo sapiens miR-548b stem-loop Proteins 0.000 description 2
- 108091061614 Homo sapiens miR-548d-1 stem-loop Proteins 0.000 description 2
- 108091061568 Homo sapiens miR-548d-2 stem-loop Proteins 0.000 description 2
- 108091063734 Homo sapiens miR-556 stem-loop Proteins 0.000 description 2
- 108091063721 Homo sapiens miR-576 stem-loop Proteins 0.000 description 2
- 108091063723 Homo sapiens miR-582 stem-loop Proteins 0.000 description 2
- 108091063772 Homo sapiens miR-589 stem-loop Proteins 0.000 description 2
- 108091061594 Homo sapiens miR-590 stem-loop Proteins 0.000 description 2
- 108091061599 Homo sapiens miR-593 stem-loop Proteins 0.000 description 2
- 108091061779 Homo sapiens miR-616 stem-loop Proteins 0.000 description 2
- 108091061644 Homo sapiens miR-624 stem-loop Proteins 0.000 description 2
- 108091061649 Homo sapiens miR-625 stem-loop Proteins 0.000 description 2
- 108091061622 Homo sapiens miR-628 stem-loop Proteins 0.000 description 2
- 108091061631 Homo sapiens miR-629 stem-loop Proteins 0.000 description 2
- 108091061677 Homo sapiens miR-654 stem-loop Proteins 0.000 description 2
- 108091086460 Homo sapiens miR-708 stem-loop Proteins 0.000 description 2
- 108091086454 Homo sapiens miR-744 stem-loop Proteins 0.000 description 2
- 108091060465 Homo sapiens miR-767 stem-loop Proteins 0.000 description 2
- 108091086461 Homo sapiens miR-876 stem-loop Proteins 0.000 description 2
- 108091086647 Homo sapiens miR-877 stem-loop Proteins 0.000 description 2
- 108091086506 Homo sapiens miR-888 stem-loop Proteins 0.000 description 2
- 108091070377 Homo sapiens miR-93 stem-loop Proteins 0.000 description 2
- 108091070376 Homo sapiens miR-96 stem-loop Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- 208000020340 Immunotactoid glomerulopathy Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 102100040488 Junctophilin-3 Human genes 0.000 description 2
- 108091007773 MIR100 Proteins 0.000 description 2
- 108091007685 MIR541 Proteins 0.000 description 2
- 229910015837 MSH2 Inorganic materials 0.000 description 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 2
- 108091007780 MiR-122 Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 102100021511 Neuronal acetylcholine receptor subunit alpha-7 Human genes 0.000 description 2
- 101150056950 Ntrk2 gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010067472 Organising pneumonia Diseases 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000003221 Renal coloboma syndrome Diseases 0.000 description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000034972 Sudden Infant Death Diseases 0.000 description 2
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 102100040296 TATA-box-binding protein Human genes 0.000 description 2
- 101710145783 TATA-box-binding protein Proteins 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 2
- 108010091356 Tumor Protein p73 Proteins 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 2
- 102100030018 Tumor protein p73 Human genes 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 208000011392 nephropathic cystinosis Diseases 0.000 description 2
- 208000024691 pancreas disease Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000002464 short-rib thoracic dysplasia 9 with or without polydactyly Diseases 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 201000011296 tyrosinemia Diseases 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102100021408 14-3-3 protein beta/alpha Human genes 0.000 description 1
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- LLWPKTDSDUQBFY-UHFFFAOYSA-N 2-[6-(aminomethyl)-2,4-dioxo-1H-pyrimidin-5-yl]acetic acid Chemical compound C(=O)(O)CC=1C(NC(NC=1CN)=O)=O LLWPKTDSDUQBFY-UHFFFAOYSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- FDFPSNISSMYYDS-UHFFFAOYSA-N 2-ethyl-N,2-dimethylheptanamide Chemical compound CCCCCC(C)(CC)C(=O)NC FDFPSNISSMYYDS-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- VKWIASMEGJUYIK-UHFFFAOYSA-N 2-pent-1-enyl-7H-purin-6-amine Chemical compound CCCC=Cc1nc(N)c2[nH]cnc2n1 VKWIASMEGJUYIK-UHFFFAOYSA-N 0.000 description 1
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- UDZRZGNQQSUDNP-UHFFFAOYSA-N 6-(aminomethyl)-5-methoxy-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound COC=1C(NC(NC=1CN)=S)=O UDZRZGNQQSUDNP-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- 102100036512 7-dehydrocholesterol reductase Human genes 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 101150012579 ADSL gene Proteins 0.000 description 1
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 1
- 102100033936 AP-3 complex subunit beta-1 Human genes 0.000 description 1
- 102100030841 AT-rich interactive domain-containing protein 4A Human genes 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 102100022890 ATP synthase subunit beta, mitochondrial Human genes 0.000 description 1
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000032035 Acute focal bacterial nephritis Diseases 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 206010069688 Acute phosphate nephropathy Diseases 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102100032158 Adenylate cyclase type 6 Human genes 0.000 description 1
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 1
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000011374 Alagille syndrome Diseases 0.000 description 1
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102100034283 Annexin A5 Human genes 0.000 description 1
- 102100034273 Annexin A7 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 1
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 1
- 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000036075 Autosomal dominant tubulointerstitial kidney disease Diseases 0.000 description 1
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 1
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 description 1
- 102100027955 BAG family molecular chaperone regulator 4 Human genes 0.000 description 1
- 102100037135 BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 Human genes 0.000 description 1
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 1
- 102100037140 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Human genes 0.000 description 1
- 101150050047 BHLHE40 gene Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 1
- 241000701844 Bacillus virus phi29 Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 1
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 102100027515 Baculoviral IAP repeat-containing protein 6 Human genes 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 102100027517 Baculoviral IAP repeat-containing protein 8 Human genes 0.000 description 1
- 208000004884 Balkan Nephropathy Diseases 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 102100021971 Bcl-2-interacting killer Human genes 0.000 description 1
- 102100021894 Bcl-2-like protein 12 Human genes 0.000 description 1
- 102100023932 Bcl-2-like protein 2 Human genes 0.000 description 1
- 102100022541 Bcl-2-related ovarian killer protein Human genes 0.000 description 1
- 208000025760 Benign familial haematuria Diseases 0.000 description 1
- 102100026151 Bifunctional apoptosis regulator Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- 101150104237 Birc3 gene Proteins 0.000 description 1
- 102100027058 Bleomycin hydrolase Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100031746 Bone sialoprotein 2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 101000944273 Bos taurus Inward rectifier potassium channel 2 Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010048782 Breast calcifications Diseases 0.000 description 1
- 206010006253 Breast fibrosis Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000007596 Byssinosis Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- 102100037675 CCAAT/enhancer-binding protein gamma Human genes 0.000 description 1
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 102100027209 CD2-associated protein Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 108700020472 CDC20 Proteins 0.000 description 1
- 101150110330 CRAT gene Proteins 0.000 description 1
- 101710083734 CTP synthase Proteins 0.000 description 1
- 102100039866 CTP synthase 1 Human genes 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 102100029398 Calpain small subunit 1 Human genes 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100024955 Caspase recruitment domain-containing protein 6 Human genes 0.000 description 1
- 102100026089 Caspase recruitment domain-containing protein 9 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 102100038918 Caspase-6 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 102100038909 Caveolin-2 Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101150023302 Cdc20 gene Proteins 0.000 description 1
- 102100032141 Cell death activator CIDE-A Human genes 0.000 description 1
- 102100032142 Cell death activator CIDE-B Human genes 0.000 description 1
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 description 1
- 102100025828 Centromere protein C Human genes 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- 208000025678 Ciliary Motility disease Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102100026191 Class E basic helix-loop-helix protein 40 Human genes 0.000 description 1
- 102100026127 Clathrin heavy chain 1 Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 description 1
- 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102100033775 Collagen alpha-5(IV) chain Human genes 0.000 description 1
- 102100033773 Collagen alpha-6(IV) chain Human genes 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000008147 Core Binding Factor beta Subunit Human genes 0.000 description 1
- 108010060313 Core Binding Factor beta Subunit Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100033283 Creatine kinase U-type, mitochondrial Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000009506 Cyclin-Dependent Kinase Inhibitor p19 Human genes 0.000 description 1
- 108010009361 Cyclin-Dependent Kinase Inhibitor p19 Proteins 0.000 description 1
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 description 1
- 102100033144 Cyclin-dependent kinase 18 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 102100028202 Cytochrome c oxidase subunit 6C Human genes 0.000 description 1
- 102100025644 Cytochrome c oxidase subunit 7A2, mitochondrial Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 1
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 1
- 102100021389 DNA replication licensing factor MCM4 Human genes 0.000 description 1
- 102100027642 DNA-binding protein inhibitor ID-2 Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 1
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 description 1
- 102100038605 Death-associated protein kinase 2 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010059256 Dialysis disequilibrium syndrome Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102100022263 Disks large homolog 3 Human genes 0.000 description 1
- 102100039216 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Human genes 0.000 description 1
- 101100326757 Drosophila melanogaster Capr gene Proteins 0.000 description 1
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 1
- 102100040856 Dual specificity protein kinase CLK3 Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100031748 E3 ubiquitin-protein ligase SIAH2 Human genes 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- 201000004315 EAST syndrome Diseases 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 102100039562 ETS translocation variant 3 Human genes 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 206010014172 Ectopic ureter Diseases 0.000 description 1
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000025127 Erdheim-Chester disease Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 1
- 102100020987 Eukaryotic translation initiation factor 5 Human genes 0.000 description 1
- 102100020903 Ezrin Human genes 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 102100037584 FAST kinase domain-containing protein 4 Human genes 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 102100029531 Fas-activated serine/threonine kinase Human genes 0.000 description 1
- 102100021062 Ferritin light chain Human genes 0.000 description 1
- 206010068279 Fibrillary glomerulonephritis Diseases 0.000 description 1
- 102100031510 Fibrillin-2 Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000010006 Fraser Syndrome Diseases 0.000 description 1
- 102100021265 Frizzled-2 Human genes 0.000 description 1
- 102100039818 Frizzled-5 Human genes 0.000 description 1
- 102100028461 Frizzled-9 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100030280 G-protein coupled receptor 39 Human genes 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 102100028496 Galactocerebrosidase Human genes 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000009432 Galloway-Mowat syndrome Diseases 0.000 description 1
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 1
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 201000006004 Gitelman syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 102100035341 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 208000002777 Gynatresia Diseases 0.000 description 1
- 206010070737 HIV associated nephropathy Diseases 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 1
- 102100028765 Heat shock 70 kDa protein 4 Human genes 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 102000048988 Hemochromatosis Human genes 0.000 description 1
- 108700022944 Hemochromatosis Proteins 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
- 102100028716 Hermansky-Pudlak syndrome 3 protein Human genes 0.000 description 1
- 102100028715 Hermansky-Pudlak syndrome 4 protein Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101150065637 Hfe gene Proteins 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 102100022901 Histone acetyltransferase KAT2A Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100025448 Homeobox protein SIX6 Human genes 0.000 description 1
- 101000818893 Homo sapiens 14-3-3 protein beta/alpha Proteins 0.000 description 1
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 101000612655 Homo sapiens 26S proteasome non-ATPase regulatory subunit 1 Proteins 0.000 description 1
- 101000928720 Homo sapiens 7-dehydrocholesterol reductase Proteins 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000779239 Homo sapiens AP-3 complex subunit beta-1 Proteins 0.000 description 1
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 1
- 101000903027 Homo sapiens ATP synthase subunit beta, mitochondrial Proteins 0.000 description 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000775489 Homo sapiens Adenylate cyclase type 6 Proteins 0.000 description 1
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 1
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 description 1
- 101000780144 Homo sapiens Annexin A7 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
- 101000833314 Homo sapiens Arf-GAP domain and FG repeat-containing protein 1 Proteins 0.000 description 1
- 101000975992 Homo sapiens Asparagine synthetase [glutamine-hydrolyzing] Proteins 0.000 description 1
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 description 1
- 101000697866 Homo sapiens BAG family molecular chaperone regulator 4 Proteins 0.000 description 1
- 101000740576 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 Proteins 0.000 description 1
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 1
- 101000740545 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Proteins 0.000 description 1
- 101000936081 Homo sapiens Baculoviral IAP repeat-containing protein 6 Proteins 0.000 description 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 101000936076 Homo sapiens Baculoviral IAP repeat-containing protein 8 Proteins 0.000 description 1
- 101000970576 Homo sapiens Bcl-2-interacting killer Proteins 0.000 description 1
- 101000971073 Homo sapiens Bcl-2-like protein 12 Proteins 0.000 description 1
- 101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 1
- 101000899346 Homo sapiens Bcl-2-related ovarian killer protein Proteins 0.000 description 1
- 101000764928 Homo sapiens Bifunctional apoptosis regulator Proteins 0.000 description 1
- 101000984541 Homo sapiens Bleomycin hydrolase Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101100168465 Homo sapiens CAPNS1 gene Proteins 0.000 description 1
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 101000880590 Homo sapiens CCAAT/enhancer-binding protein gamma Proteins 0.000 description 1
- 101000710837 Homo sapiens CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 1
- 101000914499 Homo sapiens CD2-associated protein Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000974816 Homo sapiens Calcium/calmodulin-dependent protein kinase type IV Proteins 0.000 description 1
- 101000898052 Homo sapiens Calnexin Proteins 0.000 description 1
- 101000761252 Homo sapiens Caspase recruitment domain-containing protein 6 Proteins 0.000 description 1
- 101000983508 Homo sapiens Caspase recruitment domain-containing protein 9 Proteins 0.000 description 1
- 101000933112 Homo sapiens Caspase-4 Proteins 0.000 description 1
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 description 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 1
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
- 101000775570 Homo sapiens Cell death activator CIDE-A Proteins 0.000 description 1
- 101000775568 Homo sapiens Cell death activator CIDE-B Proteins 0.000 description 1
- 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 description 1
- 101000710873 Homo sapiens Collagen alpha-3(IV) chain Proteins 0.000 description 1
- 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101000710886 Homo sapiens Collagen alpha-5(IV) chain Proteins 0.000 description 1
- 101000710885 Homo sapiens Collagen alpha-6(IV) chain Proteins 0.000 description 1
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 1
- 101001135413 Homo sapiens Creatine kinase U-type, mitochondrial Proteins 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 description 1
- 101000944341 Homo sapiens Cyclin-dependent kinase 18 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000861049 Homo sapiens Cytochrome c oxidase subunit 6C Proteins 0.000 description 1
- 101000856741 Homo sapiens Cytochrome c oxidase subunit 7A2, mitochondrial Proteins 0.000 description 1
- 101000950906 Homo sapiens DNA fragmentation factor subunit alpha Proteins 0.000 description 1
- 101000950965 Homo sapiens DNA fragmentation factor subunit beta Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 1
- 101000615280 Homo sapiens DNA replication licensing factor MCM4 Proteins 0.000 description 1
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 1
- 101001081582 Homo sapiens DNA-binding protein inhibitor ID-2 Proteins 0.000 description 1
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
- 101000793922 Homo sapiens Dipeptidyl peptidase 1 Proteins 0.000 description 1
- 101000902100 Homo sapiens Disks large homolog 3 Proteins 0.000 description 1
- 101000670093 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Proteins 0.000 description 1
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 1
- 101000749304 Homo sapiens Dual specificity protein kinase CLK3 Proteins 0.000 description 1
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 1
- 101000707245 Homo sapiens E3 ubiquitin-protein ligase SIAH2 Proteins 0.000 description 1
- 101000813726 Homo sapiens ETS translocation variant 3 Proteins 0.000 description 1
- 101001002481 Homo sapiens Eukaryotic translation initiation factor 5 Proteins 0.000 description 1
- 101000854648 Homo sapiens Ezrin Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101001028251 Homo sapiens FAST kinase domain-containing protein 4 Proteins 0.000 description 1
- 101000917570 Homo sapiens Fas-activated serine/threonine kinase Proteins 0.000 description 1
- 101001065295 Homo sapiens Fas-binding factor 1 Proteins 0.000 description 1
- 101000818390 Homo sapiens Ferritin light chain Proteins 0.000 description 1
- 101000846890 Homo sapiens Fibrillin-2 Proteins 0.000 description 1
- 101000819477 Homo sapiens Frizzled-2 Proteins 0.000 description 1
- 101000885585 Homo sapiens Frizzled-5 Proteins 0.000 description 1
- 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 description 1
- 101001009541 Homo sapiens G-protein coupled receptor 39 Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 description 1
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 description 1
- 101000893424 Homo sapiens Glucokinase regulatory protein Proteins 0.000 description 1
- 101000903717 Homo sapiens Glycogen synthase kinase-3 alpha Proteins 0.000 description 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101001024278 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001078692 Homo sapiens Heat shock 70 kDa protein 4 Proteins 0.000 description 1
- 101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 description 1
- 101000985492 Homo sapiens Hermansky-Pudlak syndrome 3 protein Proteins 0.000 description 1
- 101000985501 Homo sapiens Hermansky-Pudlak syndrome 4 protein Proteins 0.000 description 1
- 101001046967 Homo sapiens Histone acetyltransferase KAT2A Proteins 0.000 description 1
- 101000835956 Homo sapiens Homeobox protein SIX6 Proteins 0.000 description 1
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001050274 Homo sapiens Keratin, type I cytoskeletal 9 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101001008558 Homo sapiens Laminin subunit beta-2 Proteins 0.000 description 1
- 101000946306 Homo sapiens Laminin subunit gamma-1 Proteins 0.000 description 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 1
- 101001044093 Homo sapiens Lipopolysaccharide-induced tumor necrosis factor-alpha factor Proteins 0.000 description 1
- 101001001294 Homo sapiens Lysosomal acid phosphatase Proteins 0.000 description 1
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101001115426 Homo sapiens MAGUK p55 subfamily member 3 Proteins 0.000 description 1
- 101100457032 Homo sapiens MGST1 gene Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 1
- 101000577891 Homo sapiens Myeloid cell nuclear differentiation antigen Proteins 0.000 description 1
- 101000589002 Homo sapiens Myogenin Proteins 0.000 description 1
- 101001022780 Homo sapiens Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
- 101001128456 Homo sapiens Myosin regulatory light polypeptide 9 Proteins 0.000 description 1
- 101000632748 Homo sapiens NADH-ubiquinone oxidoreductase chain 2 Proteins 0.000 description 1
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 1
- 101000581986 Homo sapiens Neurocan core protein Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 description 1
- 101000600779 Homo sapiens Neuromedin-B receptor Proteins 0.000 description 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101000633516 Homo sapiens Nuclear receptor subfamily 2 group F member 6 Proteins 0.000 description 1
- 101000973960 Homo sapiens Nucleolar protein 3 Proteins 0.000 description 1
- 101001128748 Homo sapiens Nucleoside diphosphate kinase 3 Proteins 0.000 description 1
- 101000979623 Homo sapiens Nucleoside diphosphate kinase B Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 101000613577 Homo sapiens Paired box protein Pax-2 Proteins 0.000 description 1
- 101000741800 Homo sapiens Peptidyl-prolyl cis-trans isomerase H Proteins 0.000 description 1
- 101001090065 Homo sapiens Peroxiredoxin-2 Proteins 0.000 description 1
- 101001090047 Homo sapiens Peroxiredoxin-4 Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101000777658 Homo sapiens Platelet glycoprotein 4 Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000693735 Homo sapiens Prefoldin subunit 4 Proteins 0.000 description 1
- 101001129610 Homo sapiens Prohibitin 1 Proteins 0.000 description 1
- 101001129654 Homo sapiens Prohibitin-2 Proteins 0.000 description 1
- 101000983170 Homo sapiens Proliferation-associated protein 2G4 Proteins 0.000 description 1
- 101000959489 Homo sapiens Protein AF-9 Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 1
- 101000702384 Homo sapiens Protein sprouty homolog 2 Proteins 0.000 description 1
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 1
- 101000738322 Homo sapiens Prothymosin alpha Proteins 0.000 description 1
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 description 1
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 1
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 101000713813 Homo sapiens Quinone oxidoreductase PIG3 Proteins 0.000 description 1
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 1
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000591210 Homo sapiens Receptor-type tyrosine-protein phosphatase-like N Proteins 0.000 description 1
- 101001096365 Homo sapiens Replication factor C subunit 2 Proteins 0.000 description 1
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 description 1
- 101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 1
- 101001106395 Homo sapiens Rho GTPase-activating protein 5 Proteins 0.000 description 1
- 101000581118 Homo sapiens Rho-related GTP-binding protein RhoC Proteins 0.000 description 1
- 101000581122 Homo sapiens Rho-related GTP-binding protein RhoD Proteins 0.000 description 1
- 101000867469 Homo sapiens Segment polarity protein dishevelled homolog DVL-3 Proteins 0.000 description 1
- 101000632266 Homo sapiens Semaphorin-3C Proteins 0.000 description 1
- 101000700735 Homo sapiens Serine/arginine-rich splicing factor 7 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000651890 Homo sapiens Slit homolog 2 protein Proteins 0.000 description 1
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 description 1
- 101000880098 Homo sapiens Sushi repeat-containing protein SRPX Proteins 0.000 description 1
- 101000653663 Homo sapiens T-complex protein 1 subunit epsilon Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
- 101000666385 Homo sapiens Transcription factor Dp-2 Proteins 0.000 description 1
- 101000904150 Homo sapiens Transcription factor E2F3 Proteins 0.000 description 1
- 101000866336 Homo sapiens Transcription factor E2F5 Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 101001028730 Homo sapiens Transcription factor JunB Proteins 0.000 description 1
- 101001050297 Homo sapiens Transcription factor JunD Proteins 0.000 description 1
- 101000708741 Homo sapiens Transcription factor RelB Proteins 0.000 description 1
- 101000837456 Homo sapiens Transducin beta-like protein 3 Proteins 0.000 description 1
- 101000669432 Homo sapiens Transducin-like enhancer protein 1 Proteins 0.000 description 1
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 description 1
- 101000639802 Homo sapiens U2 small nuclear ribonucleoprotein B'' Proteins 0.000 description 1
- 101000671649 Homo sapiens Upstream stimulatory factor 2 Proteins 0.000 description 1
- 101000808108 Homo sapiens Uroplakin-3a Proteins 0.000 description 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 1
- 108091070511 Homo sapiens let-7c stem-loop Proteins 0.000 description 1
- 108091070508 Homo sapiens let-7e stem-loop Proteins 0.000 description 1
- 108091070526 Homo sapiens let-7f-2 stem-loop Proteins 0.000 description 1
- 108091069046 Homo sapiens let-7g stem-loop Proteins 0.000 description 1
- 108091068928 Homo sapiens miR-107 stem-loop Proteins 0.000 description 1
- 108091045829 Homo sapiens miR-1183 stem-loop Proteins 0.000 description 1
- 108091044910 Homo sapiens miR-1200 stem-loop Proteins 0.000 description 1
- 108091044902 Homo sapiens miR-1202 stem-loop Proteins 0.000 description 1
- 108091044907 Homo sapiens miR-1204 stem-loop Proteins 0.000 description 1
- 108091044908 Homo sapiens miR-1205 stem-loop Proteins 0.000 description 1
- 108091044909 Homo sapiens miR-1206 stem-loop Proteins 0.000 description 1
- 108091044803 Homo sapiens miR-1207 stem-loop Proteins 0.000 description 1
- 108091044804 Homo sapiens miR-1208 stem-loop Proteins 0.000 description 1
- 108091044926 Homo sapiens miR-1227 stem-loop Proteins 0.000 description 1
- 108091044954 Homo sapiens miR-1229 stem-loop Proteins 0.000 description 1
- 108091044903 Homo sapiens miR-1234 stem-loop Proteins 0.000 description 1
- 108091044936 Homo sapiens miR-1236 stem-loop Proteins 0.000 description 1
- 108091044937 Homo sapiens miR-1237 stem-loop Proteins 0.000 description 1
- 108091044938 Homo sapiens miR-1238 stem-loop Proteins 0.000 description 1
- 108091044971 Homo sapiens miR-1243 stem-loop Proteins 0.000 description 1
- 108091044882 Homo sapiens miR-1247 stem-loop Proteins 0.000 description 1
- 108091044695 Homo sapiens miR-1248 stem-loop Proteins 0.000 description 1
- 108091044697 Homo sapiens miR-1249 stem-loop Proteins 0.000 description 1
- 108091044886 Homo sapiens miR-1250 stem-loop Proteins 0.000 description 1
- 108091044588 Homo sapiens miR-1252 stem-loop Proteins 0.000 description 1
- 108091044693 Homo sapiens miR-1253 stem-loop Proteins 0.000 description 1
- 108091044694 Homo sapiens miR-1255a stem-loop Proteins 0.000 description 1
- 108091044870 Homo sapiens miR-1256 stem-loop Proteins 0.000 description 1
- 108091044871 Homo sapiens miR-1257 stem-loop Proteins 0.000 description 1
- 108091044872 Homo sapiens miR-1258 stem-loop Proteins 0.000 description 1
- 108091069006 Homo sapiens miR-125b-1 stem-loop Proteins 0.000 description 1
- 108091069087 Homo sapiens miR-125b-2 stem-loop Proteins 0.000 description 1
- 108091044875 Homo sapiens miR-1261 stem-loop Proteins 0.000 description 1
- 108091044868 Homo sapiens miR-1262 stem-loop Proteins 0.000 description 1
- 108091044860 Homo sapiens miR-1263 stem-loop Proteins 0.000 description 1
- 108091060475 Homo sapiens miR-1264 stem-loop Proteins 0.000 description 1
- 108091044761 Homo sapiens miR-1265 stem-loop Proteins 0.000 description 1
- 108091044758 Homo sapiens miR-1267 stem-loop Proteins 0.000 description 1
- 108091062150 Homo sapiens miR-1271 stem-loop Proteins 0.000 description 1
- 108091044765 Homo sapiens miR-1272 stem-loop Proteins 0.000 description 1
- 108091044777 Homo sapiens miR-1275 stem-loop Proteins 0.000 description 1
- 108091044768 Homo sapiens miR-1276 stem-loop Proteins 0.000 description 1
- 108091044774 Homo sapiens miR-1277 stem-loop Proteins 0.000 description 1
- 108091044612 Homo sapiens miR-1278 stem-loop Proteins 0.000 description 1
- 108091069005 Homo sapiens miR-128-1 stem-loop Proteins 0.000 description 1
- 108091044609 Homo sapiens miR-1282 stem-loop Proteins 0.000 description 1
- 108091044584 Homo sapiens miR-1284 stem-loop Proteins 0.000 description 1
- 108091044829 Homo sapiens miR-1286 stem-loop Proteins 0.000 description 1
- 108091044798 Homo sapiens miR-1287 stem-loop Proteins 0.000 description 1
- 108091044585 Homo sapiens miR-1288 stem-loop Proteins 0.000 description 1
- 108091067642 Homo sapiens miR-129-1 stem-loop Proteins 0.000 description 1
- 108091069093 Homo sapiens miR-129-2 stem-loop Proteins 0.000 description 1
- 108091044796 Homo sapiens miR-1290 stem-loop Proteins 0.000 description 1
- 108091044797 Homo sapiens miR-1291 stem-loop Proteins 0.000 description 1
- 108091044586 Homo sapiens miR-1292 stem-loop Proteins 0.000 description 1
- 108091044790 Homo sapiens miR-1293 stem-loop Proteins 0.000 description 1
- 108091044792 Homo sapiens miR-1294 stem-loop Proteins 0.000 description 1
- 108091060453 Homo sapiens miR-1296 stem-loop Proteins 0.000 description 1
- 108091044816 Homo sapiens miR-1297 stem-loop Proteins 0.000 description 1
- 108091061957 Homo sapiens miR-1298 stem-loop Proteins 0.000 description 1
- 108091044817 Homo sapiens miR-1299 stem-loop Proteins 0.000 description 1
- 108091062151 Homo sapiens miR-1301 stem-loop Proteins 0.000 description 1
- 108091044964 Homo sapiens miR-1302-1 stem-loop Proteins 0.000 description 1
- 108091033925 Homo sapiens miR-1302-10 stem-loop Proteins 0.000 description 1
- 108091033832 Homo sapiens miR-1302-11 stem-loop Proteins 0.000 description 1
- 108091044965 Homo sapiens miR-1302-2 stem-loop Proteins 0.000 description 1
- 108091044966 Homo sapiens miR-1302-3 stem-loop Proteins 0.000 description 1
- 108091044969 Homo sapiens miR-1302-4 stem-loop Proteins 0.000 description 1
- 108091044970 Homo sapiens miR-1302-5 stem-loop Proteins 0.000 description 1
- 108091044961 Homo sapiens miR-1302-6 stem-loop Proteins 0.000 description 1
- 108091044962 Homo sapiens miR-1302-7 stem-loop Proteins 0.000 description 1
- 108091044968 Homo sapiens miR-1302-8 stem-loop Proteins 0.000 description 1
- 108091033923 Homo sapiens miR-1302-9 stem-loop Proteins 0.000 description 1
- 108091044974 Homo sapiens miR-1303 stem-loop Proteins 0.000 description 1
- 108091044975 Homo sapiens miR-1304 stem-loop Proteins 0.000 description 1
- 108091044980 Homo sapiens miR-1305 stem-loop Proteins 0.000 description 1
- 108091044603 Homo sapiens miR-1306 stem-loop Proteins 0.000 description 1
- 108091044678 Homo sapiens miR-1307 stem-loop Proteins 0.000 description 1
- 108091045232 Homo sapiens miR-1321 stem-loop Proteins 0.000 description 1
- 108091045233 Homo sapiens miR-1322 stem-loop Proteins 0.000 description 1
- 108091060456 Homo sapiens miR-1323 stem-loop Proteins 0.000 description 1
- 108091045230 Homo sapiens miR-1324 stem-loop Proteins 0.000 description 1
- 108091066990 Homo sapiens miR-133b stem-loop Proteins 0.000 description 1
- 108091069094 Homo sapiens miR-134 stem-loop Proteins 0.000 description 1
- 108091068985 Homo sapiens miR-137 stem-loop Proteins 0.000 description 1
- 108091069092 Homo sapiens miR-138-1 stem-loop Proteins 0.000 description 1
- 108091069015 Homo sapiens miR-138-2 stem-loop Proteins 0.000 description 1
- 108091069090 Homo sapiens miR-149 stem-loop Proteins 0.000 description 1
- 108091068997 Homo sapiens miR-152 stem-loop Proteins 0.000 description 1
- 108091070491 Homo sapiens miR-16-1 stem-loop Proteins 0.000 description 1
- 108091068927 Homo sapiens miR-16-2 stem-loop Proteins 0.000 description 1
- 108091070489 Homo sapiens miR-17 stem-loop Proteins 0.000 description 1
- 108091067618 Homo sapiens miR-181a-2 stem-loop Proteins 0.000 description 1
- 108091067627 Homo sapiens miR-182 stem-loop Proteins 0.000 description 1
- 108091078084 Homo sapiens miR-1825 stem-loop Proteins 0.000 description 1
- 108091078047 Homo sapiens miR-1827 stem-loop Proteins 0.000 description 1
- 108091068958 Homo sapiens miR-184 stem-loop Proteins 0.000 description 1
- 108091068954 Homo sapiens miR-185 stem-loop Proteins 0.000 description 1
- 108091068956 Homo sapiens miR-186 stem-loop Proteins 0.000 description 1
- 108091069033 Homo sapiens miR-188 stem-loop Proteins 0.000 description 1
- 108091067982 Homo sapiens miR-197 stem-loop Proteins 0.000 description 1
- 108091067677 Homo sapiens miR-198 stem-loop Proteins 0.000 description 1
- 108091067484 Homo sapiens miR-199b stem-loop Proteins 0.000 description 1
- 108091070519 Homo sapiens miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091070495 Homo sapiens miR-19b-2 stem-loop Proteins 0.000 description 1
- 108091067470 Homo sapiens miR-204 stem-loop Proteins 0.000 description 1
- 108091067482 Homo sapiens miR-205 stem-loop Proteins 0.000 description 1
- 108091069013 Homo sapiens miR-206 stem-loop Proteins 0.000 description 1
- 108091067468 Homo sapiens miR-210 stem-loop Proteins 0.000 description 1
- 108091067466 Homo sapiens miR-212 stem-loop Proteins 0.000 description 1
- 108091067578 Homo sapiens miR-215 stem-loop Proteins 0.000 description 1
- 108091067465 Homo sapiens miR-217 stem-loop Proteins 0.000 description 1
- 108091067464 Homo sapiens miR-218-1 stem-loop Proteins 0.000 description 1
- 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 description 1
- 108091069517 Homo sapiens miR-224 stem-loop Proteins 0.000 description 1
- 108091070373 Homo sapiens miR-24-1 stem-loop Proteins 0.000 description 1
- 108091070374 Homo sapiens miR-24-2 stem-loop Proteins 0.000 description 1
- 108091070372 Homo sapiens miR-26a-1 stem-loop Proteins 0.000 description 1
- 108091065428 Homo sapiens miR-26a-2 stem-loop Proteins 0.000 description 1
- 108091086975 Homo sapiens miR-297 stem-loop Proteins 0.000 description 1
- 108091086636 Homo sapiens miR-298 stem-loop Proteins 0.000 description 1
- 108091065449 Homo sapiens miR-299 stem-loop Proteins 0.000 description 1
- 108091068837 Homo sapiens miR-29b-1 stem-loop Proteins 0.000 description 1
- 108091068845 Homo sapiens miR-29b-2 stem-loop Proteins 0.000 description 1
- 108091086634 Homo sapiens miR-300 stem-loop Proteins 0.000 description 1
- 108091044773 Homo sapiens miR-302f stem-loop Proteins 0.000 description 1
- 108091060457 Homo sapiens miR-320b-1 stem-loop Proteins 0.000 description 1
- 108091062096 Homo sapiens miR-320b-2 stem-loop Proteins 0.000 description 1
- 108091060471 Homo sapiens miR-320c-1 stem-loop Proteins 0.000 description 1
- 108091078079 Homo sapiens miR-320c-2 stem-loop Proteins 0.000 description 1
- 108091078081 Homo sapiens miR-320d-1 stem-loop Proteins 0.000 description 1
- 108091078082 Homo sapiens miR-320d-2 stem-loop Proteins 0.000 description 1
- 108091067007 Homo sapiens miR-324 stem-loop Proteins 0.000 description 1
- 108091067011 Homo sapiens miR-326 stem-loop Proteins 0.000 description 1
- 108091067005 Homo sapiens miR-328 stem-loop Proteins 0.000 description 1
- 108091066993 Homo sapiens miR-339 stem-loop Proteins 0.000 description 1
- 108091066987 Homo sapiens miR-345 stem-loop Proteins 0.000 description 1
- 108091066970 Homo sapiens miR-346 stem-loop Proteins 0.000 description 1
- 108091067267 Homo sapiens miR-370 stem-loop Proteins 0.000 description 1
- 108091067570 Homo sapiens miR-372 stem-loop Proteins 0.000 description 1
- 108091067535 Homo sapiens miR-375 stem-loop Proteins 0.000 description 1
- 108091067554 Homo sapiens miR-381 stem-loop Proteins 0.000 description 1
- 108091067543 Homo sapiens miR-382 stem-loop Proteins 0.000 description 1
- 108091067545 Homo sapiens miR-383 stem-loop Proteins 0.000 description 1
- 108091033149 Homo sapiens miR-384 stem-loop Proteins 0.000 description 1
- 108091053847 Homo sapiens miR-410 stem-loop Proteins 0.000 description 1
- 108091053842 Homo sapiens miR-412 stem-loop Proteins 0.000 description 1
- 108091061665 Homo sapiens miR-421 stem-loop Proteins 0.000 description 1
- 108091032093 Homo sapiens miR-422a stem-loop Proteins 0.000 description 1
- 108091032109 Homo sapiens miR-423 stem-loop Proteins 0.000 description 1
- 108091032930 Homo sapiens miR-429 stem-loop Proteins 0.000 description 1
- 108091032636 Homo sapiens miR-433 stem-loop Proteins 0.000 description 1
- 108091032861 Homo sapiens miR-448 stem-loop Proteins 0.000 description 1
- 108091032929 Homo sapiens miR-449a stem-loop Proteins 0.000 description 1
- 108091053854 Homo sapiens miR-484 stem-loop Proteins 0.000 description 1
- 108091092234 Homo sapiens miR-488 stem-loop Proteins 0.000 description 1
- 108091092227 Homo sapiens miR-489 stem-loop Proteins 0.000 description 1
- 108091092304 Homo sapiens miR-492 stem-loop Proteins 0.000 description 1
- 108091092305 Homo sapiens miR-493 stem-loop Proteins 0.000 description 1
- 108091092307 Homo sapiens miR-494 stem-loop Proteins 0.000 description 1
- 108091092297 Homo sapiens miR-495 stem-loop Proteins 0.000 description 1
- 108091092298 Homo sapiens miR-496 stem-loop Proteins 0.000 description 1
- 108091092282 Homo sapiens miR-498 stem-loop Proteins 0.000 description 1
- 108091064509 Homo sapiens miR-502 stem-loop Proteins 0.000 description 1
- 108091064515 Homo sapiens miR-503 stem-loop Proteins 0.000 description 1
- 108091064516 Homo sapiens miR-504 stem-loop Proteins 0.000 description 1
- 108091064365 Homo sapiens miR-505 stem-loop Proteins 0.000 description 1
- 108091064363 Homo sapiens miR-506 stem-loop Proteins 0.000 description 1
- 108091092274 Homo sapiens miR-512-1 stem-loop Proteins 0.000 description 1
- 108091092275 Homo sapiens miR-512-2 stem-loop Proteins 0.000 description 1
- 108091064511 Homo sapiens miR-516a-1 stem-loop Proteins 0.000 description 1
- 108091064512 Homo sapiens miR-516a-2 stem-loop Proteins 0.000 description 1
- 108091064417 Homo sapiens miR-518d stem-loop Proteins 0.000 description 1
- 108091064474 Homo sapiens miR-519b stem-loop Proteins 0.000 description 1
- 108091092280 Homo sapiens miR-519c stem-loop Proteins 0.000 description 1
- 108091092281 Homo sapiens miR-520a stem-loop Proteins 0.000 description 1
- 108091064423 Homo sapiens miR-520h stem-loop Proteins 0.000 description 1
- 108091064426 Homo sapiens miR-522 stem-loop Proteins 0.000 description 1
- 108091064465 Homo sapiens miR-523 stem-loop Proteins 0.000 description 1
- 108091063810 Homo sapiens miR-539 stem-loop Proteins 0.000 description 1
- 108091086476 Homo sapiens miR-543 stem-loop Proteins 0.000 description 1
- 108091063773 Homo sapiens miR-548a-1 stem-loop Proteins 0.000 description 1
- 108091063768 Homo sapiens miR-548a-2 stem-loop Proteins 0.000 description 1
- 108091044615 Homo sapiens miR-548i-1 stem-loop Proteins 0.000 description 1
- 108091044616 Homo sapiens miR-548i-2 stem-loop Proteins 0.000 description 1
- 108091044617 Homo sapiens miR-548i-3 stem-loop Proteins 0.000 description 1
- 108091044611 Homo sapiens miR-548i-4 stem-loop Proteins 0.000 description 1
- 108091044789 Homo sapiens miR-548k stem-loop Proteins 0.000 description 1
- 108091044760 Homo sapiens miR-548m stem-loop Proteins 0.000 description 1
- 108091044861 Homo sapiens miR-548n stem-loop Proteins 0.000 description 1
- 108091044614 Homo sapiens miR-548p stem-loop Proteins 0.000 description 1
- 108091063753 Homo sapiens miR-551a stem-loop Proteins 0.000 description 1
- 108091063755 Homo sapiens miR-552 stem-loop Proteins 0.000 description 1
- 108091063758 Homo sapiens miR-553 stem-loop Proteins 0.000 description 1
- 108091063741 Homo sapiens miR-555 stem-loop Proteins 0.000 description 1
- 108091063735 Homo sapiens miR-557 stem-loop Proteins 0.000 description 1
- 108091063736 Homo sapiens miR-558 stem-loop Proteins 0.000 description 1
- 108091063737 Homo sapiens miR-559 stem-loop Proteins 0.000 description 1
- 108091063743 Homo sapiens miR-561 stem-loop Proteins 0.000 description 1
- 108091063744 Homo sapiens miR-562 stem-loop Proteins 0.000 description 1
- 108091063748 Homo sapiens miR-563 stem-loop Proteins 0.000 description 1
- 108091063727 Homo sapiens miR-564 stem-loop Proteins 0.000 description 1
- 108091063731 Homo sapiens miR-567 stem-loop Proteins 0.000 description 1
- 108091063725 Homo sapiens miR-568 stem-loop Proteins 0.000 description 1
- 108091063732 Homo sapiens miR-569 stem-loop Proteins 0.000 description 1
- 108091063733 Homo sapiens miR-570 stem-loop Proteins 0.000 description 1
- 108091063730 Homo sapiens miR-571 stem-loop Proteins 0.000 description 1
- 108091063726 Homo sapiens miR-572 stem-loop Proteins 0.000 description 1
- 108091063804 Homo sapiens miR-573 stem-loop Proteins 0.000 description 1
- 108091063808 Homo sapiens miR-574 stem-loop Proteins 0.000 description 1
- 108091063720 Homo sapiens miR-575 stem-loop Proteins 0.000 description 1
- 108091063716 Homo sapiens miR-577 stem-loop Proteins 0.000 description 1
- 108091063717 Homo sapiens miR-578 stem-loop Proteins 0.000 description 1
- 108091063718 Homo sapiens miR-579 stem-loop Proteins 0.000 description 1
- 108091063722 Homo sapiens miR-581 stem-loop Proteins 0.000 description 1
- 108091063764 Homo sapiens miR-583 stem-loop Proteins 0.000 description 1
- 108091063765 Homo sapiens miR-584 stem-loop Proteins 0.000 description 1
- 108091063771 Homo sapiens miR-586 stem-loop Proteins 0.000 description 1
- 108091063776 Homo sapiens miR-587 stem-loop Proteins 0.000 description 1
- 108091063767 Homo sapiens miR-588 stem-loop Proteins 0.000 description 1
- 108091061591 Homo sapiens miR-591 stem-loop Proteins 0.000 description 1
- 108091061592 Homo sapiens miR-592 stem-loop Proteins 0.000 description 1
- 108091061597 Homo sapiens miR-595 stem-loop Proteins 0.000 description 1
- 108091061598 Homo sapiens miR-596 stem-loop Proteins 0.000 description 1
- 108091061785 Homo sapiens miR-597 stem-loop Proteins 0.000 description 1
- 108091061784 Homo sapiens miR-599 stem-loop Proteins 0.000 description 1
- 108091061683 Homo sapiens miR-601 stem-loop Proteins 0.000 description 1
- 108091061684 Homo sapiens miR-602 stem-loop Proteins 0.000 description 1
- 108091061789 Homo sapiens miR-603 stem-loop Proteins 0.000 description 1
- 108091061787 Homo sapiens miR-604 stem-loop Proteins 0.000 description 1
- 108091061689 Homo sapiens miR-605 stem-loop Proteins 0.000 description 1
- 108091061690 Homo sapiens miR-606 stem-loop Proteins 0.000 description 1
- 108091061774 Homo sapiens miR-607 stem-loop Proteins 0.000 description 1
- 108091061775 Homo sapiens miR-608 stem-loop Proteins 0.000 description 1
- 108091061772 Homo sapiens miR-609 stem-loop Proteins 0.000 description 1
- 108091061780 Homo sapiens miR-612 stem-loop Proteins 0.000 description 1
- 108091061781 Homo sapiens miR-613 stem-loop Proteins 0.000 description 1
- 108091061778 Homo sapiens miR-615 stem-loop Proteins 0.000 description 1
- 108091061642 Homo sapiens miR-617 stem-loop Proteins 0.000 description 1
- 108091061645 Homo sapiens miR-618 stem-loop Proteins 0.000 description 1
- 108091061650 Homo sapiens miR-620 stem-loop Proteins 0.000 description 1
- 108091061647 Homo sapiens miR-621 stem-loop Proteins 0.000 description 1
- 108091061648 Homo sapiens miR-622 stem-loop Proteins 0.000 description 1
- 108091061653 Homo sapiens miR-623 stem-loop Proteins 0.000 description 1
- 108091061633 Homo sapiens miR-626 stem-loop Proteins 0.000 description 1
- 108091061621 Homo sapiens miR-627 stem-loop Proteins 0.000 description 1
- 108091061636 Homo sapiens miR-630 stem-loop Proteins 0.000 description 1
- 108091061637 Homo sapiens miR-632 stem-loop Proteins 0.000 description 1
- 108091061638 Homo sapiens miR-633 stem-loop Proteins 0.000 description 1
- 108091061634 Homo sapiens miR-634 stem-loop Proteins 0.000 description 1
- 108091061626 Homo sapiens miR-635 stem-loop Proteins 0.000 description 1
- 108091061623 Homo sapiens miR-636 stem-loop Proteins 0.000 description 1
- 108091061618 Homo sapiens miR-637 stem-loop Proteins 0.000 description 1
- 108091061613 Homo sapiens miR-638 stem-loop Proteins 0.000 description 1
- 108091061611 Homo sapiens miR-639 stem-loop Proteins 0.000 description 1
- 108091061625 Homo sapiens miR-640 stem-loop Proteins 0.000 description 1
- 108091061624 Homo sapiens miR-641 stem-loop Proteins 0.000 description 1
- 108091061630 Homo sapiens miR-643 stem-loop Proteins 0.000 description 1
- 108091061604 Homo sapiens miR-645 stem-loop Proteins 0.000 description 1
- 108091061602 Homo sapiens miR-647 stem-loop Proteins 0.000 description 1
- 108091061609 Homo sapiens miR-648 stem-loop Proteins 0.000 description 1
- 108091061610 Homo sapiens miR-649 stem-loop Proteins 0.000 description 1
- 108091061608 Homo sapiens miR-650 stem-loop Proteins 0.000 description 1
- 108091061616 Homo sapiens miR-652 stem-loop Proteins 0.000 description 1
- 108091061679 Homo sapiens miR-653 stem-loop Proteins 0.000 description 1
- 108091061680 Homo sapiens miR-655 stem-loop Proteins 0.000 description 1
- 108091061564 Homo sapiens miR-656 stem-loop Proteins 0.000 description 1
- 108091061671 Homo sapiens miR-657 stem-loop Proteins 0.000 description 1
- 108091061674 Homo sapiens miR-658 stem-loop Proteins 0.000 description 1
- 108091061675 Homo sapiens miR-659 stem-loop Proteins 0.000 description 1
- 108091061672 Homo sapiens miR-660 stem-loop Proteins 0.000 description 1
- 108091061615 Homo sapiens miR-661 stem-loop Proteins 0.000 description 1
- 108091061570 Homo sapiens miR-662 stem-loop Proteins 0.000 description 1
- 108091044906 Homo sapiens miR-663b stem-loop Proteins 0.000 description 1
- 108091086478 Homo sapiens miR-665 stem-loop Proteins 0.000 description 1
- 108091060464 Homo sapiens miR-668 stem-loop Proteins 0.000 description 1
- 108091060463 Homo sapiens miR-671 stem-loop Proteins 0.000 description 1
- 108091086709 Homo sapiens miR-675 stem-loop Proteins 0.000 description 1
- 108091067630 Homo sapiens miR-7-2 stem-loop Proteins 0.000 description 1
- 108091060481 Homo sapiens miR-758 stem-loop Proteins 0.000 description 1
- 108091086475 Homo sapiens miR-760 stem-loop Proteins 0.000 description 1
- 108091062099 Homo sapiens miR-766 stem-loop Proteins 0.000 description 1
- 108091062100 Homo sapiens miR-769 stem-loop Proteins 0.000 description 1
- 108091087853 Homo sapiens miR-770 stem-loop Proteins 0.000 description 1
- 108091061966 Homo sapiens miR-802 stem-loop Proteins 0.000 description 1
- 108091086477 Homo sapiens miR-873 stem-loop Proteins 0.000 description 1
- 108091086462 Homo sapiens miR-875 stem-loop Proteins 0.000 description 1
- 108091086652 Homo sapiens miR-885 stem-loop Proteins 0.000 description 1
- 108091086472 Homo sapiens miR-887 stem-loop Proteins 0.000 description 1
- 108091086467 Homo sapiens miR-889 stem-loop Proteins 0.000 description 1
- 108091086511 Homo sapiens miR-890 stem-loop Proteins 0.000 description 1
- 108091086639 Homo sapiens miR-892a stem-loop Proteins 0.000 description 1
- 108091087068 Homo sapiens miR-920 stem-loop Proteins 0.000 description 1
- 108091087064 Homo sapiens miR-922 stem-loop Proteins 0.000 description 1
- 108091087063 Homo sapiens miR-924 stem-loop Proteins 0.000 description 1
- 108091070381 Homo sapiens miR-92a-2 stem-loop Proteins 0.000 description 1
- 108091087086 Homo sapiens miR-933 stem-loop Proteins 0.000 description 1
- 108091087085 Homo sapiens miR-934 stem-loop Proteins 0.000 description 1
- 108091087083 Homo sapiens miR-936 stem-loop Proteins 0.000 description 1
- 108091087082 Homo sapiens miR-937 stem-loop Proteins 0.000 description 1
- 108091087106 Homo sapiens miR-938 stem-loop Proteins 0.000 description 1
- 108091087105 Homo sapiens miR-939 stem-loop Proteins 0.000 description 1
- 108091087115 Homo sapiens miR-942 stem-loop Proteins 0.000 description 1
- 108091087118 Homo sapiens miR-943 stem-loop Proteins 0.000 description 1
- 108091087117 Homo sapiens miR-944 stem-loop Proteins 0.000 description 1
- 108091070375 Homo sapiens miR-95 stem-loop Proteins 0.000 description 1
- 108091068856 Homo sapiens miR-98 stem-loop Proteins 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 102000016252 Huntingtin Human genes 0.000 description 1
- 108050004784 Huntingtin Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 206010021131 Hypouricaemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100035692 Importin subunit alpha-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100033000 Integrin beta-4 Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 102100023129 Keratin, type I cytoskeletal 9 Human genes 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 201000003129 Kidney Papillary Necrosis Diseases 0.000 description 1
- 206010023423 Kidney hypermobility Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027454 Laminin subunit beta-2 Human genes 0.000 description 1
- 102100030874 Leptin Human genes 0.000 description 1
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 1
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 102100021607 Lipopolysaccharide-induced tumor necrosis factor-alpha factor Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 102100035699 Lysosomal acid phosphatase Human genes 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 description 1
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 108010041980 MAP-kinase-activated kinase 3 Proteins 0.000 description 1
- 102000017274 MDM4 Human genes 0.000 description 1
- 108050005300 MDM4 Proteins 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 108091007772 MIRLET7C Proteins 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000013836 Malacoplakia Diseases 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 102000019010 Methylmalonyl-CoA Mutase Human genes 0.000 description 1
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 description 1
- 229940122938 MicroRNA inhibitor Drugs 0.000 description 1
- 102100026741 Microsomal glutathione S-transferase 1 Human genes 0.000 description 1
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100326241 Mus musculus Bnipl gene Proteins 0.000 description 1
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 1
- 101100203797 Mus musculus Spinkl gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 102100027994 Myeloid cell nuclear differentiation antigen Human genes 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102100029839 Myocilin Human genes 0.000 description 1
- 101710196550 Myocilin Proteins 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 102100031787 Myosin regulatory light polypeptide 9 Human genes 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 102100028488 NADH-ubiquinone oxidoreductase chain 2 Human genes 0.000 description 1
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 1
- 208000000175 Nail-Patella Syndrome Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102100030466 Neurocan core protein Human genes 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 102100037283 Neuromedin-B receptor Human genes 0.000 description 1
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 241000557624 Nucifraga Species 0.000 description 1
- 102100029528 Nuclear receptor subfamily 2 group F member 6 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 102100022400 Nucleolar protein 3 Human genes 0.000 description 1
- 102100032209 Nucleoside diphosphate kinase 3 Human genes 0.000 description 1
- 102100023258 Nucleoside diphosphate kinase B Human genes 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100031942 Oncostatin-M Human genes 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 102100031822 Optineurin Human genes 0.000 description 1
- 101710131459 Optineurin Proteins 0.000 description 1
- 208000030649 Orofaciodigital Syndromes Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 108010047613 PTB-Associated Splicing Factor Proteins 0.000 description 1
- 102100040852 Paired box protein Pax-2 Human genes 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100038827 Peptidyl-prolyl cis-trans isomerase H Human genes 0.000 description 1
- 208000025584 Pericardial disease Diseases 0.000 description 1
- 102100034763 Peroxiredoxin-2 Human genes 0.000 description 1
- 102100034768 Peroxiredoxin-4 Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 208000005746 Phosphoenolpyruvate carboxykinase deficiency Diseases 0.000 description 1
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100031574 Platelet glycoprotein 4 Human genes 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 102100039277 Pleiotrophin Human genes 0.000 description 1
- 108010012887 Poly(A)-Binding Protein I Proteins 0.000 description 1
- 102100026090 Polyadenylate-binding protein 1 Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- 206010036182 Porphyria acute Diseases 0.000 description 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
- 208000030331 Posterior urethral valve Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100025542 Prefoldin subunit 4 Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102100031169 Prohibitin 1 Human genes 0.000 description 1
- 102100031156 Prohibitin-2 Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 102100026899 Proliferation-associated protein 2G4 Human genes 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 102100039686 Protein AF-9 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 1
- 102100030400 Protein sprouty homolog 2 Human genes 0.000 description 1
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 1
- 102100037925 Prothymosin alpha Human genes 0.000 description 1
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- 102100036522 Quinone oxidoreductase PIG3 Human genes 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 1
- 102100039100 Ras-related protein Rab-5A Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100034091 Receptor-type tyrosine-protein phosphatase-like N Human genes 0.000 description 1
- 206010065427 Reflux nephropathy Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000003604 Renal agenesis Diseases 0.000 description 1
- 206010038366 Renal aneurysm Diseases 0.000 description 1
- 206010064655 Renal aplasia Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010068033 Renal fusion anomaly Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100037851 Replication factor C subunit 2 Human genes 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 1
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 1
- 108010003494 Retinoblastoma-Like Protein p130 Proteins 0.000 description 1
- 102000004642 Retinoblastoma-Like Protein p130 Human genes 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000001368 Retrocaval Ureter Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 102100021428 Rho GTPase-activating protein 5 Human genes 0.000 description 1
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 description 1
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 1
- 101100501116 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TUF1 gene Proteins 0.000 description 1
- 208000034517 Saldino-Mainzer syndrome Diseases 0.000 description 1
- 208000009548 Schimke immuno-osseous dysplasia Diseases 0.000 description 1
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 1
- 206010062553 Scleroderma renal crisis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 1
- 102100032754 Segment polarity protein dishevelled homolog DVL-3 Human genes 0.000 description 1
- 102100027980 Semaphorin-3C Human genes 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 102100029287 Serine/arginine-rich splicing factor 7 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100027339 Slit homolog 3 protein Human genes 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 1
- 102100027780 Splicing factor, proline- and glutamine-rich Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100037352 Sushi repeat-containing protein SRPX Human genes 0.000 description 1
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100029886 T-complex protein 1 subunit epsilon Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 102000003715 TNF receptor-associated factor 4 Human genes 0.000 description 1
- 108090000008 TNF receptor-associated factor 4 Proteins 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- 102000003623 TRPC6 Human genes 0.000 description 1
- 101150026786 TUFM gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 description 1
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 description 1
- 102100038312 Transcription factor Dp-2 Human genes 0.000 description 1
- 102100024027 Transcription factor E2F3 Human genes 0.000 description 1
- 102100031632 Transcription factor E2F5 Human genes 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102100037168 Transcription factor JunB Human genes 0.000 description 1
- 102100023118 Transcription factor JunD Human genes 0.000 description 1
- 102100032727 Transcription factor RelB Human genes 0.000 description 1
- 102100028683 Transducin beta-like protein 3 Human genes 0.000 description 1
- 102100039362 Transducin-like enhancer protein 1 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100032762 Transformation/transcription domain-associated protein Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 102100022387 Transforming protein RhoA Human genes 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 1
- 206010044668 Trigonitis Diseases 0.000 description 1
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- 101710140697 Tumor protein 63 Proteins 0.000 description 1
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 1
- 208000032001 Tyrosinemia type 1 Diseases 0.000 description 1
- 102100034461 U2 small nuclear ribonucleoprotein B'' Human genes 0.000 description 1
- 108010082433 UDP-glucose-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 101150020913 USP7 gene Proteins 0.000 description 1
- 102100021013 Ubiquitin carboxyl-terminal hydrolase 7 Human genes 0.000 description 1
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 description 1
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 102100040103 Upstream stimulatory factor 2 Human genes 0.000 description 1
- 208000006353 Ureterocele Diseases 0.000 description 1
- 206010046437 Urethral caruncle Diseases 0.000 description 1
- 206010058463 Urethral meatus stenosis Diseases 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 206010046479 Urethral valves Diseases 0.000 description 1
- 241000736772 Uria Species 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 102100038854 Uroplakin-3a Human genes 0.000 description 1
- 108010075653 Utrophin Proteins 0.000 description 1
- 102000011856 Utrophin Human genes 0.000 description 1
- 101150004676 VGF gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 208000012634 Venoocclusive liver disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047370 Vesicoureteric reflux Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 description 1
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 1
- 101100163844 Zea mays R-S gene Proteins 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 201000005271 biliary atresia Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010071434 biotinidase deficiency Diseases 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 108010031373 centromere protein C Proteins 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108010014510 connexin 40 Proteins 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 208000022401 dense deposit disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000027180 double uterus-hemivagina-renal agenesis syndrome Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000000080 familial hypocalciuric hypercalcemia Diseases 0.000 description 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 description 1
- 201000010766 fat necrosis of breast Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 201000004098 fibrolamellar carcinoma Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 108010011989 karyopherin alpha 2 Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000002898 library design Methods 0.000 description 1
- 208000003173 lipoprotein glomerulopathy Diseases 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000026807 lung carcinoid tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000010560 malakoplakia Diseases 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000009242 medullary sponge kidney Diseases 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 201000003694 methylmalonic acidemia Diseases 0.000 description 1
- 108091029111 miR-1283-1 stem-loop Proteins 0.000 description 1
- 108091090307 miR-1283-2 stem-loop Proteins 0.000 description 1
- 108091071809 miR-1283-3 stem-loop Proteins 0.000 description 1
- 108091072878 miR-1289 stem-loop Proteins 0.000 description 1
- 108091073573 miR-1289-1 stem-loop Proteins 0.000 description 1
- 108091036184 miR-1289-2 stem-loop Proteins 0.000 description 1
- 108091040501 miR-129 stem-loop Proteins 0.000 description 1
- 108091050874 miR-19a stem-loop Proteins 0.000 description 1
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 1
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 1
- 108091088477 miR-29a stem-loop Proteins 0.000 description 1
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 1
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 1
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 1
- 108091049902 miR-33a stem-loop Proteins 0.000 description 1
- 108091079013 miR-34b Proteins 0.000 description 1
- 108091084018 miR-34b stem-loop Proteins 0.000 description 1
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 description 1
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 description 1
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 description 1
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 description 1
- 108091040651 miR-371 stem-loop Proteins 0.000 description 1
- 108091048101 miR-374b stem-loop Proteins 0.000 description 1
- 108091063385 miR-526b stem-loop Proteins 0.000 description 1
- 108091056126 miR-769 stem-loop Proteins 0.000 description 1
- 108091062872 miR-892b stem-loop Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 206010031129 orthostatic proteinuria Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940090668 parachlorophenol Drugs 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010059929 phospholamban Proteins 0.000 description 1
- 102000005681 phospholamban Human genes 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 208000002212 pyonephrosis Diseases 0.000 description 1
- 108010032037 rab5 GTP-Binding Proteins Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000006292 refeeding syndrome Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 206010038351 renal abscess Diseases 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 101150005766 rns gene Proteins 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000000470 submucous plexus Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 201000008618 vesicoureteral reflux Diseases 0.000 description 1
- 208000031355 vesicoureteral reflux 1 Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Abstract
The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same. d proteins and isolated nucleic acids encoding the same.
Description
_ 1 _ AAV CAPSID DESIGNS RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. § ll9(e) of the filing date of US. provisional application serial numbers USSN 62/486,642, filed April 18, 2017, entitled "AAV CAPSID S", 62/417,756, filed November 4, 2016, ed "AAV CAPSID DESIGNS", and 62/408,022, filed October 13, 2016, entitled "AAV CAPSID DESIGNS", the entire contents of each application which are incorporated herein by reference.
FIELD OF THE DISCLOSURE The disclosure in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno—associated viruses in cells. In some aspects, the disclosure provides novel AAVs and methods of use thereof as well as d kits.
OUND Recombinant AAV adeno—associated viruses (rAAVs) are capable of driving stable and sustained transgene expression in target tissues without notable toxicity and host immunogenicity. Thus, rAAVs are promising delivery vehicles for long—term therapeutic gene expression. However, low uction ency and restricted tissue ms by currently available rAAV s can limit their application as feasible and efficacious therapies. Additionally, faithful clinical translation of leading therapeutic AAV serotypes derived from non—human tissues is a concern. Accordingly, a need remains for new AAV vectors for gene delivery.
SUMMARY The disclosure in some aspects relates to novel AAVs for gene therapy applications.
In some embodiments, AAVs described herein comprise amino acid variations in one or more capsid proteins that confer new or enhanced tissue tropism properties. According to some embodiments, variants of AAV2, AAV2/3 (e.g., AAV2/3 hybrid), and AAV8 have been identified and are sed herein that possess useful tissue targeting ties. For example, variants of AAV8 are provided that are useful for transducing cells, such as, human hepatocytes (e.g., present in liver ), central nervous system cells (CNS cells), and others. Variants of AAV2, AAV2/3 (e.g., AAV2/3 hybrid), and AAV8 are provided that, in _ 2 _ some embodiments, are useful for targeting cells of the ocular tissue (e.g., the eye), gastrointestinal tract, respiratory , breast tissue, pancreatic tissue, y tract tissue, uterine tissue, tissue associate with certain cancers (e.g., breast cancer, prostate cancer, etc), and other tissues. In some embodiments, the variant AAVs bed herein target tissue other than the tissue ed by their corresponding wild—type AAVs.
The disclosure in some aspects provides an ed nucleic acid comprising a sequence encoding a polypeptide selected from the group consisting of: SEQ ID NO: 1—409, 435—868, and 1726—1988, which encodes an AAV capsid protein. In some embodiments, a fragment of the isolated nucleic acid is provided. In certain embodiments, the fragment of the isolated nucleic acid does not encode a peptide that is identical to a ce of any one of SEQ ID NOs: 869, 870, or 871.
In some aspects, the disclosure provides a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO: 410—434, 876—1718, and 1989—2251. In some embodiments, the nucleic acid s an AAV capsid protein, or a variant thereof and/or an AAV assembly—activating protein (AAP), or a variant thereof. In some embodiments, the AAP is in a different open reading frame of the nucleic acid than the AAV capsid protein. In some embodiments, the AAP is AAV2 AAP (AAP—2), or variant thereof.
The disclosure in some aspects provides an isolated AAV capsid protein comprising an amino acid sequence ed from the group consisting of: SEQ ID NOs: 1—409, 435—868, and 1726—1988. In some embodiments, the isolated AAV capsid protein comprises a sequence selected from: SEQ ID NOs: 1—409, 837—852 or 1726—1814, wherein an amino acid of the sequence that is not identical to a corresponding amino acid of the sequence set forth as SEQ ID NO: 869 is replaced with a conservative substitution.
In some s, the disclosure provides AAV2/3 hybrid capsid proteins. In some embodiments, the isolated AAV capsid protein comprises a sequence selected from: SEQ ID NOs: 435—628 and 1815—1988, wherein an amino acid of the sequence that is not identical to a ponding amino acid of the sequence set forth as SEQ ID NO: 869 or 870 is ed with a conservative substitution.
In some embodiments, the isolated AAV capsid protein comprises a sequence selected from: SEQ ID NOs: 6 or 853—868, wherein an amino acid of the sequence that is not identical to a corresponding amino acid of the sequence set forth as SEQ ID NO: 871 is replaced with a conservative substitution. _ 3 _ In certain aspects of the disclosure, a composition is provided that comprises any of the foregoing isolated AAV capsid proteins. In some embodiments, the composition further comprises a pharmaceutically acceptable r. In some embodiments a composition of one or more of the isolated AAV capsid proteins of the disclosure and a physiologically compatible carrier is provided.
In certain aspects of the disclosure, a recombinant AAV (rAAV) is provided that comprises any of the foregoing isolated AAV capsid proteins. In some ments, a composition comprising the rAAV is provided. In certain embodiments, the composition sing the rAAV further ses a pharmaceutically acceptable carrier. A recombinant AAV is also provided, wherein the recombinant AAV includes one or more of the isolated AAV capsid proteins of the disclosure.
In some aspects of the disclosure, a host cell is provided that contains a nucleic acid that comprises a coding sequence ed from the group consisting of: SEQ ID NO: 410— 434, 876—1718 and 1989—225 1, that is operably linked to a promoter. In some embodiments, a ition comprising the host cell and a sterile cell culture medium is provided. In some ments, a composition comprising the host cell and a cryopreservative is provided.
According to some aspects of the disclosure, a method for delivering a transgene to a subject is provided. In some embodiments, the method ses stering any of the foregoing rAAVs to a subject, wherein the rAAV comprises at least one transgene, and wherein the rAAV infects cells of a target tissue of the subject. In some embodiments, subject is selected from a mouse, a rat, a rabbit, a dog, a cat, a sheep, a pig, and a non—human primate. In one embodiment, the subject is a human.
In some ments, the at least one transgene is a protein coding gene. In certain ments, the at least one transgene encodes a small interfering nucleic acid. In certain embodiments, the small interfering nucleic acid is a miRNA. In certain embodiments, the small ering nucleic acid is a miRNA sponge or TuD RNA that inhibits the activity of at least one miRNA in the subject. In n embodiments, the miRNA is expressed in a cell of the target tissue In certain ments, the target tissue is liver, central nervous system (CNS), ocular, gastrointestinal, respiratory, , pancreas, urinary tract, or uterine tissue.
In some embodiments, the transgene expresses a transcript that comprises at least one binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than the target tissue, by hybridizing to the binding site. _ 4 _ In certain embodiments, the rAAV is administered to the subject intravenously, transdermally, intraocularly, intrathecally, intracererbally, orally, intramuscularly, subcutaneously, asally, or by inhalation.
According to some aspects of the disclosure, a method for generating a somatic transgenic animal model is provided. In some embodiments, the method comprises stering any of the foregoing rAAVs to a non—human animal, wherein the rAAV ses at least one transgene, and wherein the rAAV s cells of a target tissue of the man animal.
In some embodiments, the transgene is at least one protein coding gene. In certain embodiments, the transgene encodes at least one small interfering nucleic acid. In some embodiments, the transgene encodes at least one reporter molecule. In certain embodiments, the small interfering nucleic acid is a miRNA. In certain embodiments, the small interfering nucleic acid is a miRNA sponge or TuD RNA that inhibits the activity of at least one miRNA in the animal. In certain embodiments, the miRNA is expressed in a cell of the target tissue In certain embodiments, the target tissue is liver, central nervous system (CNS), ocular, gastrointestinal, respiratory, breast, pancreas, y tract, or uterine tissue.
In some embodiments, the transgene expresses a transcript that ses at least one binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than the target tissue, by hybridizing to the g site.
According to some s of the disclosure, s are provided for generating a c transgenic animal model that comprise administering any of the foregoing rAAVs to a non—human animal, n the rAAV comprises at least one transgene, wherein the transgene expresses a transcript that comprises at least one binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than a target tissue, by hybridizing to the binding site of the transcript.
In some embodiments, the transgene comprises a tissue specific promoter or inducible promoter. In certain embodiments, the tissue specific promoter is a liver—specific thyroxin binding in (TBG) er, an insulin promoter, a on promoter, a somatostatin promoter, mucin—2 promoter, a pancreatic polypeptide (PPY) promoter, a synapsin—l (Syn) promoter, a retinoschisin promoter, a K12 promoter, a CClO promoter, a surfactant protein C (SP—C) promoter, a PRCl promoter, a RRM2 er, uroplakin 2 (UPII) promoter, or a lactoferrin promoter. _ 5 _ In certain embodiments, the rAAV is administered to the animal intravenously, transdermally, intraocularly, intrathecally, orally, intramuscularly, subcutaneously, asally, or by inhalation. According to some s of the disclosure, a somatic transgenic animal model is provided that is produced by any of the foregoing methods.
In other aspects of the disclosure, a kit for producing a rAAV is provided. In some embodiments, the kit comprises a container housing an isolated nucleic acid having a ce of any one of SEQ ID NO: 410—434, 876—1718, and 1989—2251. In some embodiments, the kit comprises a container housing an isolated nucleic acid encoding a polypeptide having a sequence of any one of SEQ ID NO: l—409, 435—868, or 1726—1988. In some embodiments, the kit further comprises instructions for producing the rAAV. In some embodiments, the kit further comprises at least one container housing a recombinant AAV vector, wherein the inant AAV vector comprises a transgene.
In other aspects of the disclosure, a kit is provided that ses a container housing a recombinant AAV having any of the foregoing isolated AAV capsid proteins. In some embodiments, the container of the kit is a syringe.
In other aspects, the disclosure relates to the use of AAV based vectors as vehicles for, delivery of genes, eutic, prophylactic, and research purposes as well as the development of somatic transgenic animal models.
In some s, the disclosure relates to AAV serotypes that have demonstrated distinct /cell type tropism and can achieve stable somatic gene transfer in animal tissues at levels similar to those of adenoviral vectors (e.g., up to 100% in viva tissue transduction depending upon target tissue and vector dose) in the e of vector related toxicology. In other aspects, the disclosure relates to AAV serotypes having liver, central nervous system (CNS), ocular, gastrointestinal, respiratory, breast, pancreas, urinary tract, or e tissue— targeting lities. These tissues are associated with a broad spectrum of human diseases including neurological, metabolic, diabetic, ocular, respiratory, gastrointestinal, urinary tract, and reproductive diseases and certain cancers.
In some ments the rAAV includes at least one transgene. The ene may be one which causes a pathological state. In some embodiments, the transgene encoding a protein that treats a pathological state.
In another aspect the novel AAVs of the disclosure may be used in a method for delivering a transgene to a subject. The method is performed by administering a rAAV of the _ 6 _ disclosure to a subject, wherein the rAAV comprises at least one transgene. In some embodiments the rAAV targets a predetermined tissue of the subject.
In r aspect the AAVs of the disclosure may be used in a method for generating a somatic transgenic animal model. The method is performed by administering a rAAV of the disclosure to an animal, wherein the rAAV comprises at least one transgene, n the transgene causes a pathological state, and wherein the rAAV targets a predetermined tissue of the animal.
The transgene may express a number of genes including cancer related genes, pro— apoptotic genes and apoptosis—related genes. In some embodiments the transgene expresses a small ering nucleic acid capable of inhibiting expression of a cancer d gene. In other embodiments the transgene expresses a small interfering nucleic acid capable of inhibiting expression of an apoptosis—related gene. The small interfering nucleic acid in other embodiments is a miRNA or shRNA. ing to other ments the transgene expresses a toxin, optionally wherein the toxin is DTA. In other ments the transgene expresses a reporter gene that is optionally a reporter enzyme, such as alactosidase or a Fluorescent protein, such as GFP or luciferase.
The transgene may express a miRNA. In other embodiments the transgene expresses a miRNA , wherein miRNA sponge inhibits the activity of one or more miRNAs in the animal. The miRNA may be an endogenous miRNA or it may be expressed in a cell of a liver, central nervous system (CNS), ocular, gastrointestinal, respiratory, breast, pancreas, urinary tract, or uterine tissue, in some embodiments.
The rAAV may transduce many ent types of tissue, such as neurons, squamous epithelial cells, renal proximal or distal convoluted tubular cells, mucosa gland cells, blood vessel endothelial cells, endometrial cells, retinal cells, or certain cancer cells (e.g., breast cancer cells, prostate cancer cells, etc).
In some embodiments the rAAV is administered at a dose of 1010, 1011, 1012, 1013, 1014, or 1015 genome copies per subject. In some embodiments the rAAV is administered at a dose of 1010, 1011, 1012, 1013, or 1014 genome copies per kg. The rAAV may be administered by any route. For instance it may be administered intravenously (e.g., by portal vein injection) in some embodiments.
In some embodiments the transgene includes a tissue specific promoter such as a liver—specific thyroxin binding globulin (TBG) promoter, an n promoter, a glucagon _ 7 _ promoter, a somatostatin er, mucin—2 promoter, a pancreatic polypeptide (PPY) promoter, a synapsin—l (Syn) promoter, a retinoschisin promoter, a K12 promoter, a CClO promoter, a surfactant protein C (SP—C) promoter, a PRCl promoter, a RRM2 promoter, uroplakin 2 (UPII) promoter, or a lactoferrin promoter.
The somatic enic animal model may be a mammal, such as a mouse, a rat, a rabbit, a dog, a cat, a sheep, a pig, a non—human primate.
In some embodiments a putative therapeutic agent may be administered to the somatic enic animal model to determine the effect of the putative therapeutic agent on the pathological state in the animal.
In another aspect the disclosure is a somatic transgenic animal produced by the methods described herein.
A kit for producing a rAAV that generates a somatic transgenic animal having a pathological state in a ermined tissue is provided according to another aspect of the disclosure. The kit es at least one container g a recombinant AAV vector, at least one container housing a rAAV packaging component, and instructions for constructing and packaging the recombinant AAV.
The rAAV packaging ent may include a host cell expressing at least one rep gene and/or at least one cap gene. In some ments the host cell is a 293 cell. In other embodiments the host cell expresses at least one helper virus gene product that affects the production of rAAV ning the recombinant AAV vector. The at least one cap gene may encode a capsid protein from an AAV serotype that targets the ermined tissue.
In other ments a rAAV packaging ent includes a helper virus optionally wherein the helper virus is an adenovirus or a herpes virus.
The rAAV vector and components therein may include any of the elements described herein. For ce, in some embodiments the rAAV vector comprises a transgene, such as any of the transgenes described herein. In some embodiments the transgene expresses a miRNA inhibitor (e.g., a miRNA sponge or TuD RNA), wherein miRNA inhibitor inhibits the activity of one or more miRNAs in the somatic transgenic animal.
Each of the limitations of the disclosure can encompass various embodiments of the sure. It is, therefore, anticipated that each of the limitations of the disclosure involving any one element or combinations of elements can be included in each aspect of the disclosure. This disclosure is not limited in its application to the details of construction and _ 8 _ the arrangement of components set forth in the following description or illustrated in the drawings. The disclosure is capable of other embodiments and of being practiced or of being carried out in various ways.
BRIEF DESCRIPTION OF THE DRAWINGS FIGs. lA—lB show workflow tics for the identification of AAV variants. s high—throughput detection of novel AAV ts in selected human tissues.
Proviral capsid sequences are amplified using ycle PCR, followed by low—cycle PCR to barcode the amplicon libraries for multiplexed single—molecule, real—time (SMRT) cing. shows a summary of the ne for bioinformatics analysis of sequencing data.
FIGs. 2A—2D show data relating to in viva detection of FFLuc transgene activity with different administrations of selected AAV8 variants. shows rase activities of different AAV8 variants were evaluated at week 6 after IV (intravenous), IM (intramuscular), or IN (intranasal) injection. FIGs. 2B—2D data relating to tion of FFLuc activity for each variant, B2 (), B3 (), and B61 (), compared to AAV8 (meaniSD, n=3, t test).
FIGs. 3A—3B show data relating to evaluation of FFLuc transgene activity delivered by the AAV8 variant B61 compared to AAV9 at day 21 after neonatal injection. Luciferase activities and genome copies of brain () and spinal cord () were detected (meaniSD, n=5, t test).
FIGs. 4A—4B show data relating to in viva detection of FFLuc ene activity after right hindlimb uscular (IM) injection of the AAV8 variant B44 compared to AAV8. shows whole animal Luciferase expression of variant B44 was evaluated at week 6 after IM injection. shows evaluation of muscle (RTA, right tibialis anterior; LTA, left tibialis anterior), liver, and heart. Luciferase activities (left bar graph) and relative ratios (right bar graph) for B44 compared to AAV8 (meaniSD, n=3). shows a phylogenic comparison of AAV8 variants (B2, B3, B6l) to other AAV serotypes. shows a schematic depiction of a workflow for the in viva characterization of novel AAV variants by high—throughput tropism screening. _ 9 _ shows a schematic depiction of a workflow for the NHP characterization of novel AAV variants by high—throughput tropism screening. shows a scatter plot displaying the distribution of ct AAV2 capsid variants (409 total) and AAV2/3 variants (194 total) harboring one or more —amino—acid variants. shows diagrams of vector constructs used in the multiplexed screening of discovered capsid variants. Unique 6—bp barcodes were cloned into transgenes and packaged into candidate capsid variants. shows a schematic of an d transgene and high—throughput sequencing library design to assess capsid variant tropism profiling. The indexed and adapter cassette containing a 6—bp barcode (1° barcode) and a BstEII restriction site can be cloned into vector constructs using flanking BerI and SacI sites. Whole crude DNA from rAAV—treated tissues containing both host genome and vector genomes was cut with BstEII enzyme. The resulting ’— overhang was used to ically ligate to an adapter containing a second barcode, which allows for further multiplexed cing and streamlining; and a 5’—biotin modification, which can be used to select for adapter—containing fragments using magnetic bead enrichment. Enriched material can then undergo PCR amplification using primers ic to r and transgene sequences to produce ies for high—throughput sequencing. SEQ ID NOs.: 1719—1725 are shown from top to bottom.
DETAILED DESCRIPTION Adeno—associated virus (AAV) is a small (~26 nm) replication—defective, non— enveloped virus that generally depends on the presence of a second virus, such as adenovirus or herpes virus, for its growth in cells. AAV is not known to cause disease and induces a very mild immune response. AAV can infect both dividing and non—dividing cells and may incorporate its genome into that of the host cell. These features make AAV a very attractive candidate for ng viral vectors for gene therapy. Prototypical AAV vectors based on serotype 2 provided a proof—of—concept for non—toxic and stable gene transfer in murine and large animal models, but exhibited poor gene transfer efficiency in many major target s.
The disclosure in some aspects seeks to overcome this shortcoming by ing novel AAVs having distinct tissue targeting capabilities for gene therapy and research applications.
WO 71831 _ 10 _ In some aspects of the disclosure new AAV capsid proteins are provided that have distinct tissue targeting capabilities. In some embodiments, an AAV capsid protein is isolated from the tissue to which an AAV comprising the capsid protein targets. In some aspects, methods for delivering a transgene to a target tissue in a subject are provided. The transgene delivery methods may be used for gene therapy (e.g., to treat disease) or research (e. g., to create a somatic enic animal model) applications.
Methods for Discovering AAVs Much of the biology of AAV is influenced by its capsid. Consequently, methods for discovering novel AAVs have been largely focused on isolating DNA sequences for AAV capsids. A central feature of the adeno—associated virus (AAV) latent life cycle is persistence in the form of integrated and/or episomal genomes in a host cell. Methods used for isolating novel AAV include PCR based molecular rescue of latent AAV DNA genomes, infectious virus rescue of latent proviral genome from tissue DNAs in vitro in the presence of adenovirus helper function, and rescue of ar proviral genome from tissue DNAs by rolling—circle—linear amplification, mediated by an rmal phage Phi—29 polymerase. All of these isolation methods take advantage of the latency of AAV proviral DNA genomes and focus on rescuing persistent viral genomic DNA.
In some aspects, the sure relates to the discovery that novel AAV variants with desirable tissue tropisms can be identified from in vivo tissues of a subject. Without Wishing to be bound by any particular theory, the use of in vivo tissue ts the natural oir of genomic diversity observed among viral genomic sequences isolated from both normal and tumor tissues of a subject. Thus in some embodiments, in vivo tissues act as natural incubators for viral (e.g., viral capsid protein) diversity through ive pressure and/or immune evasion.
In some aspects, the sure s to the discovery that PCR products resulting from amplification of AAV DNA (e.g., AAV DNA isolated or extracted from a host cell or in vivo tissue of a subject) can be subjected to high—throughput single—molecule, real—time (SMRT) sequencing to identify novel capsid protein ts. As used herein, e— molecule, real—time (SMRT) sequencing" refers to a parallelized single le sequencing method, for example as described by Roberts et al. (2013) Genome Biology 14:405, doi: 10.1 —2013—l4—7—405. Without Wishing to be bound by any particular theory, the use of SMRT sequencing removes the need to m viral genome reconstruction and chimera prediction from aligned read fragments obtained from other conventional high— throughput genome sequencing methodologies.
Endogenous latent AAV genomes are transcriptionally active in mammalian cells (e. g., cells of nonhuman primate tissues such as liver, spleen and lymph nodes). Without Wishing to be bound by theory, it is hypothesized that to maintain AAV persistence in host, low levels of transcription from AAV genes could be required and the resulting cap RNA could serve as more suitable and abundant substrates to retrieve functional cap sequences for vector development. Both rep and cap gene transcripts are detected with variable abundances by RNA detection methods (e.g., ). The presence of cap gene ripts and ability to generate cDNA of cap RNA through e transcription (RT) in vitro significantly increases abundance of templates for PCR—based rescue of novel cap sequences from tissues and enhances the sensitivity of novel AAV discovery.
Novel cap sequences may also be identified by transfecting cells with total cellular DNAs isolated from the tissues that harbor proviral AAV genomes at very low abundance, The cells may be further transfected with genes that provide helper virus function (e.g., adenovirus) to r and/or boost AAV gene transcription in the transfected cells. In some ments, novel cap sequences of the disclosure may be identified by isolating cap mRNA from the transfected cells, creating cDNA from the mRNA (e.g., by RT—PCR) and sequencing the cDNA.
Isolated Capsid Proteins and Nucleic Acids Encoding the Same AAVs ed from mammals, ularly non—human primates, are useful for ng gene transfer s for clinical development and human gene therapy applications.
The disclosure provides in some aspects novel AAVs that have been discovered in s in vivo tissues (e.g., liver, brain, gastric, respiratory, breast, pancreatic, rectal, prostate, ic, and cervical tissues) using the methods disclosed herein. In some embodiments, the tissue(s) in which a novel AAV variant is discovered is a cancerous tissue (e.g., a tumor or a cancer cell). In some embodiments, nucleic acids encoding capsid proteins of these novel AAVs have been discovered in viral genomic DNA isolated from the human tissues. Examples of tissues in which novel AAV capsid proteins have been ered are described in Table l.
Nucleic acid and protein sequences as well as other information regarding the AAVs are set forth in Tables 3—5 and 8, and in the sequence listing.
Isolated nucleic acids of the disclosure that encode AAV capsid proteins include any nucleic acid having a sequence as set forth in any one of SEQ ID NOs: 410—435, 876—1718, or 1989—225 1, as well as any nucleic acid having a sequence with ntial homology thereto.
In some ments, isolated nucleic acids of the disclosure include any c acid having a sequence encoding a polypeptide having a sequence as set forth in any one of SEQ ID NOs: 1—409, 435—868, and 1726—1988. In some embodiments, the disclosure provides an isolated nucleic acid that has substantial homology with a nucleic acid having a sequence as set forth in any one of SEQ ID NOs: 410—435, 876—1718, and 1989—2251, but that does not encode a protein having an amino acid sequence as set forth in SEQ ID NOs: 869, 870, or In some embodiments, isolated AAV capsid proteins of the disclosure include any protein having an amino acid sequence as set forth in any one of SEQ ID NOs: 1—409, 837— 852, or 1726—1814 as well as any protein having ntial homology thereto. In some embodiments, the disclosure provides an isolated capsid protein that has ntial homology with a protein having a sequence as set forth in any one of SEQ ID NOs 1—409, 837—852, or 1726—1814, but that does not have an amino acid sequence as set forth in SEQ ID NO: 869.
In some embodiments, isolated AAV capsid proteins of the sure include any protein having an amino acid sequence as set forth in any one of SEQ ID NOs: 435—628 or 1815—1988 as well as any n having substantial homology thereto. In some embodiments, the disclosure provides an ed capsid protein that has substantial homology with a protein having a sequence as set forth in any one of SEQ ID NOs 435—628 or 1815—1988, but that does not have an amino acid sequence as set forth in SEQ ID NO: 869 or 870.
In some embodiments, isolated AAV capsid proteins of the disclosure include any n having an amino acid sequence as set forth in any one of SEQ ID NOs: 629—836 or 8 as well as any protein having substantial homology thereto. In some embodiments, the disclosure provides an isolated capsid protein that has substantial homology with a n having a sequence as set forth in any one of SEQ ID NOs 629—836 or 853-868, but that does not have an amino acid sequence as set forth in SEQ ID NO: 871. _ 13 _ "Homology" refers to the percent identity between two cleotide or two polypeptide moieties. The term "substantial homology", when referring to a c acid, or fragment thereof, indicates that, when lly aligned with appropriate tide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in about 90 to 100% of the aligned sequences. When referring to a polypeptide, or fragment thereof, the term "substantial homology" indicates that, when optimally aligned with appropriate gaps, ions or deletions with another polypeptide, there is tide sequence identity in about 90 to 100% of the aligned sequences. The term "highly conserved" means at least 80% identity, preferably at least 90% identity, and more preferably, over 97% identity. In some cases, highly conserved may refer to 100% identity.
Identity is readily determined by one of skill in the art by, for example, the use of algorithms and er programs known by those of skill in the art.
As described herein, alignments between sequences of nucleic acids or polypeptides are med using any of a y of publicly or commercially available Multiple Sequence Alignment Programs, such as al W", accessible h Web s on the intemet.
Alternatively, Vector NTI ies may also be used. There are also a number of algorithms known in the art that can be used to measure nucleotide sequence identity, including those contained in the programs described above. As another example, polynucleotide sequences can be compared using BLASTN, which provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. Similar ms are available for the comparison of amino acid sequences, e.g., the "Clustal X" program, BLASTP. Typically, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program that provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. Alignments may be used to identify corresponding amino acids between two proteins or peptides. A "corresponding amino acid" is an amino acid of a protein or peptide sequence that has been aligned with an amino acid of another protein or peptide sequence. Corresponding amino acids may be identical or entical. A corresponding amino acid that is a non—identical amino acid may be ed to as a variant amino acid. Table 6 provides examples of variant amino acids.
Alternatively for nucleic acids, homology can be determined by ization of polynucleotides under conditions that form stable duplexes between homologous regions, followed by digestion with single—stranded—specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent ions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the A "nucleic acid" sequence refers to a DNA or RNA sequence. In some ments, the term nucleic acid captures sequences that include any of the known base analogues of DNA and RNA such as, but not limited to 4—acetylcytosine, oxy—N6—methyladenosine, inylcytosine, isocytosine, boxyhydroxyl—methyl) uracil, S—fluorouracil, 5— bromouracil, 5—carboxymethylaminomethyl—2—thiouracil, 5—carboxymethyl— aminomethyluracil, dihydrouracil, inosine, pentenyladenine, l—methyladenine, l— methylpseudo—uracil, l—methylguanine, l—methylinosine, 2,2—dimethyl—guanine, 2— methyladenine, 2—methylguanine, 3—methyl—cytosine, 5—methylcytosine, N6—methyladenine, 7—methylguanine, 5—methylaminomethyluracil, 5—methoxy—amino—methyl—2—thiouracil, beta— D—mannosquueosine, 5'—methoxycarbonylmethyluracil, 5—methoxyuracil, 2—methylthio—N6— isopentenyladenine, uracil—5—oxyacetic acid methylester, uracil—5—oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2—thiocytosine, 5—methyl—2—thiouracil, 2—thiouracil, 4— thiouracil, 5—methyluracil, —uracil—5—oxyacetic acid ester, uracil—5—oxyacetic acid, pseudouracil, queosine, 2—thiocytosine, and 2,6—diaminopurine.
In some embodiments, proteins and nucleic acids of the disclosure are isolated. As used herein, the term "isolated" means artificially obtained or produced. As used herein with respect to nucleic acids, the term "isolated" generally means: (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) ed, as by ge and gel separation; or (iv) sized by, for example, chemical synthesis. An isolated nucleic acid is one that is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which ' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been sed is ered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or _ 15 _ expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a c acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. As used herein with respect to proteins or peptides, the term "isolated" lly refers to a protein or peptide that has been artificially obtained or produced (6.g. , by chemical synthesis, by recombinant DNA technology, etc).
It should be appreciated that conservative amino acid substitutions may be made to provide functionally equivalent variants, or homologs of the capsid proteins. In some aspects the sure embraces sequence alterations that result in conservative amino acid substitutions. As used herein, a conservative amino acid substitution refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ry skill in the art such as are found in references that e such s, e.g., lar Cloning: A tory Manual, J.
Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made among amino acids within the ing groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. Therefore, one can make conservative amino acid substitutions to the amino acid sequence of the proteins and polypeptides disclosed herein.
An example of an isolated nucleic acid that encodes a polypeptide comprising an AAV capsid protein is a nucleic acid having a sequence selected from the group consisting of: SEQ ID NO: 410—434, 876—1718, and 1989—2251. A fragment of an ed nucleic acid encoding an AAV capsid sequence may be useful for constructing a nucleic acid ng a desired capsid sequence. Fragments may be of any appropriate length. In some embodiments, a fragment (portion) of an ed nucleic acid encoding an AAV capsid sequence may be useful for constructing a nucleic acid encoding a desired capsid sequence.
Fragments may be of any appropriate length (e.g., at least 6, at least 9, at least 18, at least 36, at least 72, at least 144, at least 288, at least 576, at least 1152 or more nucleotides in length).
For example, a fragment of nucleic acid sequence encoding a polypeptide of a first AAV capsid protein may be used to construct, or may be incorporated within, a nucleic acid _ l6 _ sequence encoding a second AAV capsid sequence to alter the properties of the AAV capsid.
In some embodiments, AAV capsid proteins that comprise capsid sequence fragments from multiple AAV serotypes are referred to as chimeric AAV capsids. The fragment may be a fragment that does not encode a peptide that is identical to a sequence of any one of SEQ ID NOs: 869, 870, or 871. For example, a fragment of nucleic acid sequence encoding a variant amino acid red with a known AAV serotype) may be used to construct, or may be orated within, a nucleic acid sequence encoding an AAV capsid sequence to alter the ties of the AAV capsid. In some embodiments, a nucleic acid sequence encoding an AAV variant may comprise about 1 to about 100 amino acid variants compared with a known AAV serotype (e.g., AAV serotype 2, AAV2/3 (e.g., AAV2/3 hybrid) or AAVS). In some embodiments, a nucleic acid sequence encoding an AAV variant may comprise about 5 to about 50 amino acid variants compared with a known AAV serotype (e.g., AAV serotype 2, AAV2/3 (e.g., AAV2/3 hybrid) or AAVS). In some ments, a nucleic acid ce encoding an AAV variant may comprise about 10 to about 30 amino acid ts compared with a known AAV serotype (e.g., AAV serotype 2, AAV2/3 (e.g., AAV2/3 hybrid) or AAVS). In some embodiments, a nucleic acid sequence encoding an AAV variant may comprise l, or 2, or 3, or 4, 5, or 6, or 7, or 8, or 9, or 10, or ll, or 12, or 13, or 14, or 15, or 16, or 17, or 18, or 19, or 20 amino acid variants compared with a known AAV serotype (e.g., AAV serotype 2, AAV2/3 (e.g., AAV2/3 hybrid) or AAVS). For example, a nucleic sequence encoding an AAV variant (e.g., SEQ ID NO: 861 may comprise 3 amino acid ts compared with a known AAV serotype (e.g., AAVS). A recombinant cap sequence may be ucted having one or more of the 3 amino acid ts by incorporating fragments of a nucleic acid ce comprising a region encoding a variant amino acid into the sequence of a nucleic acid encoding the known AAV pe. The fragments may be incorporated by any appropriate method, including using site directed mutagenesis. Thus, new AAV variants may be created having new ties.
In some aspects, the sure provides isolated nucleic acids encoding AAV ly—activating proteins (AAPs), or variants thereof. As used herein, an "assembly activating protein" or "AAP" is a protein chaperone that functions to target newly synthesized capsid proteins (e.g., VP proteins, such as AAV VPl, VP2, and VP3) to the nucleolus of a cell thereby promoting encapsidation of viral genomes. Generally, an AAP is encoded in the cap gene of an adeno—associated virus. For example, AAP—2 is encoded in the cap gene of _ 17 _ AAV2. Other examples of AAPs include but are not limited to AAP—l, AAP—3, AAP—4, AAP—5, AAP—8, AAP—9, AAP—ll and AAP—l2, for example as described by Sonntag et al. J.
Virol. 2011 Dec. 85(23): 12686—12697. In some embodiments, an AAP is translated from a different open reading frame (ORF) of the cap gene than a capsid protein (e.g., VPl, VP2, VP3). For example, in some embodiments, a capsid protein (e.g., AAV2 VPl, VP2, VP3) is translated from ORF l of a cap gene and an AAP (e.g., AAP—2) is translated from ORF 2 of the cap gene. In some embodiments, an isolated nucleic acid encoding an AAP comprises or consists of a ce selected from SEQ ID NO: 410—434 and 876—1718.
Recombinant AA Vs In some aspects, the disclosure es isolated AAVs. As used herein with respect to AAVs, the term "isolated" refers to an AAV that has been artificially obtained or produced. Isolated AAVs may be produced using inant methods. Such AAVs are referred to herein as "recombinant AAVs". Recombinant AAVs (rAAVs) preferably have tissue—specific targeting capabilities, such that a transgene of the rAAV will be delivered specifically to one or more ermined tissue(s). The AAV capsid is an important element in determining these tissue—specific targeting lities. Thus, an rAAV having a capsid appropriate for the tissue being targeted can be selected. In some embodiments, the rAAV comprises a capsid protein having an amino acid sequence as set forth in any one of SEQ ID NOs 1—409, 435—852, 859—874, or 988, or a protein having substantial homology Methods for obtaining recombinant AAVs having a d capsid protein are well known in the art. (See, for example, US 2003/0138772), the contents of which are incorporated herein by reference in their entirety). Typically the methods involve culturing a host cell which contains a nucleic acid sequence encoding an AAV capsid protein (e.g., a nucleic acid ng a polypeptide having a sequence as set forth in any one of SEQ ID NOs 1—409, 435—868, or 1726—1988) or fragment thereof; a functional rep gene; a recombinant AAV vector composed of, AAV inverted terminal s (ITRs) and a transgene; and sufficient helper functions to permit ing of the inant AAV vector into the AAV capsid proteins. In some embodiments, capsid proteins are structural proteins encoded by a cap gene of an AAV. In some embodiments, AAVs comprise three capsid proteins, virion proteins 1 to 3 (named VPl, VP2 and VP3), all of which may be expressed from a single cap _ 18 _ gene. Accordingly, in some embodiments, the VP1, VP2 and VP3 proteins share a common core sequence. In some embodiments, the molecular s of VPl, VP2 and VP3 are respectively about 87 kDa, about 72 kDa and about 62 kDa. In some embodiments, upon translation, capsid proteins form a spherical 60—mer n shell around the viral genome. In some embodiments, the protein shell is primarily comprised of a VP3 capsid n. In some embodiments, the ons of the capsid proteins are to protect the viral genome, deliver the genome and interact with the host. In some s, capsid proteins deliver the viral genome to a host in a tissue specific manner. In some embodiments, VPl and/or VP2 capsid proteins may contribute to the tissue tropism of the packaged AAV. In some embodiments, the tissue tropism of the packaged AAV is determined by the VP3 capsid protein. In some ments, the tissue tropism of an AAV is enhanced or changed by mutations occurring in the capsid proteins.
In some aspects, the instant disclosure describes variants of wild—type AAV serotypes In some ments, the variants have altered tissue tropism. In some embodiments, the AAV ts described herein comprise amino acid variations (e.g., substitution, on, insertion) within the cap gene. As discussed above, all three capsid proteins are transcribed from a single cap gene. Accordingly, in some embodiments, an amino acid variation within a cap gene is present in all three capsid proteins encoded by said cap gene. Alternatively, in some embodiments, an amino acid variation may not be present in all three capsid proteins.
In some ments, an amino acid variation occurs only in the VP1 capsid protein. In some embodiments, an amino acid variation occurs only in the VP2 capsid protein. In some embodiments, an amino acid variation occurs only within the VP3 capsid protein. In some embodiments, an AAV t comprises more than one variation in a cap gene. In some embodiments, the more than one variation occur within the same capsid protein (e.g., within VP3). In some embodiments, the more than one variation occur within different capsid proteins (e.g., at least one variation in VP2 and at least one variation in VP3).
In some embodiments, the AAV variants described herein are variants of AAV2, AAV2/3 (e.g., AAV2/3 ) or AAV8. AAV2 is known to efficiently transduce human central nervous system (CNS) tissue, kidney tissue, ocular tissue (e.g., photoreceptor cells and retinal pigment epithelium (RPE)), and other tissues. Accordingly, in some embodiments, the AAV3 variants described herein may be useful for delivering gene therapy to CNS , kidney tissue, or ocular tissue. It is also known that AAV3 efficiently _ 19 _ transduces cancerous human hepatocytes. Accordingly, in some embodiments, the AAV3 variants bed herein may be useful for delivering gene therapy to cancerous and normal human cytes. AAV8 is known to target tissue of the liver , respiratory tissue, and the eye. Accordingly, in some embodiments, the AAV8 variants bed herein may be useful for delivering gene therapy to the liver tissue, respiratory tissue or the eye.
It should be appreciated that the AAV2, AAV2/3 (e.g., AAV2/3 hybrid) and AAV8 variants described herein may comprise one or more variations Within the cap gene compared with a corresponding Wild—type AAV. Therefore, in some ments, the AAV2, AAV2/3 (e.g., AAV2/3 hybrid) and AAV8 variants described herein may have a tissue tropism useful for delivering gene therapy to additional tissue types that are not targeted by Wild—type AAV2, AAV2/3 (e.g., AAV2/3 hybrid) or AAV8. For example, in some embodiments, AAV8 variants described herein (e.g., B61; SEQ ID NO: 865) may be useful for delivering gene therapy to the central nervous system (CNS). In some embodiments, AV2, AAV2/3 (e.g., AAV2/3 hybrid), or AAV8 variants described herein may be useful for targeting cells of the kidney or cells of the liver. In some embodiments, AAV2, AAV2/3 (e.g., AAV2/3 hybrid), or AAV8 variants described herein may be useful for targeting gene therapy to the liver, spleen, heart or brain.
In some aspects, AAV variants described herein may be useful for the treatment of CNS—related disorders. As used herein, a "CNS—related disorder" is a disease or ion of the central nervous system. A CNS—related disorder may affect the spinal cord (e.g., a myelopathy), brain (e.g., a encephalopathy) or tissues surrounding the brain and spinal cord.
A CNS—related disorder may be of a genetic origin, either inherited or acquired through a somatic on. A CNS—related er may be a psychological condition or disorder, e.g., ion Deficient Hyperactivity Disorder, Autism Spectrum Disorder, Mood Disorder, Schizophrenia, Depression, Rett Syndrome, etc. A CNS—related disorder may be an autoimmune er. A CNS—related disorder may also be a cancer of the CNS, e.g., brain cancer. A CNS—related disorder that is a cancer may be a primary cancer of the CNS, e.g., an astrocytoma, glioblastomas, etc, or may be a cancer that has metastasized to CNS tissue, e.g., a lung cancer that has metastasized to the brain. Further non—limiting examples of CNS— related disorders, include Parkinson’s Disease, Lysosomal Storage Disease, Ischemia, Neuropathic Pain, ophic lateral sis (ALS), Multiple Sclerosis (MS), and n disease (CD). _ 20 _ In some embodiments, AAV variants described herein may be useful for delivering gene therapy to cardiac cells (e.g., heart tissue). Accordingly, in some embodiments, AAV variants described herein may be useful for the treatment of cardiovascular disorders. As used herein, a "cardiovascular disorder" is a disease or ion of the cardiovascular . A cardiovascular disease may affect the heart, atory system, arteries, veins, blood vessels and/or capillaries. A vascular disorder may be of a genetic , either inherited or acquired h a somatic mutation. Non—limiting examples of cardiovascular disorders e tic heart disease, valvular heart disease, hypertensive heart disease, aneurysm, atherosclerosis, hypertension (e.g., high blood pressure), peripheral arterial e (PAD), ischemic heart e, angina, coronary heart disease, ry artery disease, myocardial tion, cerebral vascular disease, transient ischemic attack, inflammatory heart disease, cardiomyopathy, pericardial disease, congenital heart disease, heart failure, stroke, and myocarditis due to Chagas disease.
In some embodiments, AAV variants described herein may target the lung and/or tissue of the pulmonary system (e.g., respiratory system). Accordingly, in some embodiments, AAV variants described herein may be useful for treatment of pulmonary disease. As used herein a "pulmonary disease" is a disease or condition of the pulmonary system. A pulmonary disease may affect the lungs or s involved in breathing. A pulmonary disease may be of a genetic origin, either inherited or acquired through a somatic mutation. A pulmonary disease may be a cancer of the lung, including but not limited to, non—small cell lung cancer, small cell lung cancer, and lung carcinoid tumor. Further non— limiting es of ary diseases include acute bronchitis, acute respiratory distress me (ARDS), asbestosis, asthma, bronchiectasis, bronchiolitis, iolitis obliterans zing pneumonia (B OOP), bronchopulmonary dysplasia, byssinosis, chronic bronchitis, coccidioidomycosis (Cocci), chronic obstructive pulmonary disorder (COPD), cryptogenic organizing pneumonia (COP), cystic fibrosis, emphysema, Hantavirus Pulmonary Syndrome, lasmosis, Human Metapneumovirus, hypersensitivity pneumonitis, influenza, lymphangiomatosis, mesothelioma, Middle Eastern Respiratory Syndrome, non—tuberculosis Mycobacterium, Pertussis, Pneumoconiosis (Black Lung Disease), pneumonia, primary ciliary dyskinesia, primary pulmonary hypertension, pulmonary arterial hypertension, pulmonary fibrosis, pulmonary vascular disease, Respiratory Syncytial Virus (RSV), sarcoidosis, Severe Acute Respiratory Syndrome (SARS), silicosis, sleep apnea, Sudden Infant Death Syndrome (SIDS), and tuberculosis.
In some ments, AAV variants bed herein may target liver tissue.
Accordingly, in some embodiments, AAV variants described herein may be useful for treatment of hepatic disease. As used herein a "hepatic disease" is a disease or condition of the liver. A hepatic disease may be of a genetic origin, either inherited or acquired through a somatic mutation. A hepatic disease may be a cancer of the liver, including but not limited to hepatocellular carcinoma (HCC), fibrolamellar carcinoma, cholangiocarcinoma, arcoma and blastoma. Further non—limiting examples of pulmonary diseases include Alagille Syndrome, Alpha 1 Anti—Trypsin Deficiency, autoimmune hepatitis, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease, galactosemia, gallstones, Gilbert’s Syndrome, hemochromatosis, liver e in pregnancy, neonatal hepatitis, primary biliary cirrhosis, primary sing cholangitis, ria, Reye’s Syndrome, sarcoidosis, toxic hepatitis, Type 1 Glycogen Storage Disease, tyrosinemia, viral hepatitis A, B, C, Wilson Disease, and schistosomiasis.
In some embodiments, AAV variants described herein may target kidney tissue. ingly, in some embodiments, AAV variants described herein may be useful for treatment of kidney disease. As used herein a "kidney disease" is a disease or condition of the liver. A kidney disease may be of a genetic origin, either inherited or acquired through a somatic mutation. A kidney disease may be a cancer of the kidney, including but not limited to renal cell cancer, clear cell , papillary cancer type 1, papillary cancer type 2, chromophobe cancer, oncocytic cell cancer, collecting duct cancer, transitional cell cancer of the renal pelvis and Wilm’ s tumor. Further non—limiting examples of kidney disease include Abderhalden—Kaufmann—Lignac syndrome (Nephropathic Cystinosis), Acute Kidney e/Acute Kidney Injury, Acute Lobar Nephronia, Acute Phosphate Nephropathy, Acute r Necrosis, Adenine oribosyltransferase Deficiency, Adenovirus Nephritis, Alport Syndrome, Amyloidosis, Angiomyolipoma, Analgesic Nephropathy, Angiotensin Antibodies and Focal Segmental Glomerulosclerosis, Antiphospholipid me, Anti— TNF-Ot Therapy—related ulonephritis, APOLl Mutations, Apparent Mneralocorticoid Excess Syndrome, lochic Acid Nephropathy, Balkan Endemic Nephropathy, Bartter Syndrome, Beeturia, B—Thalassemia Renal Disease, Bile Cast Nephropathy, BK Polyoma, Clq pathy, Cardiorenal me, CFHRS nephropathy, Cholesterol Emboli, Churg— Strauss syndrome, Chyluria, Collapsing Glomerulopathy, Collapsing Glomerulopathy Related to CMV, Congenital Nephrotic Syndrome, Conorenal syndrome (Mainzer—Saldino Syndrome or Saldino—Mainzer Disease), Contrast Nephropathy, Copper Sulfate Intoxication, Cortical Necrosis, obuinemia, Crystal—Induced Acute Kidney injury, Cystic Kidney Disease, ed, uria, Dense Deposit Disease (MPGN Type 2), Dent Disease (X— linked Recessive Nephrolithiasis), Dialysis Disequilibrium Syndrome, Diabetic Kidney Disease, Diabetes Insipidus, EAST syndrome, Ectopic Ureter, Edema, Erdheim—Chester Disease, Fabry’s Disease, Familial Hypocalciuric Hypercalcemia, i Syndrome, Fraser syndrome, Fibronectin ulopathy, Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy, Fraley syndrome, Focal Segmental Glomerulosclerosis, Focal Sclerosis, Focal Glomerulosclerosis, Galloway Mowat syndrome, Gitelman Syndrome, Glomerular Diseases, Glomerular Tubular Reflux, Glycosuria, Goodpasture Syndrome, Hemolytic Uremic Syndrome (HUS), al tic Uremic Syndrome (aHUS), Hemophagocytic Syndrome, Hemorrhagic Cystitis, Hemosiderosis d to Paroxysmal Nocturnal Hemoglobinuria and Hemolytic Anemia, Hepatic Veno—Occlusive Disease, Sinusoidal Obstruction Syndrome, Hepatitis C—Associated Renal e, Hepatorenal Syndrome, HIV— Associated Nephropathy ), Horseshoe Kidney (Renal Fusion), Hunner's Ulcer, Hyperaldosteronism, alcemia, alemia, Hypermagnesemia, Hypematremia, Hyperoxaluria, Hyperphosphatemia, Hypocalcemia, Hypokalemia, Hypokalemia—induced renal dysfunction, Hypomagnesemia, Hyponatremia, Hypophosphatemia, IgA Nephropathy, IgG4 Nephropathy, Interstitial Cystitis, Painful Bladder Syndrome, Interstitial Nephritis, k's syndrome, Kidney , Nephrolithiasis, pirosis Renal e, Light Chain Deposition Disease, Monoclonal Immunoglobulin Deposition Disease, Liddle Syndrome, Lightwood—Albright Syndrome, Lipoprotein Glomerulopathy, Lithium Nephrotoxicity, LMXlB Mutations Cause Hereditary FSGS, Loin Pain Hematuria, Lupus, ic Lupus Erythematosis, Lupus Kidney Disease, Lupus tis, Lyme Disease— Associated ulonephritis, Malarial Nephropathy, Malignant Hypertension, Malakoplakia, Meatal Stenosis, Medullary Cystic Kidney Disease, Medullary Sponge Kidney, Megaureter, Melamine Toxicity and the Kidney, Membranoproliferative Glomerulonephritis, Membranous Nephropathy, MesoAmerican Nephropathy, Metabolic Acidosis, Metabolic Alkalosis, Microscopic Polyangiitis, Milk—alkalai syndrome, Minimal Change Disease, Multicystic dysplastic kidney, Multiple Myeloma, Myeloproliferative _ 23 _ Neoplasms and Glomerulopathy, Nail—patella Syndrome, Nephrocalcinosis, Nephrogenic Systemic is, ptosis (Floating Kidney, Renal Ptosis), Nephrotic Syndrome, Neurogenic Bladder, Nodular Glomerulosclerosis, Non—Gonococcal, Nutcracker syndrome, Orofaciodigital Syndrome, Orthostatic Hypotension, Orthostatic Proteinuria, Osmotic Diuresis, Page , Papillary Necrosis, Papillorenal Syndrome (Renal—Coloboma Syndrome, Isolated Renal asia), The Peritoneal—Renal Syndrome, Posterior Urethral Valve, Post—infectious Glomerulonephritis, Post—streptococcal Glomerulonephritis, Polyarteritis Nodosa, Polycystic Kidney Disease, Posterior Urethral Valves, Preeclampsia, Proliferative Glomerulonephritis with Monoclonal IgG Deposits (Nasr Disease), Proteinuria (Protein in Urine), Pseudohyperaldosteronism, hypoparathyroidism, ary—Renal me, Pyelonephritis (Kidney Infection), Pyonephrosis, ion Nephropathy, Refeeding syndrome, Reflux Nephropathy, Rapidly Progressive Glomerulonephritis, Renal Abscess, Peripnephric Abscess, Renal Agenesis, Renal Artery Aneurysm, Renal Artery Stenosis, Renal Cell Cancer, Renal Cyst, Renal Hypouricemia with Exercise—induced Acute Renal Failure, Renal tion, Renal Osteodystrophy, Renal Tubular Acidosis, Reset Osmostat, Retrocaval Ureter, Retroperitoneal Fibrosis, Rhabdomyolysis, Rhabdomyolysis related to Bariatric Sugery, Rheumatoid Arthritis—Associated Renal e, Sarcoidosis Renal Disease, Salt Wasting, Renal and Cerebral, Schimke immuno—osseous dysplasia, Scleroderma Renal Crisis, Serpentine Fibula—Polycystic Kidney me, Exner Syndrome, Sickle Cell Nephropathy, Silica Exposure and Chronic Kidney Disease, Kidney Disease ing Hematopoietic Cell Transplantation, Kidney e Related to Stem Cell Transplantation, Thin Basement Membrane Disease, Benign Familial Hematuria, Trigonitis, Tuberous Sclerosis, Tubular Dysgenesis, Tumor Lysis Syndrome, Uremia, Uremic Optic Neuropathy, Ureterocele, Urethral Caruncle, Urethral Stricture, Urinary Incontinence, Urinary Tract Infection, Urinary Tract Obstruction, intestinal Fistula, Vesicoureteral Reflux, Von Hippel—Lindau e, Warfarin—Related pathy, Wegener’s Granulomatosis, omatosis with Polyangiitis, and Wunderlich syndrome.
In some embodiments, AAV variants described herein may be useful for delivering gene therapy to ocular tissue (e.g., tissue or cells of the eye). Accordingly, in some embodiments, AAV variants bed herein may be useful for the treatment of ocular disorders. As used herein, an "ocular disorder" is a disease or ion of the eye. An ocular disease may affect the eye, sclera, cornea, anterior chamber, posterior chamber, iris, _ 24 _ pupil, lens, vitreous humor, retina, or optic nerve. An ocular disorder may be of a genetic origin, either inherited or acquired through a somatic on. Non—limiting examples of ocular diseases and disorders include but are not limited to: age—related macular degeneration, retinopathy, diabetic retinopathy, macular edema, glaucoma, retinitis tosa and eye cancer.
In some embodiments, AAV variants described herein may be useful for delivering gene therapy to gastrointestinal tissue (e.g., tissue of the intestinal tract). Accordingly, in some embodiments, AAV ts described herein may be useful for the treatment of gastrointestinal tract disorders. As used herein, a "gastrointestinal tract disorder" is a disease or ion of the gastrointestinal tract. A gastrointestinal disease may affect the mucosa (e.g., epithelium, lamina propria, muscularis mucosae, eta), submucosa (e.g., submucous plexus, enteric nervous , eta), muscular layer of the gastrointestinal tract, the serosa and/or adventitia, oral cavity, esophagus, pylorus, stomach duodenum, small intestine, caecum, appendix, colon, anal canal, or rectum. A gastrointestinal tract disorder may be of a genetic , either ted or ed h a somatic mutation. Non—limiting examples of gastrointestinal tract diseases and disorders e but are not limited to: inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis, irritable bowel syndrome, Celiac disease, gastroesophageal reflux disease (GERD), sua, diverticulitus, diarrhea, and certain cancers (e.g., bowel cancer, h cancer, colon cancer, rectal , etc.) In some embodiments, AAV variants described herein may be useful for delivering gene therapy to breast tissue (e.g., tissue of the breast). Accordingly, in some embodiments, AAV variants described herein may be useful for the treatment of breast disorders. As used herein, a "breast disorder" is a disease or condition of the breast. A breast disease may affect the fibrous tissue, fatty tissue, lobules, or ducts of the breast. A breast disorder may be of a genetic origin, either ted or acquired through a somatic on. Non—limiting examples of breast diseases and disorders include but are not limited to: mastitis, breast calcification, fat necrosis, fibroadenoma, fibrosis and simple cysts, galactorrhea, hyperplasia and breast cancer.
In some embodiments, AAV variants described herein may be useful for delivering gene therapy to pancreatic tissue (e.g., tissue of the pancreas). Accordingly, in some embodiments, AAV variants described herein may be useful for the treatment of pancreatic _ 25 _ disorders. As used herein, a "pancreatic er" is a disease or condition of the pancreas.
A pancreatic disease may affect the head of the pancreas, neck of the pancreas, body of the pancreas, tail of the pancreas, pancreatic islets (e.g., islets of Langerhans), acini, or columnar epithelium. A pancreatic disorder may be of a genetic origin, either inherited or acquired through a somatic mutation. Non—limiting examples of pancreatic diseases and disorders include but are not limited to: es (e.g., diabetes mellitus type 1 and diabetes mellitus type 2), pancreatitis (e.g., acute pancreatitis, chronic pancreatitis), and pancreatic cancer.
In some embodiments, AAV variants described herein may be useful for delivering gene therapy to urinary tract tissue (e.g., tissue of the urinary tract, such as bladder tissue). ingly, in some embodiments, AAV variants described herein may be useful for the ent of urinary tract disorders. As used herein, a "urinary tract disorder" is a disease or condition of the urinary tract. A y tract disease may affect the bladder, ureters, urethera, or prostate. A urinary tract disorder may be of a genetic origin, either inherited or ed h a somatic mutation. miting examples of y tract diseases and disorders include but are not limited to: urinary tract infections, kidney stones, bladder control problems (e.g., urinary retention, urinary incontinence, eta), cystitis, and r cancer.
In some embodiments, AAV variants described herein may be useful for delivering gene therapy to uterine tissue (e.g., tissue of the uterus). Accordingly, in some embodiments, AAV variants described herein may be useful for the treatment of uterine disorders. As used herein, a "uterine disorder" is a disease or ion of the uterus. A uterine disease may affect the cervix, cervical canal, body of the uterus (fundus), trium, myometrium, or perimetrium. A e disorder may be of a genetic origin, either inherited or acquired through a somatic mutation. Non—limiting es of uterine diseases and ers include but are not limited to: adenomyosis, endometriosis, endometrial hyperplasia, Asherman’ s syndrome, and endometrial cancer.
The components to be cultured in the host cell to package a rAAV vector in an AAV capsid may be provided to the host cell in trans. Alternatively, any one or more of the ed components (e.g., recombinant AAV vector, rep sequences, cap sequences, and/or helper functions) may be provided by a stable host cell which has been ered to contain one or more of the required components using methods known to those of skill in the art.
Most suitably, such a stable host cell Will contain the required component(s) under the control _ 26 _ of an inducible promoter. However, the required component(s) may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein, in the discussion of regulatory elements suitable for use with the transgene.
In still another alternative, a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the l of one or more ble promoters. For example, a stable host cell may be generated which is derived from 293 cells (which contain El helper functions under the control of a constitutive promoter), but which contain the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.
The recombinant AAV , rep sequences, cap sequences, and helper functions required for producing the rAAV of the disclosure may be delivered to the packaging host cell using any appropriate genetic element (vector). In some embodiments, a single nucleic acid encoding all three capsid ns (e.g., VPl, VP2 and VP3) is red into the packaging host cell in a single . In some embodiments, nucleic acids encoding the capsid proteins are delivered into the packaging host cell by two vectors; a first vector comprising a first nucleic acid encoding two capsid proteins (e.g., VPl and VP2) and a second vector comprising a second nucleic acid encoding a single capsid protein (e.g., VP3).
In some embodiments, three vectors, each comprising a nucleic acid encoding a different capsid protein, are delivered to the ing host cell. The selected genetic t may be delivered by any le method, ing those described . The methods used to construct any embodiment of this sure are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic ques. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a tion on the present disclosure. See, e.g., K. Fisher et al, J. Virol., 70:520—532 (1993) and US. Pat. No. 5,478,745.
In some embodiments, recombinant AAVs may be produced using the triple transfection method (described in detail in US. Pat. No. 6,001,650). Typically, the recombinant AAVs are produced by transfecting a host cell with a recombinant AAV vector (comprising a transgene) to be packaged into AAV les, an AAV helper on vector, and an accessory function vector. An AAV helper function vector encodes the "AAV helper function" sequences (6.g. and cap), which function in trans for productive AAV , rep replication and encapsidation. Preferably, the AAV helper function vector supports ent AAV vector production without generating any detectable wild—type AAV virions (e.g., AAV virions containing functional rep and cap genes). Non—limiting examples of vectors suitable for use with the present disclosure include , described in U.S. Pat. No. 6,001,650 and pRep6cap6 vector, described in US. Pat. No. 6,156,303, the entirety of both incorporated by reference herein. The accessory function vector encodes nucleotide ces for non—AAV derived viral and/or cellular functions upon which AAV is dependent for replication (e.g., "accessory functions"). The accessory ons include those functions required for AAV replication, including, without limitation, those moieties involved in activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of cap expression products, and AAV capsid ly. Viral—based accessory functions can be derived from any of the known helper viruses such as adenovirus, herpesvirus (other than herpes simplex virus type—l), and vaccinia virus.
In some aspects, the disclosure es transfected host cells. The term "transfection" is used to refer to the uptake of foreign DNA by a cell, and a cell has been "transfected" when exogenous DNA has been introduced inside the cell (e.g., across the cell membrane). A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a tory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic s in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13:197. Such techniques can be used to uce one or more exogenous c acids, such as a nucleotide integration vector and other nucleic acid molecules, into suitable host cells.
A "host cell" refers to any cell that harbors, or is capable of harboring, a substance of interest. Often a host cell is a mammalian cell. A host cell may be used as a recipient of an AAV helper construct, an AAV minigene d, an accessory function vector, or other er DNA associated with the production of recombinant AAVs. The term includes the progeny of the original cell that has been ected. Thus, a "host cell" as used herein may refer to a cell that has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation. _ 28 _ As used herein, the term "cell line" refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single itor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal tions.
Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants.
As used , the terms "recombinant cell" refers to a cell into which an exogenous DNA segment, such as DNA segment that leads to the transcription of a ically—active polypeptide or production of a biologically active nucleic acid such as an RNA, has been uced.
Cells may also be transfected with a vector (e.g., helper vector) that provides helper functions to the AAV. The vector providing helper functions may provide irus functions, including, e.g., Ela, Elb, E2a, and E4ORF6. The sequences of adenovirus gene providing these functions may be obtained from any known adenovirus serotype, such as serotypes 2, 3, 4, 7, l2 and 40, and further including any of the presently identified human types known in the art. Thus, in some ments, the methods involve transfecting the cell with a vector expressing one or more genes necessary for AAV replication, AAV gene transcription, and/or AAV packaging.
As used herein, the term r" includes any genetic element, such as a plasmid, phage, transposon, , chromosome, artificial some, virus, virion, etc, that is capable of replication when associated with the proper l elements and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors. In some embodiments, useful vectors are contemplated to be those vectors in which the nucleic acid segment (e.g., nucleic acid sequence) to be transcribed is oned under the transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, that is required to initiate the specific transcription of a gene. The phrases "operatively oned," "under control" or "under transcriptional control" means that the promoter is in the correct on and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. The term "expression vector or construct" means any type of genetic construct containing a nucleic acid in which part or all of the nucleic acid ng sequence is capable of being transcribed. In some embodiments, _ 29 _ expression includes transcription of the nucleic acid, for e, to generate a biologically— active polypeptide product or inhibitory RNA (e.g., shRNA, miRNA, miRNA inhibitor) from a transcribed gene.
In some cases, an isolated capsid gene can be used to construct and package recombinant AAVs, using methods well known in the art, to determine functional teristics associated with the capsid protein encoded by the gene. For example, isolated capsid genes can be used to uct and package a recombinant AAV (rAAV) comprising a er gene (e.g., B—Galactosidase, GFP, Luciferase, etc). The rAAV can then be delivered to an animal (e.g., mouse) and the tissue targeting properties of the novel ed capsid gene can be determined by examining the expression of the reporter gene in various tissues (e.g., heart, liver, kidneys) of the animal. Other methods for characterizing the novel isolated capsid genes are disclosed herein and still others are well known in the art.
The foregoing methods for packaging recombinant s in desired AAV capsids to produce the rAAVs of the disclosure are not meant to be ng and other suitable methods will be apparent to the skilled artisan.
Recombinant AAV vectors "Recombinant AAV (rAAV) vectors" of the disclosure are typically composed of, at a minimum, a ene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs). It is this recombinant AAV vector which is packaged into a capsid protein and delivered to a ed target cell. In some embodiments, the transgene is a nucleic acid sequence, heterologous to the vector sequences, that encodes a ptide, protein, functional RNA molecule (e.g., miRNA, miRNA inhibitor) or other gene product, of interest.
The c acid coding sequence is operatively linked to regulatory components in a manner that permits transgene transcription, translation, and/or expression in a cell of a target tissue.
The AAV sequences of the vector typically se the cis—acting 5' and 3' inverted terminal repeat sequences (See, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P.
Tijsser, CRC Press, pp. 155 168 (1990)). The ITR sequences are about 145 bp in length.
Preferably, ntially the entire sequences encoding the ITRs are used in the molecule, although some degree of minor modification of these sequences is permissible. The ability to modify these ITR sequences is within the skill of the art. (See, e.g., texts such as Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory, New WO 71831 York (1989); and K. Fisher et al., J Virol., 70:520 532 (1996)). An example of such a molecule employed in the present disclosure is a "cis—acting" plasmid ning the transgene, in which the selected transgene sequence and associated regulatory elements are flanked by the 5' and 3' AAV ITR sequences. The AAV ITR sequences may be obtained from any known AAV, including tly identified mammalian AAV types.
In some embodiments, the disclosure provides a self—complementary AAV vector. As used herein, the term "self—complementary AAV vector" (scAAV) refers to a vector containing a double—stranded vector genome generated by the absence of a terminal resolution site (TR) from one of the ITRs of the AAV. The absence of a TR prevents the initiation of replication at the vector terminus where the TR is not present. In l, scAAV s generate single—stranded, inverted repeat genomes, with a wild—type (wt) AAV TR at each end and a mutated TR (mTR) in the middle.
In some embodiments, the rAAVs of the present disclosure are pseudotyped rAAVs.
Pseudotyping is the process of producing viruses or viral vectors in combination with foreign viral envelope proteins. The result is a typed virus particle. With this method, the foreign viral envelope proteins can be used to alter host tropism or an increased/decreased stability of the virus particles. In some aspects, a pseudotyped rAAV comprises nucleic acids from two or more different AAVs, wherein the nucleic acid from one AAV encodes a capsid protein and the nucleic acid of at least one other AAV s other viral proteins and/or the viral . In some embodiments, a pseudotyped rAAV refers to an AAV sing an inverted terminal repeat (ITR) of one AAV serotype and a capsid protein of a different AAV serotype. For example, a pseudotyped AAV vector containing the ITRs of serotype X encapsidated with the proteins of Y will be designated as AAVX/Y (e.g., AAV2/l has the ITRs of AAV2 and the capsid of AAVl). In some embodiments, pseudotyped rAAVs may be useful for combining the tissue—specific targeting lities of a capsid protein from one AAV serotype with the viral DNA from another AAV serotype, thereby allowing targeted delivery of a transgene to a target tissue.
In addition to the major elements fied above for the recombinant AAV vector, the vector also includes conventional control elements ary which are operably linked to the transgene in a manner which permits its ription, ation and/or expression in a cell transfected with the plasmid vector or infected with the virus produced by the disclosure.
As used herein, "operably linked" sequences include both expression control sequences that _ 31 _ are contiguous with the gene of interest and sion control sequences that act in trans or at a distance to control the gene of interest.
Expression control ces include appropriate transcription initiation, ation, promoter and enhancer sequences; efficient RNA processing signals such as splicing and enylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
A great number of expression control sequences, including ers that are native, constitutive, inducible and/or —specific, are known in the art and may be utilized.
As used herein, a nucleic acid sequence (e.g., coding sequence) and regulatory sequences are said to be "operably" linked when they are covalently linked in such a way as to place the expression or transcription of the nucleic acid sequence under the ce or control of the regulatory sequences. If it is desired that the nucleic acid sequences be translated into a functional n, two DNA sequences are said to be operably linked if induction of a promoter in the 5’ regulatory sequences results in the transcription of the coding sequence and if the nature of the e between the two DNA sequences does not (1) result in the introduction of a frame—shift mutation, (2) interfere with the ability of the promoter region to direct the ription of the coding sequences, or (3) interfere with the ability of the corresponding RNA ript to be translated into a protein. Thus, a promoter region would be operably linked to a nucleic acid sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. Similarly two or more coding regions are operably linked when they are linked in such a way that their transcription from a common promoter results in the sion of two or more proteins having been translated in frame. In some embodiments, operably linked coding sequences yield a fusion protein. In some embodiments, operably linked coding sequences yield a functional RNA (e.g., shRNA, miRNA, miRNA inhibitor).
For nucleic acids encoding proteins, a polyadenylation sequence generally is inserted following the transgene ces and before the 3' AAV ITR sequence. A rAAV construct useful in the present disclosure may also contain an intron, desirably located between the er/enhancer sequence and the transgene. One possible intron sequence is derived from SV—40, and is referred to as the SV—40 T intron sequence. Another vector element that may be used is an internal ribosome entry site (IRES). An IRES sequence is used to produce more dmnmmpdflmmfimfipmasmgegmemmmfim.AnHHEsammmewmmflmumdm produce a protein that contains more than one polypeptide chains. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein at, for example, pages 3.18 3.26 and 16.17 16WmflAmwdamflQmmflmmmhmMMWMMEw%%MMWmW&SmaNm York, 1989]. In some embodiments, a Foot and Mouth Disease Virus 2A sequence is ed in polyprotein; this is a small peptide (approximately 18 amino acids in length) that has been shown to mediate the cleavage of polyproteins (Ryan, M D et al., EMBO, 1994; 4: 928—933; Mattion, N M et al., J Virology, November 1996; p. 127; Furler, S et al., (3ene'Therapy,2001;8:864—873;andliahnn,(Ietal,ThelflantJournaL :453—459) The cleavage activity of the 2A sequence has previously been demonstrated in artificial systems including plasmids and gene therapy vectors (AAV and iruses) (Ryan, M D et al., EMBO, 1994; 4: 928—933; Mattion, N M et al., J Virology, November 1996; p. 8124— 8127; Furler, S et al., Gene Therapy, 2001; 8: 864—873; and Halpin, C et al., The Plant Journal, 1999; 4: 453—459; de Felipe, P et al., Gene y, 1999; 6: 198—208; de Felipe, P et al., Human Gene Therapy, 2000; 11: 931.; and Klump, H et al., Gene y, 2001;8:811—817) The precise nature of the regulatory sequences needed for gene expression in host cells may vary between species, tissues or cell types, but shall in general include, as necessary, 5’ non—transcribed and 5’ non—translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, enhancer ts, and the like. Especially, such 5’ non—transcribed regulatory sequences Will include a promoter region that es a promoter sequence for transcriptional control of the operably joined gene. tory sequences may also include enhancer ces or upstream tor sequences as desired. The s of the disclosure may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is Within the ability and discretion of one of ordinary skill in the art.
Examples of constitutive promoters include, Without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, —530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the B— _ 33 _ actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFlor promoter [Invitrogen].
Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific logical state, e.g., acute phase, a particular entiation state of the cell, or in replicating cells only. Inducible promoters and inducible systems are ble from a variety of commercial sources, including, without limitation, Invitrogen, Clontech and Ariad.
Many other systems have been described and can be y selected by one of skill in the art.
Examples of inducible ers regulated by exogenously supplied promoters include the zinc—inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)—inducible mouse mammary tumor virus (MMTV) er, the T7 rase promoter system (W0 98/10088); the ecdysone insect promoter (No et al, Proc. Natl. Acad. Sci. USA, 6— 3351 (1996)), the tetracycline—repressible system (Gossen et al, Proc. Natl. Acad. Sci. USA, 89:5547—555 l (1992)), the tetracycline—inducible system (Gossen et al, Science, 268: 1766— 1769 (1995), see also Harvey et al, Curr. Opin. Chem. Biol., 2:512—518 (1998)), the RU486— inducible system (Wang et al, Nat. Biotech., 15 :239—243 (1997) and Wang et al, Gene Ther., 4:432—441 (1997)) and the rapamycin—inducible system (Magari et al, J. Clin. Invest., 100:2865—2872 (1997)). Still other types of inducible promoters that may be useful in this context are those that are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
In another ment, the native promoter for the transgene will be used. The native promoter may be preferred when it is desired that expression of the transgene should mimic the native expression. The native promoter may be used when expression of the transgene must be ted temporally or developmentally, or in a tissue—specific manner, or in response to specific riptional stimuli. In a further embodiment, other native expression control elements, such as enhancer elements, polyadenylation sites or Kozak consensus ces may also be used to mimic the native sion.
In some embodiments, the regulatory sequences impart tissue—specific gene expression capabilities. In some cases, the tissue—specific regulatory sequences bind tissue— specific transcription s that induce transcription in a tissue specific manner. Such tissue—specific regulatory sequences (e.g., promoters, enhancers, etc.) are well known in the art. Exemplary tissue—specific regulatory sequences include, but are not limited to the _ 34 _ following tissue ic promoters: a liver—specific thyroxin binding globulin (TBG) promoter, an insulin promoter, a glucagon promoter, a somatostatin er, a pancreatic polypeptide (PPY) promoter, a synapsin—l (Syn) promoter, a creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, a sin heavy chain (a—MHC) promoter, a gastrointestinal—specific mucin—2 promoter, an eye—specific retinoschisin promoter, an eye— specific K12 promoter, a respiratory tissue—specific CClO promoter, a atory tissue— specific surfactant n C (SP—C) promoter, a breast tissue—specific PRCl er, a breast tissue—specific RRM2 promoter, a urinary tract tissue—specific uroplakin 2 (UPII) promoter, a uterine tissue—specific lactoferrin promoter, or a cardiac Troponin T (cTnT) promoter. Other exemplary promoters include Beta—actin promoter, hepatitis B virus core er, Sandig et al., Gene Ther., 3: 1002—9 (1996); alpha—fetoprotein (AFP) promoter, Arbuthnot et al., Hum. Gene Ther., 7: 1503—14 (1996)), bone osteocalcin er (Stein et al., Mol. Biol. Rep., 24:185—96 (1997)); bone sialoprotein promoter (Chen et al., J. Bone Miner. Res., 11:654—64 (1996)), CD2 promoter (Hansal et al., J. Immunol., 161:1063—8 ; immunoglobulin heavy chain promoter; T cell receptor 0t—chain promoter, neuronal such as neuron—specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol., —15 (1993)), neurofilament light—chain gene promoter (Piccioli et al., Proc. Natl. Acad.
Sci. USA, 88:5611—5 (1991)), and the neuron—specific vgf gene promoter (Piccioli et al., Neuron, 15:373—84 (1995)), among others Which Will be nt to the skilled artisan.
In some embodiments, one or more bindings sites for one or more of miRNAs are orated in a transgene of a rAAV vector, to inhibit the expression of the transgene in one or more tissues of an subject harboring the transgene. The skilled artisan Will appreciate that binding sites may be selected to l the expression of a transgene in a tissue specific manner. For example, binding sites for the liver—specific miR—l22 may be incorporated into a transgene to inhibit expression of that transgene in the liver. The target sites in the mRNA may be in the 5' UTR, the 3' UTR or in the coding region. Typically, the target site is in the 3’ UTR of the mRNA. Furthermore, the transgene may be designed such that multiple miRNAs regulate the mRNA by recognizing the same or multiple sites. The presence of multiple miRNA binding sites may result in the cooperative action of multiple RISCs and provide highly efficient inhibition of expression. The target site sequence may se a total of 5—100, 10—60, or more nucleotides. The target site sequence may comprise at least 5 nucleotides of the sequence of a target gene binding site. inant AAV Vector: Transgene Coding Sequences The composition of the transgene sequence of the rAAV vector will depend upon the use to which the resulting vector will be put. For example, one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal. In another example, the transgene encodes a therapeutic protein or therapeutic functional RNA. In another example, the transgene encodes a protein or functional RNA that is ed to be used for research purposes, e. g., to create a somatic transgenic animal model harboring the transgene, e. g., to study the function of the transgene product. In another e, the transgene encodes a n or functional RNA that is intended to be used to create an animal model of e. Appropriate transgene coding sequences will be apparent to the skilled artisan.
Reporter sequences that may be provided in a transgene include, without limitation, DNA sequences encoding B—lactamase, B —galactosidase (LacZ), ne atase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art. When ated with regulatory elements which drive their expression, the reporter sequences, provide signals detectable by tional means, including enzymatic, radiographic, colorimetric, fluorescence or other ographic assays, fluorescent activating cell sorting assays and immunological assays, ing enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and immunohistochemistry. For example, where the marker sequence is the LacZ gene, the presence of the vector carrying the signal is detected by assays for ctosidase ty.
Where the transgene is green fluorescent protein or luciferase, the vector carrying the signal may be measured visually by color or light production in a luminometer. Such reporters can, for example, be useful in verifying the —specific targeting capabilities and tissue specific promoter regulatory activity of an rAAV.
In some aspects, the disclosure provides rAAV s for use in methods of preventing or treating one or more genetic deficiencies or dysfunctions in a mammal, such as for example, a polypeptide deficiency or polypeptide excess in a mammal, and particularly for treating or reducing the severity or extent of deficiency in a human manifesting one or more of the disorders linked to a deficiency in such polypeptides in cells and tissues. The method involves administration of an rAAV vector that encodes one or more therapeutic peptides, polypeptides, siRNAs, microRNAs, antisense nucleotides, etc. in a pharmaceutically—acceptable carrier to the subject in an amount and for a period of time sufficient to treat the deficiency or disorder in the subject suffering from such a disorder.
Thus, the disclosure embraces the delivery of rAAV vectors ng one or more peptides, ptides, or proteins, which are useful for the treatment or prevention of disease states in a mammalian subject. Exemplary therapeutic proteins include one or more polypeptides ed from the group consisting of growth factors, interleukins, interferons, poptosis factors, cytokines, anti—diabetic factors, anti—apoptosis agents, coagulation factors, anti—tumor factors. Other non—limiting es of therapeutic proteins include BDNF, CNTF, CSF, EGF, FGF, G-SCF, GM-CSF, gonadotropin, IFN, IFG-l, M-CSF, NGF, PDGF, PEDF, TGF, VEGF, , TNF, prolactin, somatotropin, XIAPl, IL—l, IL—2, IL—3, IL—4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-10 (187A), viral IL-10, IL-11, IL-12, IL-l3, IL- l4, IL-15, IL-16 IL-l7, and IL-18.
The rAAV vectors may comprise a gene to be transferred to a t to treat a disease associated with d expression, lack of expression or dysfunction of the gene.
Exemplary genes and associated disease states include, but are not d to: glucose—6— phosphatase, associated with glycogen storage deficiency type lA; phosphoenolpyruvate— carboxykinase, associated with Pepck deficiency; galactose—l phosphate uridyl transferase, associated with galactosemia; phenylalanine hydroxylase, associated with phenylketonuria; branched chain alpha—ketoacid dehydrogenase, associated with Maple syrup urine disease; fumarylacetoacetate hydrolase, associated with tyrosinemia type 1; methylmalonyl—CoA mutase, ated with methylmalonic acidemia; medium chain acyl CoA dehydrogenase, associated with medium chain acetyl CoA deficiency; omithine transcarbamylase, associated with omithine transcarbamylase ency; argininosuccinic acid synthetase, associated with linemia; low density lipoprotein receptor protein, associated with al hypercholesterolemia; UDP—glucouronosyltransferase, associated with r—Najjar disease; adenosine deaminase, associated with severe combined immunodeficiency disease; hypoxanthine e phosphoribosyl transferase, associated with Gout and Lesch—Nyan syndrome; biotinidase, associated with biotinidase deficiency; beta—glucocerebrosidase, associated with Gaucher disease; beta—glucuronidase, associated with Sly syndrome; peroxisome membrane protein 70 kDa, associated with Zellweger syndrome; porphobilinogen deaminase, ated with acute intermittent porphyria; alpha—l antitrypsin _ 37 _ for treatment of alpha—l antitrypsin deficiency (emphysema); erythropoietin for treatment of anemia due to thalassemia or to renal failure; vascular endothelial growth factor, angiopoietin—l, and fibroblast growth factor for the treatment of ischemic diseases; thrombomodulin and tissue factor pathway inhibitor for the treatment of occluded blood vessels as seen in, for example, atherosclerosis, osis, or sms; aromatic amino acid decarboxylase (AADC), and tyrosine hydroxylase (TH) for the treatment of Parkinson's disease; the beta adrenergic or, anti—sense to, or a mutant form of, phospholamban, the sarco(endo)plasmic reticulum adenosine triphosphatase—2 (SERCAZ), and the cardiac adenylyl cyclase for the treatment of congestive heart failure; a tumor suppessor gene such as p53 for the treatment of various s; a ne such as one of the various interleukins for the ent of inflammatory and immune disorders and cancers; dystrophin or minidystrophin and utrophin or miniutrophin for the treatment of muscular dystrophies; and, insulin for the treatment of diabetes.
In some embodiments, the disclosure relates to an AAV comprising a nucleic acid ng a n or functional RNA useful for the treatment of a condition, disease or disorder associated with the central nervous system (CNS). The following is a non—limiting list of genes associated with CNS disease: DRD2, GRIAl, GRIA2,GRINl, , SYP, SYTl, CHRNA7, 3Rtau/4rTUS, APP, BAX, BCL-Z, GRIKl, GFAP, IL-l, AGER, ated with Alzheimer’s e; UCH—Ll, SKPl, EGLNl, Nurr—l, BDNF, TrkB, gstml, SlO6B, associated with Parkinson’s Disease; IT15, PRNP, JPH3, TBP, ATXNl, ATXN2, ATXN3, Atrophin l, FTL, TITF—l, associated with Huntington’s Disease; FXN, associated with Freidrich’s ataxia; ASPA, associated with Canavan’s Disease; DMD, associated with muscular dystrophy; and SMNl, UBEl, DYNClHl associated with spinal muscular atrophy.
In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising c acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some embodiments, the disclosure relates to a nucleic acid encoding a protein or functional RNA useful for the treatment of a condition, disease or disorder ated with the cardiovascular system. The following is a non—limiting list of genes ated with cardiovascular disease: VEGF, FGF, SDF—l, connexin 40, connexin 43, SCN4a, HIFlOt, SERCaZa, ADCYl, and ADCY6. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some embodiments, the disclosure relates to an AAV comprising a nucleic acid encoding a protein or functional RNA useful for the treatment of a condition, disease or disorder associated with the pulmonary system. The ing is a non—limiting list of genes associated with pulmonary disease: TNFOL, TGFBl, , SFTPAZ, SFTPB, SFTPC, HPSl, HPS3, HPS4, ADTB3A, ILlA, ILlB, LTA, 1L6, CXCR1, and CXCR2. In some ments, the disclosure relates to recombinant AAVs comprising nucleic acids that s one or more of the foregoing genes or nts thereof. In some embodiments, the sure relates to recombinant AAVs comprising nucleic acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some embodiments, the disclosure relates to an AAV comprising a nucleic acid encoding a protein or functional RNA useful for the treatment of a condition, disease or manmxamodmedwfihdlemxThefiflowngisanmrhmfimghmofgmmsamodmed with liver disease: dl—AT, HFE, ATP7B, fumarylacetoacetate hydrolase (FAH), glucose—6— phosphatase, NCAN, GCKR, LYPLALl, and . In some embodiments, the disclosure relates to recombinant AAVs sing nucleic acids that express one or more of dwmmgmggmmmfigmmmmmmfhmmmmmmmmmmdwmmbwmnmmMo recombinant AAVs comprising c acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some embodiments, the disclosure relates to an AAV comprising a nucleic acid ng a protein or functional RNA useful for the treatment of a condition, disease or dfionmramodmedwfihflxfldmuw.ThefiflowngisanmrhmfimgHMIfigmwsamodamd with kidney e: PKDl, PKDZ, PKHDl, NPHS l, NPHSZ, PLCEl, CD2AP, LAMB2, TRPC6, WTl, LMXlB, SMARCALl, COQZ, PDSSZ, SCARB3, FNl, COL4A5, COL4A6, COL4A3, COL4A4, FOXlC, RET, UPK3A, BMP4, SIXZ, CDCSL, USF2, ROBOZ, SLIT2, EYAl, MYOG, SIXl, SIXS, FRASl, FREMZ, GATA3, KALl, PAX2, TCF2, and SALLl.
In some ments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some embodiments, the disclosure relates to an AAV comprising a nucleic acid encoding a protein or functional RNA useful for the treatment of a condition, disease or disorder associated with the eye. The following is a non—limiting list of genes associated with ocular disease: CFH, C3, MT-ND2, ARMSZ, TIMP3, CAMK4, FMNl, RHO, USH2A, RPGR, RP2, TMCO, SIXl, SIX6, LRPlZ, ZFPMZ, TBKl, GALC, myocilin, CYPlBl, CAVl, CAV2, optineurin and CDKNZB. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more functional RNAs that inhibit expression of one or more of the ing genes.
In some ments, the disclosure relates to an AAV comprising a nucleic acid encoding a protein or functional RNA useful for the treatment of a ion, disease or dBmdmwwmmfiEduflthmfi.Thefiflowngisanmrhmfimghmofgmmsamodmedwfih breast disease: BRCAl, BRCA2, Tp53, PTEN, HER2, BRAF, and PARPl. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more onal RNAs that t expression of one or more of the foregoing genes.
In some embodiments, the disclosure relates to an AAV comprising a c acid encoding a protein or onal RNA useful for the treatment of a condition, disease or dmmdmwwmmmmdWfihmegfiumnmmthmd.Thefiflowmgfianonhmfimghmof genes associated with gastrointestinal disease: CYP2Cl9, CCL26, APC, IL12, ILlO, and IL— 18. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic mflflmummammmnmmmfimemmgmggmmmfigmmmmmmfhmmm ments, the sure relates to recombinant AAVs comprising nucleic acids that express one or more functional RNAs that inhibit sion of one or more of the foregoing genes In some embodiments, the disclosure relates to an AAV sing a nucleic acid encoding a protein or functional RNA useful for the treatment of a condition, e or disorder associated with the pancreas. The ing is a non—limiting list of genes _ 40 _ associated with pancreatic disease: PRSSl, SPINKl, STKl l, MLHl, KRASZ, p16, p53, and BRAF. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising c acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some embodiments, the sure relates to an AAV comprising a nucleic acid encoding a protein or onal RNA useful for the treatment of a condition, disease or er associated with the urinary tract. The ing is a miting list of genes associated with urinary tract e: HSPAlB, CXCRl & 2, TLR2, TLR4, TGF—l, FGFR3, RB l, HRAS, TP53, and TSCl. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to recombinant AAVs comprising c acids that express one or more functional RNAs that inhibit expression of one or more of the foregoing genes.
In some ments, the disclosure relates to an AAV comprising a nucleic acid encoding a protein or functional RNA useful for the treatment of a condition, disease or disorder associated with the uterus. The following is a non—limiting list of genes associated with ocular disease: DN—ER, MLHl, MSH2, MSH6, PMSl, and PMSZ. In some embodiments, the disclosure relates to recombinant AAVs comprising nucleic acids that express one or more of the foregoing genes or fragments thereof. In some embodiments, the disclosure relates to inant AAVs comprising nucleic acids that s one or more onal RNAs that inhibit expression of one or more of the foregoing genes.
The rAAVs of the disclosure can be used to restore the expression of genes that are reduced in expression, silenced, or otherwise dysfunctional in a subject (e.g., a tumor suppressor that has been silenced in a subject having cancer). The rAAVs of the disclosure can also be used to knockdown the expression of genes that are aberrantly expressed in a subject (e.g., an oncogene that is expressed in a subject having cancer). In some embodiments, an rAAV vector sing a nucleic acid ng a gene product associated with cancer (e.g., tumor suppressors) may be used to treat the cancer, by administering a rAAV harboring the rAAV vector to a subject having the cancer. In some embodiments, an rAAV vector comprising a nucleic acid encoding a small interfering nucleic acid (e.g., shRNAs, miRNAs) that inhibits the expression of a gene product associated with cancer (e.g., oncogenes) may be used to treat the cancer, by administering a rAAV harboring the rAAV vector to a subject having the cancer. In some embodiments, an rAAV vector comprising a nucleic acid encoding a gene product associated with cancer (or a functional RNA that inhibits the expression of a gene associated with cancer) may be used for research purposes, e.g., to study the cancer or to identify therapeutics that treat the cancer. The ing is a non—limiting list of exemplary genes known to be ated with the pment of cancer (e.g., oncogenes and tumor suppressors): AARS, ABCBl, ABCC4, ABIZ, ABLl, ABL2, ACKl, ACP2, ACYl, ADSL, AKl, AKRlCZ, AKTl, ALB, ANPEP, ANXA5, ANXA7, AP2Ml, APC, ARHGAP5, ARHGEFS, ARID4A, ASNS, ATF4, ATM, ATP5B, ATPSO, AXL, BARDl, BAX, BCL2, BHLHB2, BLMH, BRAF, BRCAl, BRCA2, BTK, CANX, CAPl, CAPNl, CAPNS l, CAVl, CBFB, CBLB, CCL2, CCND l, CCND2, CCND3, CCNEl, CCT5, CCYR6l, CD24, CD44, CD59, CDC20, CDC25, , CDC25B, CDC2L5, CDKlO, CDK4, CDK5, CDK9, CDKLl, CDKNlA, , CDKNlC, CDKN2A, CDKNZB, CDKN2D, CEBPG, CENPC l, CGRRF l, CHAFlA, CIB l, CKMT l, CLKl, CLK2, CLK3, CLNSlA, CLTC, COLlAl, COL6A3, COX6C, COX7A2, CRAT, CRHRl, CSFlR, CSK, CSNKlGZ, CTNNAl, CTNNBl, CTPS, CTSC, CTSD, CULl, CYR6l, DCC, DCN, DDXlO, DEK, DHCR7, DHRSZ, DHXS, DLG3, DVLl, DVL3, E2Fl, E2F3, E2F5, EGFR, EGRl, EIF5, EPHA2, ERBBZ, ERBB3, ERBB4, ERCC3, ETVl, ETV3, ETV6, F2R, FASTK, FBNl, FBN2, FES, FGFRl, FGR, FKBPS, FNl, FOS, FOSLl, FOSLZ, FOXGlA, , FRAPl, FRZB, FTL, FZD2, FZD5, FZD9, G22Pl, GAS6, GCN5L2, GDF15, GNAl3, GNAS, GNB2, GNB2Ll, GPR39, GRBZ, GSK3A, GSPTl, GTFZI, HDAC l, HDGF, HMMR, HPRTl, HRB, HSPA4, HSPA5, HSPAS, HSPB l, HSPHl, HYALl, HYOUl, ICAMl, IDl, ID2, IDUA, IER3, IFITMl, IGFlR, IGFZR, IGFBP3, , IGFBPS, ILlB, ILK, INGl, IRF3, ITGA3, lTGA6, ITGB4, JAKl, JARlDlA, JUN, JUNB, JUND, A-l, KIT, KITLG, KLKlO, KPNA2, KRASZ, KRTlS, KRTZA, KRT9, LAMBl, LAMP2, LCK, LCN2, LEP, LITAF, LRPAPl, LTF, LYN, LZTRl, MADHl, MAP2K2, MAP3K8, MAPK12, MAPKl3, MAPKAPK3, MAPREl, MARS, MAS l, MCC, MCM2, MCM4, MDM2, MDM4, MET, MGST l, MICB, MLLT3, MME, MMPl, MMPl4, MMPl7, MMP2, MNDA, MSH2, MSH6, MT3, MYB, MYBLl, MYBLZ, MYC, MYCLl, MYCN, MYD88, MYL9, MYLK, NEO l, NFl, NF2, NFKB l, NFKBZ, NFSF7, NID, NINJ l, NMBR, NMEl, NME2, NME3, NOTCHl, NOTCH2, NOTCH4, _ 42 _ NPMl, NQOl, NRlDl, NR2Fl, NR2F6, NRAS, NRGl, NSEPl, OSM,PA2G4,PABPC1, PCNA, PCTKl, PCTKZ, PCTK3, PDGFA, PDGFB, PDGFRA, PDPKl, PEAlS, PFDN4, PFDNS, PGAMl, PHB, PIK3CA, PIK3CB, PIK3CG, PIMl, PKMZ, , PLKZ, PPARD, PPARG, PPIH, PPPlCA, PPPZRSA, PRDX2, PRDX4, PRKARlA, PRKCBPl, PRNP, PRSSlS, PSMAl, PTCH, PTEN, PTGSl, PTMA, PTN, PTPRN, RAB5A, RACl, RAD50, RAFl, RALBPl, RAPlA, RARA, RARB, RASGRFl, RBl, RBBP4, RBL2, REA, REL, RELA, RELB, RET, RFC2, RGSl9, RHOA, RHOB, RHOC, RHOD, RIPKl, RPN2, l, RRM1, SARS, SELENBPl, SEMA3C, SEMA4D, SEPPl, SERPINHl, SFN, SFPQ, SFRS7, SHB, SHH, SIAH2, SIVA, SIVA TP53, SKI, SKIL, SLCl6Al, SLClA4, SLCZOAl,SMO,SMPDl,SNA12,SNDl,SNRPB2,SOCSl,SOCS3,SODl,SORTl, SPINTZ, SPRY2, SRC, SRPX, STATl, STAT2, STAT3, STATSB, STCl, TAFl, TBL3, TBRG4, TCFl, TCF7L2, TFAPZC, TFDPl, TFDP2, TGFA, TGFBl, TGFBI, TGFBR2, TGFBR3, THBSl, TIE, TIMPl, TIMP3, TJPl, TK1, TLE1, TNF, lOA, TNFRSFlOB, TNFRSFlA, TNFRSFlB, TNFRSF6, TNFSF7, TNKl, TOBl, TP53, TP53BP2, TP53I3, TP73, TPBG, TPTl, TRADD, TRAMl, TRRAP, TSG101, TUFM, TXNRDl, TYRO3, UBC, , UCHLl, USP7, VDACl, VEGF, VHL, VIL2, WEE1, WNTl, WNTZ, WNTZB, WNT3, WNTSA, WTl, XRCCl, YES I, YWHAB, YWHAZ, ZAP70, and ZNF9.
A rAAV vector may comprise as a transgene, a nucleic acid encoding a protein or functional RNA that modulates apoptosis. The following is a non—limiting list of genes ated with apoptosis and nucleic acids encoding the ts of these genes and their homologues and encoding small interfering nucleic acids (e.g., shRNAs, miRNAs) that inhibit the expression of these genes and their homologues are useful as transgenes in certain embodiments of the disclosure: RPSZ7A, ABLl, AKTl, APAFl, BAD, BAGl, BAG3, BAG4, BAKl, BAX, BCLlO, BCL2, BCL2Al, BCL2Ll, BCL2LlO, BCL2Lll, BCL2L12, BCL2Ll3, BCL2L2, BCLAFl, BFAR, BID, BIK, NAIP, BIRC2, BIRC3, XIAP, BIRCS, BIRC6, BIRC7, BIRC8, BNIPl, BNIP2, BNIP3, BNIP3L, BOK, BRAF, , CARDl l, NLRC4, CARDl4, NOD2, NODl, CARD6, CARDS, CARD9, CASPl, CASPlO, , CASPZ, CASP3, CASP4, CASPS, CASP6, CASP7, CASPS, CASP9, CFLAR, CIDEA, CIDEB, CRADD, DAPKl, DAPK2, DFFA, DFFB, FADD, A, GDNF, HRK, IGFlR, LTA, LTBR, MCLl, NOL3, PYCARD, RIPKl, RIPKZ, TNF, TNFRSFlOA, TNFRSFlOB, TNFRSFlOC, TNFRSFlOD, TNFRSFl lB, TNFRSFlZA, TNFRSFl4, _ 43 _ TNFRSFl9, TNFRSFlA, TNFRSFlB, TNFRSFZl, TNFRSFZS, CD40, FAS, TNFRSF6B, CD27, TNFRSF9, TNFSFlO, TNFSFl4, TNFSFlS, CD40LG, FASLG, CD70, TNFSFS, , TP53, TP53BP2, TP73, TP63, TRADD, TRAFl, TRAF2, TRAF3, TRAF4, TRAFS DRD2, GRIAl, GRIA2,GRINl, SLClAl, SYP, SYTl, CHRNA7, 3Rtau/4rTUS, APP, BAX, BCL-2, GRIKl, GFAP, IL-l, AGER, , SKPl, EGLNl, Nurr-l, BDNF, TrkB,gstml, $1063, lTlS, PRNP, JPH3, TBP, ATXNl, ATXN2, ATXN3, Atrophin l, FTL, TITF-l, FXN, ASPA, DMD, and SMNl, UBEl, DYNClHl.
The skilled artisan Will also realize that in the case of transgenes encoding proteins or polypeptides, that mutations that results in conservative amino acid substitutions may be made in a transgene to provide onally equivalent variants, or homologs of a protein or ptide. In some aspects the disclosure embraces ce tions that result in conservative amino acid substitution of a ene. In some embodiments, the transgene comprises a gene having a dominant negative mutation. For example, a transgene may express a mutant protein that interacts With the same elements as a Wild—type protein, and thereby blocks some aspect of the function of the Wild—type protein.
Useful transgene products also include miRNAs. miRNAs and other small interfering c acids regulate gene expression via target RNA transcript cleavage/degradation or translational repression of the target messenger RNA (mRNA). miRNAs are ly expressed, typically as final 19—25 non—translated RNA products. miRNAs exhibit their activity through sequence—specific interactions With the 3' untranslated regions (UTR) of target mRNAs. These endogenously expressed miRNAs form hairpin precursors that are subsequently processed into a miRNA duplex, and further into a "mature" single stranded miRNA molecule. This mature miRNA guides a multiprotein x, miRISC, which identifies target site, e.g., in the 3' UTR regions, of target mRNAs based upon their complementarity to the mature miRNA.
The following miting list of miRNA genes, and their homologues, are useful as transgenes or as s for small ering nucleic acids encoded by transgenes (e.g., miRNA sponges, antisense oligonucleotides, TuD RNAs) in certain embodiments of the methods: hsa—let—7a, hsa—let—7a*, hsa—let—7b, hsa—let—7b*, hsa—let—7c, t—7c*, hsa—let—7d, hsa—let—7d*, t—7e, hsa—let—7e*, hsa—let—7f, hsa—let—7f—l*, hsa—let—7f—2*, hsa—let—7g, hsa—let— 7g*, hsa—let—7i, hsa—let—7i*, hsa—miR—l, hsa—miR—100, hsa—miR—100*, hsa—miR—lOl, hsa—miR— 101*, hsa—miR—103, hsa—miR—105, hsa—miR—105*, hsa—miR—106a, hsa—miR—106a*, hsa—miR— _ 44 _ 106b, hsa—miR—106b*, hsa—miR—107, hsa—miR—lOa, hsa—miR—10a*, hsa—miR—lOb, hsa—miR— 10b*, hsa—miR—l 178, hsa—miR—l 179, hsa—miR—l 180, hsa—miR—l 181, hsa—miR—l 182, hsa—miR— 1183, hsa—miR—l 184, hsa—miR—l 185, hsa—miR—l 197, hsa—miR—1200, R—1201, hsa—miR— 1202, R—1203, hsa—miR—1204, hsa—miR—1205, hsa—miR—1206, R—1207—3p, hsa— miR—1207—5p, hsa—miR—1208, hsa—miR—122, hsa—miR—122*, hsa—miR—1224—3p, hsa—miR— 1224—5p, hsa—miR—1225—3p, hsa—miR—1225—5p, hsa—miR—1226, hsa—miR—1226*, hsa—miR— 1227, hsa—miR—1228, hsa—miR—1228*, hsa—miR—1229, hsa—miR—123 1, hsa—miR—1233, hsa— miR— 1234, hsa—miR— 1236, hsa—miR— 1237, hsa—miR— 1238, hsa—miR— 124, hsa—miR— 124*, hsa— miR— 1243, hsa—miR— 1244, hsa—miR— 1245, R— 1246, hsa—miR— 1247, hsa—miR— 1248, hsa— miR— 1249, hsa—miR— 1250, hsa—miR— 125 1, hsa—miR— 1252, hsa—miR— 1253, hsa—miR— 1254, hsa— miR—1255a, hsa—miR—1255b, hsa—miR—1256, hsa—miR—1257, hsa—miR—1258, hsa—miR—1259, hsa—miR—125a—3p, hsa—miR—125a—5p, R—125b, hsa—miR— 125b—1*, hsa—miR—125b—2*, hsa—miR—126, hsa—miR—126*, hsa—miR—1260, hsa—miR—1261, hsa—miR—1262, hsa—miR—1263, hsa—miR—1264, hsa—miR—1265, R—1266, hsa—miR—1267, hsa—miR—1268, hsa—miR—1269, R—1270, hsa—miR—1271, hsa—miR—1272, R—1273, hsa—miR—127—3p, R— 1274a, hsa—miR—1274b, hsa—miR—1275, hsa—miR—127—5p, hsa—miR—1276, hsa—miR—1277, hsa— miR— 1278, R— 1279, hsa—miR— 128, hsa—miR— 1280, hsa—miR— 128 1, hsa—miR— 1282, hsa— miR— 1283, hsa—miR— 1284, hsa—miR— 1285, hsa—miR— 1286, hsa—miR— 1287, hsa—miR— 1288, hsa— miR— 1289, R— 129*, hsa—miR— 1290, hsa—miR— 1291, hsa—miR— 1292, hsa—miR— 1293, hsa— miR—129—3p, hsa—miR—1294, hsa—miR—1295, hsa—miR—129—5p, hsa—miR—1296, hsa—miR—1297, hsa—miR—1298, hsa—miR—1299, hsa—miR—1300, hsa—miR—1301, hsa—miR—1302, hsa—miR—1303, hsa—miR—1304, hsa—miR—1305, hsa—miR—1306, hsa—miR—1307, R—1308, hsa—miR—130a, hsa—miR—130a*, hsa—miR—130b, hsa—miR—130b*, hsa—miR—132, hsa—miR—132*, hsa—miR—1321, hsa—miR—1322, hsa—miR—1323, hsa—miR—1324, R—133a, hsa—miR—133b, hsa—miR—134, hsa—miR— 135a, hsa—miR—135a*, hsa—miR—135b, R—135b*, hsa—miR— 136, hsa—miR— 136*, hsa—miR—137, hsa—miR—138, hsa—miR—138—1*, hsa—miR—138—2*, hsa—miR—139—3p, hsa—miR— 139—5p, hsa—miR—140—3p, hsa—miR—140—5p, hsa—miR—141, hsa—miR—141*, hsa—miR—142—3p, hsa—miR—142—5p, hsa—miR— 143, hsa—miR— 143*, hsa—miR— 144, hsa—miR— 144*, hsa—miR— 145, hsa—miR—145*, R—146a, R—146a*, hsa—miR—146b—3p, hsa—miR—146b—5p, hsa— miR— 147, hsa—miR— 147b, hsa—miR— 148a, hsa—miR—148a*, hsa—miR—148b, hsa—miR—148b*, R— 149, hsa—miR— 149*, hsa—miR— 150, hsa—miR—150*, R—151—3p, hsa—miR— 15 1— 5p, hsa—miR—152, hsa—miR—153, hsa—miR—154, hsa—miR—154*, hsa—miR—155, hsa—miR—155*, _ 45 _ hsa—miR—lSa, hsa—miR—15a*, hsa—miR—le, hsa—miR—15b*, hsa—miR—16, hsa—miR—16—1*, hsa— miR—16—2*, hsa—miR—17, R—17*, hsa—miR—IS 1a, hsa—miR—IS 121*, hsa—miR—181a—2*, hsa—miR— 18 1b, hsa—miR— 18 10, hsa—miR— 18 10*, R— 1 8 1d, hsa—miR— 1 82, hsa—miR—182*, hsa—miR—1825, hsa—miR—1826, hsa—miR—1827, hsa—miR—183, hsa—miR—183*, hsa—miR—184, R—ISS, hsa—miR—185*, hsa—miR—186, R—186*, hsa—miR—187, hsa—miR—187*, hsa— miR—188—3p, hsa—miR—lSS—Sp, hsa—miR—lSa, hsa—miR—18a*, hsa—miR—le, hsa—miR—18b*, hsa—miR—190, hsa—miR—190b, hsa—miR—191, hsa—miR—191*, hsa—miR—192, hsa—miR—192*, hsa— miR—193a—3p, hsa—miR—193a—5p, hsa—miR—193b, hsa—miR—193b*, hsa—miR—194, hsa—miR— 194*, hsa—miR—195, hsa—miR—195*, hsa—miR—196a, hsa—miR—196a*, hsa—miR—196b, hsa—miR— 197, hsa—miR—198, hsa—miR—199a—3p, hsa—miR—199a—5p, hsa—miR—199b—5p, hsa—miR—19a, hsa— miR—19a*, hsa—miR—19b, hsa—miR—19b—1*, hsa—miR—19b—2*, hsa—miR—200a, hsa—miR—200a*, hsa—miR—200b, hsa—miR—200b*, hsa—miR—2OOC, hsa—miR—2OOC*, hsa—miR—202, hsa—miR—202*, R—203, hsa—miR—204, hsa—miR—205, hsa—miR—206, hsa—miR—208a, hsa—miR—208b, hsa— a, hsa—miR—20a*, R—20b, hsa—miR—20b*, hsa—miR—21, hsa—miR—21*, hsa—miR— 210, hsa—miR—21 1, hsa—miR—212, hsa—miR—214, hsa—miR—214*, hsa—miR—215, hsa—miR—216a, hsa—miR—216b, hsa—miR—217, hsa—miR—218, hsa—miR—218—1*, R—218—2*, hsa—miR—219— 1—3p, hsa—miR—219—2—3p, hsa—miR—219—5p, R—22, hsa—miR—22*, hsa—miR—220a, hsa— miR—220b, hsa—miR—220c, hsa—miR—221, hsa—miR—221*, hsa—miR—222, hsa—miR—222*, hsa— miR—223, hsa—miR—223*, hsa—miR—224, hsa—miR—23a, hsa—miR—23a*, hsa—miR—23b, R— 23b*, hsa—miR—24, hsa—miR—24—1*, hsa—miR—24—2*, hsa—miR—25, hsa—miR—25*, R—26a, hsa—miR—26a—1*, hsa—miR—26a—2*, hsa—miR—26b, hsa—miR—26b*, hsa—miR—27a, hsa—miR—27a*, hsa—miR—27b, hsa—miR—27b*, hsa—miR—28—3p, hsa—miR—28—5p, hsa—miR—296—3p, hsa—miR— 296—5p, hsa—miR—297, hsa—miR—298, hsa—miR—299—3p, R—299—5p, hsa—miR—29a, hsa— miR—29a*, hsa—miR—29b, hsa—miR—29b—1*, hsa—miR—29b—2*, hsa—miR—29c, hsa—miR—29c*, R—300, hsa—miR—301a, R—301b, R—302a, hsa—miR—302a*, hsa—miR—302b, hsa—miR—302b*, hsa—miR—302C, hsa—miR—302C*, hsa—miR—302d, hsa—miR—302d*, hsa—miR— 302e, hsa—miR—302f, hsa—miR—30a, hsa—miR—30a*, hsa—miR—30b, R—30b*, hsa—miR— 300, R—3OC—1*, hsa—miR—3OC—2*, hsa—miR—30d, hsa—miR—30d*, hsa—miR—3OC, hsa—miR— 306*, hsa—miR—3 1, hsa—miR—3 1*, hsa—miR—32, hsa—miR—32*, hsa—miR—320a, hsa—miR—320b, hsa—miR—320c, hsa—miR—320d, hsa—miR—323—3p, hsa—miR—323—5p, hsa—miR—324—3p, hsa—miR— , R—325, hsa—miR—326, hsa—miR—328, hsa—miR—329, hsa—miR—330—3p, hsa—miR— 330—5p, hsa—miR—331—3p, hsa—miR—331—5p, hsa—miR—335, hsa—miR—335*, hsa—miR—337—3p, _ 46 _ hsa—miR—337—5p, hsa—miR—338—3p, hsa—miR—338—5p, R—339—3p, hsa—miR—339—5p, hsa— miR—33a, hsa—miR—33a*, hsa—miR—33b, hsa—miR—33b*, hsa—miR—340, hsa—miR—340*, hsa— miR—342—3p, hsa—miR—342—5p, hsa—miR—345, hsa—miR—346, hsa—miR—34a, hsa—miR—34a*, hsa— miR—34b, R—34b*, hsa—miR—34c—3p, hsa—miR—34c—5p, hsa—miR—361—3p, hsa—miR—361— 5p, hsa—miR—362—3p, hsa—miR—362—5p, hsa—miR—363, hsa—miR—363*, hsa—miR—365, hsa—miR— 367, hsa—miR—367*, hsa—miR—369—3p, hsa—miR—369—5p, hsa—miR—370, hsa—miR—371—3p, hsa— miR—371—5p, hsa—miR—372, hsa—miR—373, hsa—miR—373*, hsa—miR—374a, hsa—miR—374a*, hsa— miR—374b, hsa—miR—374b*, hsa—miR—375, hsa—miR—376a, hsa—miR—376a*, hsa—miR—376b, hsa—miR—376c, hsa—miR—377, hsa—miR—377*, hsa—miR—378, hsa—miR—378*, hsa—miR—379, hsa— miR—379*, hsa—miR—380, hsa—miR—380*, hsa—miR—381, hsa—miR—382, hsa—miR—383, hsa—miR— 384, hsa—miR—409—3p, hsa—miR—409—5p, hsa—miR—410, hsa—miR—41 1, hsa—miR—41 1*, hsa—miR— 412, hsa—miR—421, hsa—miR—422a, hsa—miR—423—3p, R—423—5p, hsa—miR—424, hsa—miR— 424*, hsa—miR—425, hsa—miR—425*, hsa—miR—429, hsa—miR—43 1, hsa—miR—43 1*, hsa—miR—432, hsa—miR—432*, hsa—miR—433, hsa—miR—448, hsa—miR—449a, hsa—miR—449b, hsa—miR—450a, hsa—miR—450b—3p, hsa—miR—450b—5p, hsa—miR—45 1, hsa—miR—452, hsa—miR—452*, hsa—miR— 453, hsa—miR—454, hsa—miR—454*, hsa—miR—455—3p, hsa—miR—455—5p, hsa—miR—483—3p, hsa— miR—483—5p, hsa—miR—484, hsa—miR—485—3p, hsa—miR—485—5p, hsa—miR—486—3p, hsa—miR— 486—5p, hsa—miR—487a, hsa—miR—487b, hsa—miR—488, R—488*, hsa—miR—489, hsa—miR— 490—3p, hsa—miR—490—5p, hsa—miR—491—3p, hsa—miR—491—5p, hsa—miR—492, hsa—miR—493, hsa— 3*, hsa—miR—494, hsa—miR—495, hsa—miR—496, hsa—miR—497, hsa—miR—497*, hsa—miR— 498, hsa—miR—499—3p, hsa—miR—499—5p, hsa—miR—SOO, hsa—miR—500*, hsa—miR—501—3p, hsa— miR—501—5p, hsa—miR—502—3p, R—502—5p, hsa—miR—503, hsa—miR—504, R—505, hsa—miR—505*, hsa—miR—506, R—507, hsa—miR—508—3p, hsa—miR—508—5p, hsa—miR—509— 3—5p, hsa—miR—509—3p, hsa—miR—509—5p, hsa—miR—SIO, hsa—miR—Sl 1, R—512—3p, hsa— miR—512—5p, hsa—miR—513a—3p, hsa—miR—513a—5p, hsa—miR—S 13b, R—S 13c, hsa—miR— 514, hsa—miR—515—3p, hsa—miR—515—5p, R—516a—3p, hsa—miR—516a—5p, hsa—miR—S 16b, hsa—miR—S 17*, hsa—miR—S 17a, hsa—miR—S 17b, hsa—miR—S 17c, hsa—miR—518a—3p, hsa—miR— 518a—5p, hsa—miR—S 18b, R—S 18c, R—S 18c*, hsa—miR—518d—3p, hsa—miR—S 18d— 5p, hsa—miR—518e, hsa—miR—518e*, hsa—miR—518f, hsa—miR—518f*, hsa—miR—519a, hsa—miR— 519b—3p, hsa—miR—519c—3p, R—S 19d, R—S 19C, hsa—miR—S 196*, hsa—miR—520a— 3p, R—520a—5p, hsa—miR—520b, hsa—miR—52OC—3p, hsa—miR—520d—3p, hsa—miR—520d—5p, hsa—miR—5206, hsa—miR—520f, hsa—miR—520g, hsa—miR—520h, R—521, hsa—miR—522, _ 47 _ hsa—miR—523, hsa—miR—524—3p, hsa—miR—524—5p, hsa—miR—525—3p, hsa—miR—525—5p, hsa— miR—526b, hsa—miR—526b*, hsa—miR—532—3p, hsa—miR—532—5p, hsa—miR—539, hsa—miR—541, hsa—miR—541*, hsa—miR—542—3p, hsa—miR—542—5p, hsa—miR—543, R—544, hsa—miR—545, hsa—miR—545*, hsa—miR—548a—3p, hsa—miR—548a—5p, hsa—miR—548b—3p, hsa—miR—548b—5p, hsa—miR—54SC—3p, hsa—miR—54SC—5p, hsa—miR—548d—3p, hsa—miR—548d—5p, R—5486, hsa—miR—548f, hsa—miR—548g, hsa—miR—548h, hsa—miR—548i, hsa—miR—548j, hsa—miR—548k, hsa—miR—5481, hsa—miR—548m, hsa—miR—548n, hsa—miR—5480, hsa—miR—548p, hsa—miR—549, hsa—miR—550, hsa—miR—550*, hsa—miR—551a, hsa—miR—551b, hsa—miR—551b*, hsa—miR—552, hsa—miR—553, R—554, hsa—miR—555, hsa—miR—556—3p, hsa—miR—556—5p, hsa—miR—557, hsa—miR—558, hsa—miR—559, hsa—miR—561, hsa—miR—562, hsa—miR—563, hsa—miR—564, hsa— miR—566, hsa—miR—567, hsa—miR—568, hsa—miR—569, hsa—miR—570, hsa—miR—571, hsa—miR— 572, hsa—miR—573, R—574—3p, hsa—miR—574—5p, hsa—miR—575, hsa—miR—576—3p, hsa— miR—576—5p, hsa—miR—577, hsa—miR—578, hsa—miR—579, hsa—miR—SSO, hsa—miR—581, hsa— miR—582—3p, hsa—miR—582—5p, hsa—miR—583, hsa—miR—584, R—585, hsa—miR—586, hsa— miR—587, hsa—miR—588, hsa—miR—589, hsa—miR—589*, hsa—miR—590—3p, hsa—miR—590—5p, hsa— miR—591, hsa—miR—592, hsa—miR—593, hsa—miR—593*, hsa—miR—595, hsa—miR—596, hsa—miR— 597, R—598, hsa—miR—599, R—600, hsa—miR—601, hsa—miR—602, hsa—miR—603, hsa—miR—604, hsa—miR—605, hsa—miR—606, hsa—miR—607, hsa—miR—608, hsa—miR—609, hsa— 0, R—61 1, hsa—miR—612, hsa—miR—613, R—614, R—615—3p, hsa— miR—615—5p, hsa—miR—616, hsa—miR—616*, hsa—miR—617, hsa—miR—618, R—619, hsa— miR—620, hsa—miR—621, hsa—miR—622, hsa—miR—623, hsa—miR—624, hsa—miR—624*, hsa—miR— 625, hsa—miR—625*, hsa—miR—626, hsa—miR—627, hsa—miR—628—3p, hsa—miR—628—5p, hsa—miR— 629, hsa—miR—629*, hsa—miR—630, hsa—miR—63 1, hsa—miR—632, hsa—miR—633, hsa—miR—634, hsa—miR—635, hsa—miR—636, hsa—miR—637, hsa—miR—638, hsa—miR—639, hsa—miR—640, hsa— miR—641, R—642, hsa—miR—643, R—644, hsa—miR—645, R—646, hsa—miR— 647, hsa—miR—648, hsa—miR—649, hsa—miR—650, hsa—miR—65 1, hsa—miR—652, hsa—miR—653, hsa—miR—654—3p, hsa—miR—654—5p, hsa—miR—655, hsa—miR—656, hsa—miR—657, hsa—miR—658, hsa—miR—659, hsa—miR—660, hsa—miR—661, hsa—miR—662, hsa—miR—663, hsa—miR—663b, hsa— miR—664, hsa—miR—664*, hsa—miR—665, hsa—miR—668, hsa—miR—671—3p, R—671—5p, hsa— miR—675, hsa—miR—7, hsa—miR—708, hsa—miR—708*, R—7—1*, hsa—miR—7—2*, hsa—miR— 720, hsa—miR—744, hsa—miR—744*, hsa—miR—758, hsa—miR—760, R—765, hsa—miR—766, hsa—miR—767—3p, hsa—miR—767—5p, hsa—miR—768—3p, hsa—miR—768—5p, hsa—miR—769—3p, hsa— _ 48 _ miR—769—5p, hsa—miR—770—5p, hsa—miR—802, hsa—miR—873, R—874, hsa—miR—875—3p, R—875—5p, hsa—miR—876—3p, hsa—miR—876—5p, hsa—miR—877, hsa—miR—877*, R— 885—3p, hsa—miR—885—5p, hsa—miR—886—3p, hsa—miR—886—5p, hsa—miR—887, hsa—miR—888, hsa— miR—888*, hsa—miR—889, hsa—miR—890, hsa—miR—89la, hsa—miR—89lb, hsa—miR—892a, hsa— miR—892b, hsa—miR—9, hsa—miR—9*, hsa—miR—920, hsa—miR—92l, hsa—miR—922, hsa—miR—923, hsa—miR—924, hsa—miR—92a, hsa—miR—92a—l*, hsa—miR—92a—2*, hsa—miR—92b, hsa—miR—92b*, hsa—miR—93, hsa—miR—93*, hsa—miR—933, hsa—miR—934, R—935, hsa—miR—936, hsa—miR— 937, hsa—miR—938, hsa—miR—939, R—940, hsa—miR—94l, hsa—miR—942, hsa—miR—943, hsa—miR—944, hsa—miR—95, hsa—miR—96, hsa—miR—96*, hsa—miR—98, hsa—miR—99a, hsa—miR— 99a*, hsa—miR—99b, and hsa—miR—99b*.
A miRNA inhibits the function of the mRNAs it targets and, as a result, inhibits expression of the polypeptides encoded by the mRNAs. Thus, blocking (partially or totally) the activity of the miRNA (e.g., silencing the miRNA) can effectively induce, or e, expression of a polypeptide Whose expression is inhibited (derepress the polypeptide). In one embodiment, ession of polypeptides encoded by mRNA targets of a miRNA is accomplished by inhibiting the miRNA activity in cells through any one of a variety of methods. For example, blocking the activity of a miRNA can be accomplished by hybridization with a small interfering nucleic acid (e.g., antisense oligonucleotide, miRNA sponge, TuD RNA) that is mentary, or substantially complementary to, the miRNA, thereby blocking interaction of the miRNA with its target mRNA. As used , an small interfering nucleic acid that is substantially complementary to a miRNA is one that is capable of hybridizing with a miRNA, and blocking the miRNA’s activity. In some embodiments, a small interfering nucleic acid that is substantially mentary to a miRNA is a small interfering c acid that is complementary to the miRNA at all but 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, 14, 15, l6, 17, or 18 bases. In some embodiments, a small interfering nucleic acid sequence that is substantially complementary to a miRNA, or is a small interfering nucleic acid ce that is complementary to the miRNA with at least one base.
A "miRNA Inhibitor" is an agent that blocks miRNA function, expression and/or processing. For instance, these molecules include but are not limited to NA specific antisense, microRNA sponges, tough decoy RNAs (TuD RNAs) and microRNA oligonucleotides (double—stranded, n, short ucleotides) that inhibit miRNA interaction with a Drosha complex. MicroRNA inhibitors can be expressed in cells from a _ 49 _ transgenes of a rAAV vector, as discussed above. MicroRNA sponges specifically inhibit miRNAs through a mentary eric seed sequence (Ebert, M.S. Nature Methods, Epub August, 12, 2007). In some embodiments, an entire family of miRNAs can be silenced using a single sponge sequence. TuD RNAs achieve efficient and long—term—suppression of specific miRNAs in mammalian cells (See, e. g., Takeshi Haraguchi, et al., Nucleic Acids Research, 2009, Vol. 37, No. 6 e43, the ts of which relating to TuD RNAs are orated herein by reference). Other methods for silencing miRNA function (derepression of miRNA targets) in cells will be apparent to one of ordinary skill in the art.
In some embodiments, the cloning capacity of the recombinant RNA vector may limit a d coding sequence and may e the complete replacement of the virus's 4.8 kilobase genome. Large genes may, therefore, not be suitable for use in a rd recombinant AAV vector, in some cases. The skilled artisan will appreciate that options are available in the art for overcoming a limited coding capacity. For example, the AAV ITRs of two genomes can anneal to form head to tail concatamers, almost doubling the capacity of the vector. Insertion of splice sites allows for the removal of the ITRs from the transcript. Other options for overcoming a limited cloning capacity will be apparent to the skilled artisan.
Somatic Transgenic Animal Models Produced Using rAAV-Based Gene Transfer The disclosure also relates to the tion of somatic transgenic animal models of disease using recombinant Adeno—Associated Virus (rAAV) based methods. The methods are based, at least in part, on the observation that AAV serotypes and variants thereof mediate efficient and stable gene transfer in a tissue specific manner in adult animals. The rAAV elements (capsid, promoter, transgene products) are combined to achieve somatic transgenic animal models that express a stable transgene in a time and tissue ic manner. The somatic transgenic animal produced by the methods of the disclosure can serve as useful models of human disease, pathological state, and/or to characterize the effects of gene for which the function (e.g., tissue specific, disease role) is unknown or not fully understood.
For example, an animal (e.g., mouse) can be infected at a distinct developmental stage (e.g., age) with a rAAV comprising a capsid having a specific tissue targeting capability (e.g., liver, heart, pancreas) and a transgene having a tissue ic promoter driving sion of a gene ed in disease. Upon infection, the rAAV infects ct cells of the target tissue and produces the t of the transgene. _ 50 _ In some embodiments, the sequence of the coding region of a transgene is modified.
The modification may alter the function of the product encoded by the ene. The effect of the modification can then be studied in vivo by generating a somatic transgenic animal model using the methods disclosed herein. In some embodiments, modification of the sequence of coding region is a nonsense mutation that results in a fragment (e.g., a truncated version). In other cases, the modification is a se mutation that s in an amino acid substitution. Other modifications are possible and will be apparent to the skilled artisan.
In some embodiments, the transgene causes a pathological state. A transgene that causes a pathological state is a gene whose product has a role in a disease or disorder (e.g., causes the disease or disorder, makes the animal susceptible to the disease or disorder) and/or may induce the disease or disorder in the animal. The animal can then be observed to evaluate any number of aspects of the disease (6.g. to ent, etc). , progression, response These examples are not meant to be ng, other aspects and examples are disclosed herein and described in more detail below.
The disclosure in some s, provide methods for producing c transgenic animal models through the targeted destruction of specific cell types. For example, models of type 1 diabetes can be produced by the targeted destruction of pancreatic Beta—islets. In other examples, the targeted destruction of specific cell types can be used to evaluate the role of specific cell types on human disease. In this regard, enes that encode ar toxins (e.g., diphtheria toxin A (DTA)) or pro—apoptotic genes (NTR, Box, etc.) can be useful as transgenes for functional ablation of specific cell types. Other ary transgenes, whose products kill cells are embraced by the methods disclosed herein and will be apparent to one of ordinary skill in the art.
The disclosure, in some aspects, provides methods for producing somatic enic animal models to study the long—term s of over—expression or knockdown of genes. The long term over expression or knockdown (e.g., by shRNA, miRNA, miRNA inhibitor, etc.) of genes in specific target tissues can disturb normal metabolic balance and establish a pathological state, thereby producing an animal model of a disease, such as, for example, cancer. The disclosure in some aspects, provides methods for ing somatic transgenic animal models to study the long—term effects of over—expression or knockdown of gene of potential oncogenes and other genes to study genesis and gene function in the targeted WO 71831 _ 51 _ tissues. Useful ene products include ns that are known to be associated with cancer and small interfering nucleic acids inhibiting the expression of such ns.
Other suitable enes may be readily selected by one of skill in the art provided that they are useful for creating animal models of —specific pathological state and/or disease.
Recombinant AAVAdministration Methods The rAAVs may be delivered to a subject in compositions according to any appropriate methods known in the art. The rAAV, preferably suspended in a physiologically compatible carrier (e.g., in a ition), may be administered to a subject, e.g., host animal, such as a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or a non—human primate (e.g., Macaque). In some embodiments a host animal does not include a human.
Delivery of the rAAVs to a mammalian subject may be by, for example, uscular injection or by administration into the bloodstream of the mammalian subject.
Administration into the bloodstream may be by injection into a vein, an artery, or any other ar conduit. In some embodiments, the rAAVs are administered into the bloodstream by way of isolated limb perfusion, a technique well known in the surgical arts, the method essentially enabling the artisan to isolate a limb from the systemic ation prior to administration of the rAAV virions. A variant of the isolated limb perfusion technique, described in US. Pat. No. 6,177,403, can also be employed by the skilled artisan to administer the virions into the vasculature of an isolated limb to potentially enhance transduction into muscle cells or tissue. Moreover, in certain instances, it may be desirable to deliver the virions to the CNS of a subject. By "CNS" is meant all cells and tissue of the brain and spinal cord of a vertebrate. Thus, the term includes, but is not limited to, neuronal cells, glial cells, astrocytes, cereobrospinal fluid (CSF), interstitial spaces, bone, cartilage and the like. Recombinant AAVs may be red directly to the CNS or brain by injection into, e.g., the ventricular region, as well as to the striatum (e.g., the caudate nucleus or putamen of the striatum), spinal cord and neuromuscular junction, or cerebellar lobule, with a needle, catheter or d device, using neurosurgical techniques known in the art, such as by stereotactic injection (see, e.g., Stein et al., J Virol 73:3424—3429, 1999; Davidson et al., PNAS 97:3428—3432, 2000; on et al., Nat. Genet. 223, 1993; and Alisky and Davidson, Hum. Gene Ther. 11:2315—2329, 2000). _ 52 _ The compositions of the disclosure may comprise an rAAV alone, or in ation with one or more other viruses (e.g., a second rAAV encoding having one or more different transgenes). In some embodiments, a composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more ent rAAVs each having one or more different transgenes.
Suitable carriers may be readily ed by one of skill in the art in view of the indication for which the rAAV is directed. For example, one suitable carrier includes saline, which may be formulated with a variety of ing solutions (e.g., ate ed saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present disclosure.
Optionally, the compositions of the disclosure may contain, in addition to the rAAV and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers. Suitable exemplary vatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. le al stabilizers include gelatin and albumin.
The rAAVs are administered in sufficient amounts to transfect the cells of a desired tissue and to provide sufficient levels of gene transfer and expression without undue adverse effects. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to the selected organ (e.g., intraportal ry to the liver), oral, inhalation ding intranasal and intratracheal delivery), cular, intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other al routes of administration. Routes of administration may be combined, if desired.
The dose of rAAV virions required to achieve a particular peutic effect," e.g., the units of dose in genome copies/per kilogram of body weight ), will vary based on several factors including, but not limited to: the route of rAAV virion administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene or RNA product. One of skill in the art can readily determine a rAAV virion dose range to treat a patient having a particular disease or disorder based on the aforementioned factors, as well as other factors that are well known in the art.
An effective amount of an rAAV is an amount sufficient to target infect an animal, target a desired tissue. In some embodiments, an effective amount of an rAAV is an amount _ 53 _ sufficient to produce a stable somatic enic animal model. The effective amount will depend primarily on factors such as the species, age, weight, health of the subject, and the tissue to be ed, and may thus vary between animals or tissues. For example, an effective amount of the rAAV is generally in the range of from about 1 ml to about 100 ml of solution containing from about 109 to 1016 genome copies. In some embodiments the rAAV is stered at a dose of 1010, 1011, 1012, 1013, 1014, or 1015 genome copies per subject. In some embodiments the rAAV is administered at a dose of 1010, 1011, 1012, 1013, or 1014 genome copies per kg. In some cases, a dosage between about 1011 to 1012 rAAV genome copies is appropriate. In certain embodiments, 1012 rAAV genome copies is effective to target heart, liver, and pancreas tissues. In some cases, stable enic animals are produced by multiple doses of an rAAV.
In some embodiments, rAAV compositions are formulated to reduce aggregation of AAV particles in the composition, particularly where high rAAV concentrations are present (e.g., ~1013 GC/ml or more). Methods for reducing aggregation of rAAVs are well—known in the art and, include, for example, on of surfactants, pH adjustment, salt concentration adjustment, etc. (See, e.g., Wright FR, et al., Molecular Therapy (2005) 12, 171—178, the contents of which are incorporated herein by reference.) Formulation of pharmaceutically—acceptable excipients and carrier solutions is well— known to those of skill in the art, as is the pment of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of ent regimens.
Typically, these ations may contain at least about 0. l% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation. Naturally, the amount of active compound in each eutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half—life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a y of dosages and treatment regimens may be desirable. _ 54 _ In certain circumstances it will be desirable to deliver the rAAV—based therapeutic constructs in suitably formulated ceutical compositions disclosed herein either subcutaneously, pancreatically, intranasally, parenterally, intravenously, intramuscularly, intrathecally, or orally, intraperitoneally, or by inhalation. In some embodiments, the administration modalities as described in U.S. Pat. Nos. 5,543,158; ,641,515 and 5,399,363 (each specifically incorporated herein by reference in its entirety) may be used to deliver rAAVs. In some embodiments, a preferred mode of administration is by portal vein injection.
The pharmaceutical forms suitable for injectable use include sterile s solutions or dispersions and sterile powders for the extemporaneous ation of sterile injectable solutions or dispersions. Dispersions may also be prepared in glycerol, liquid hylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these ations contain a preservative to prevent the growth of microorganisms. In many cases the form is e and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be ved t the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid hylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The tion of the action of microorganisms can be brought about by s cterial and antifungal , for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
For stration of an injectable aqueous solution, for example, the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal stration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to _ 55 _ 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 038 and 1570— 1580). Some variation in dosage will necessarily occur depending on the condition of the host. The person responsible for administration will, in any event, determine the appropriate dose for the dual host.
Sterile injectable solutions are prepared by incorporating the active rAAV in the required amount in the riate solvent with various other ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are ed by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum—drying and freeze—drying techniques which yield a powder of the active ingredient plus any onal desired ient from a previously sterile—filtered solution thereof.
The rAAV itions disclosed herein may also be formulated in a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hloric or phosphoric acids, or such organic acids as acetic, , tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
Upon formulation, solutions will be stered in a manner compatible with the dosage ation and in such amount as is therapeutically effective. The formulations are easily stered in a variety of dosage forms such as injectable solutions, drug—release capsules, and the like.
As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the compositions. The phrase "pharmaceutically—acceptable" refers to lar entities and compositions that do not produce an allergic or similar untoward reaction when administered to a host. _ 56 _ Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, may be used for the introduction of the compositions of the present disclosure into suitable host cells. In particular, the rAAV vector delivered trangenes may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a rticle or the like.
Such formulations may be preferred for the introduction of pharmaceutically acceptable ations of the c acids or the rAAV ucts disclosed herein. The ion and use of liposomes is generally known to those of skill in the art. Recently, liposomes were developed with improved serum stability and circulation half—times (U.S. Pat.
No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been bed (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; ,738,868 and 5,795,587).
Liposomes have been used successfully with a number of cell types that are normally ant to transfection by other procedures. In addition, liposomes are free of the DNA length aints that are typical of viral—based delivery systems. Liposomes have been used effectively to introduce genes, drugs, herapeutic agents, viruses, transcription factors and allosteric ors into a y of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome—mediated drug delivery have been ted.
Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4 um. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500.ANG., containing an aqueous on in the core.
Alternatively, nanocapsule formulations of the rAAV may be used. Nanocapsules can generally entrap substances in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 um) should be ed using polymers able to be degraded in viva. Biodegradable polyalkyl—cyanoacrylate nanoparticles that meet these requirements are contemplated for use.
In addition to the methods of delivery described above, the following techniques are also contemplated as alternative methods of delivering the rAAV itions to a host.
Sonophoresis (i. e., ultrasound) has been used and described in US. Pat. No. 5,656,016 as a _ 57 _ device for enhancing the rate and efficacy of drug tion into and through the circulatory system. Other drug delivery alternatives contemplated are intraosseous injection (U.S. Pat.
No. 5,779,708), microchip devices (U.S. Pat. No. 5,797,898), ophthalmic formulations (Bourlais et al., 1998), transdermal matrices (US. Pat. Nos. 5,770,219 and 5,783,208) and feedback—controlled delivery (US. Pat. No. 899).
Kits and Related Compositions The agents described herein may, in some embodiments, be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic or research applications. A kit may include one or more ners housing the components of the disclosure and instructions for use. Specifically, such kits may e one or more agents described herein, along with instructions describing the ed application and the proper use of these agents. In certain ments agents in a kit may be in a pharmaceutical formulation and dosage suitable for a particular application and for a method of stration of the agents. Kits for research purposes may n the components in appropriate concentrations or quantities for running various experiments.
The kit may be designed to facilitate use of the methods described herein by researchers and can take many forms. Each of the compositions of the kit, where able, may be provided in liquid form (e.g., in solution), or in solid form, (e.g., a dry powder). In certain cases, some of the compositions may be constitutable or otherwise processable (e. g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit. As used herein, "instructions" can define a component of instruction and/or promotion, and typically involve written instructions on or associated with packaging of the disclosure.
Instructions also can include any oral or electronic instructions ed in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e. g., videotape, DVD, eta), Internet, and/or web—based communications, etc. The written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological ts, which instructions can also reflects approval by the agency of manufacture, use or sale for animal administration. _ 58 _ The kit may contain any one or more of the components described herein in one or more containers. As an example, in one embodiment, the kit may e instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject. The kit may include a container housing agents described . The agents may be in the form of a liquid, gel or solid (powder). The agents may be prepared sterilely, packaged in syringe and shipped refrigerated. Alternatively it may be housed in a vial or other ner for storage. A second container may have other agents ed sterilely.
Alternatively the kit may e the active agents premixed and shipped in a syringe, vial, tube, or other container. The kit may have one or more or all of the components required to administer the agents to an animal, such as a syringe, topical application s, or iv needle tubing and bag, particularly in the case of the kits for producing specific somatic animal models.
The kit may have a variety of forms, such as a blister pouch, a shrink wrapped pouch, a vacuum le pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the ories loosely packed within the pouch, one or more tubes, containers, a box or a bag. The kit may be sterilized after the accessories are added, y allowing the individual accessories in the container to be otherwise ped. The kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art. The kit may also include other components, depending on the specific application, for example, ners, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration etc.
The instructions included within the kit may involve s for detecting a latent AAV in a cell. In addition, kits of the disclosure may include, instructions, a negative and/or positive control, containers, diluents and buffers for the sample, sample preparation tubes and a printed or electronic table of reference AAV sequence for sequence comparisons.
EXAMPLES Example 1: Isolation Of Transcriptionally Active, Novel AAV Capsid Sequences With d Tissue Tropisms and Properties From Human Tissues. _ 59 _ This example describes novel AAV capsid sequences isolated by the ing steps: 1) PCR ication of thAV genomes present in normal and diseased human tissues; 2) high—throughput single—molecule, real—time (SMRT) sequencing of PCR amplicon libraries; 3) variant identification/profiling by bioinformatic analyses; and 4) the selection of high— confidence ORFs that can be translated into full length capsid proteins. Schematic depictions of workflows used in this example are shown in FIGs. lA—lB.
This approach exploits the natural pool of genomic diversity observed among viral genomes isolated from both normal and tumor tissues. Conceptually, in viva tissues act as l incubators for viral genomic diversity through selective re and/or immune evasion. Thus, the ery of inter— and intra—tissue variability, as well as inter—patient diversity t from methods that are able to profile the full spectrum of AAV variants found among tissues and organs of human .
PCR Amplification 0fAAV genomesfrom human tissues To isolate diverse AAV ts with the potential for identifying new serotypes with unique tropisms, 844 human surgical specimens from 455 patients were collected from West China Hospital, Sichuan sity, Chengdu, China. These tissues encompass a wide—range of tissue/organ types, as well as various tumors types (Table 1). In particular, AAV variants were identified from nine normal liver tissues, 7 liver tumors, four enlarged prostate tissues, two normal lung tissues, one pancreatic tumor tissue, one breast cancer tissue, one normal breast tissue, one gastric cancer tissue, one normal gastric tissue, one brain tissue and one glioma sample.
Total c DNA was extracted from human tissues and subjected to PCR amplification of AAV capsid sequence. PCR primers used in this example are described in Table 2. Briefly, either panAAV primers for the ication of 4.1—kb AAV rep—cap sequence (e.g., RepF318, ), or panAAV primers for amplification of 2.3—kb AAV cap sequence (e.g., CapF, CapR) were used for PCR.
Table 1: Clinical specimens for thAV genome amplification Tissue quantity Or ang ——-m- Table 2: PCR primer sequences Sequence ) SEQ ID NO: 8 GCCATGCCGGGGTTCTACGAGAT ACAGGAGACCAAAGTTCAACTGAAACGA GAAACGAATTAACCGGTTTATTGATTAA High-throughput sequencing ofAAVPCR products and ormatics analysis AAV PCR products were subjected to high—throughput single—molecule, real—time (SMRT) sequencing. This approach removes the need to perform viral genome truction and chimera prediction from aligned short—read fragments obtained from other tional high—throughput genome sequencing methodologies.
Using variant analysis pipelines ped from open source bioinformatic tools more than 600 previously undescribed, high—confidence AAV2, AAV2/3 hybrid, and AAVS capsid sequence variants were identified. Specifically, 224 AAVS variants (harboring l to 10 single amino acid variants); 425 AAV2 variants (harboring l to 20 single amino acid variants); and 194 AAV2/3 hybrid variants (harboring 10 to 50 single amino acid ts) were identified.
Tables 3, 4 and 5 summarize the unique capsid protein variants. For purposes of comparison, wild—type AAV2, AAV3, and AAVS capsid amino acid sequences are described in SEQ ID NOs: 869, 870, and 871, respectively. is a scatter plot displaying the distribution of distinct AAV2 capsid variants and AAV2/3 variants harboring one or more single—amino—acid variants.
Table 3: Unique AAV2 and AAV2/3 hybrid variants (amino acid sequences) identified by SMRT cing and bioinformatics analyses.
Unique AAV2 variants _——— Patient Size of Unique SEQ ID NOs: Total unique Sample Source No. DNA (kb) variants (a.a.) variants (a.a.) 2.3 kb (cap) ll78N 4.1 kb 9955N (rep+cap) 852 _-849 U_-————__——— Sam le So Size 0f Total unique rce Pabtlient Unique p u b) variants (a. a.) variants (a. a. ) L1ver _4— "—_— Liver Tumor 2.3 kb (cap) _— Prostate l_8_75 — 458-461 N/A (420 in 518-538 DNA sequences are provided for 4.1 kb libraries.
Table 4: Unique AAVS variants (amino acid sequences) identified by SMRT sequencing and bioinformatics analyses. _ 62 _ Sample . Size of Unique variants SEQ ID NOS: Total unique Liver =4—7N "— umor_ "— _818€ _— n— Table 5: Additional AAVS variant capsid proteins B45 862 B46 863 B60 864 B61 865 B62 866 B63 867 B64 868 _ 63 _ Example 2: Identification of AAV8 variants with improved in vivo tropism.
A subset of candidate AAV8 variants (e.g., B2, B3, B44 and B61) were cloned into AAV packaging vectors by standard molecular cloning methods, and packaged with luciferase reporter genes driven by the CB6 promoter. Produced vectors were injected into mice and in vivo levels of luciferase transgene sion were ed by whole animal imaging and fication of relative luminescence. It was observed that the B2 (SEQ ID NO: 854) and B3 (SEQ ID NO: 855) variants have higher expression in liver after intramuscular injection (FIGS. 2A—2D), while after IV injection in al mice, the B61 (SEQ ID NO: 865) variant haS higher transduction efficiencies in brain and spinal cord compared to AAV9 (FIGS 3A—3B). This is notable since wild—type AAV8 haS been observed to cross the blood brain barrier less than AAV9. One AAV8 variant, B44 (SEQ ID NO: 861) haS better y transduced to liver after IM injection compared to AAV8 (FIGS. 4A—4B).
Phylogenic analySiS waS performed to compare AAV8 capSid variantS B2, B3, B44, and B61 to other AAV serotypeS. Briefly, amino acid sequences of AAV8 variantS were aligned with other published AAV sequences uSing ClustalW and Phylogenetic trees were inferred uSing the Minimum Evolution method in MEGA6.06. Results of the bioinformatics analySiS indicate that B2, B3, B44, and B61 sequences are d to Clade E [AAV8] capSid proteins. Representative amino acid substitutions in AAV8 ts are Shown in Table 6.
Table 6: Representative amino acid substitutions in AAV8 variants ve to wild—type AAV Variant Representative tutions (relative to wt AAV8) L9lQ, T234A, M374T M374T, M56lV Example 3: In vitro assessment of rAAV genome packaging efficiency and initial characterization of candidate capsid variants.
Molecular cloning ofpackaging plasmid constructs containing selected AAV capsid variants _ 64 _ AAV2 and AAV2/3 hybrid capsid variants identified by SMRT sequencing are cloned into packaging ds by replacing the conventional viral capsid genes using standard molecular cloning strategies (e.g., site—directed mutagenesis of al AAV2 or AAV2/3 capsid expression plasmids, PCR—based cloning and Gibson Assembly, or synthesized by outsourcing). shows vector constructs to be used in multiplexed screening of discovered capsid variants. A summary of the proposed transgene cassettes to be used for various diagnostic strategies is shown in Table 7.
Table 7: Transgene cassettes for s diagnostic strategies Reporter/therapeutic gene analysis CMV enhancer Tissue or cell—type specific Chicken B—actin transduction efficiency CMV enhancer Whole—animal tropism profiling and Luciferase n B—actin individual tissue quantification Thyroxin Liver—specific transduction of secreted Factor IX binding globulin factors. inical testing Multiplex assessment ofpackaging efi‘iciency by high-throughput small-scale vector production and titration for vector genomes Quantification of vector genomes of rAAV in crude lysate is used to directly test rAAV variant packaging efficiency of both first—generation (single—strand AAV) and second— generation (self—complementary AAV) vectors directly following triple—transfection of HEK 293 packaging cells. This provides a streamlined alternative to performing the full workflow for small—scale vector production followed by silver staining and conventional PCR ion of vector genomes to assess virus quality for all discovered ts. Since this method can be scaled for mance in 96—well formats, it us used to quickly identify variants that e high titer s.
Serological evaluation of novel AAV variants Candidate variants with high packaging efficiency are screened for antibody cross— reactivity to current AAVs by rd means, such as capsid immunology assays to test novel rAAVs against serum from AAV— immunized rabbits. In addition, pooled human IgG _ 65 _ (IVIG) neutralizing assays are performed for each ate variant to determine the potential for isting humoral immunity in the human population.
Example 4: In vivo analyses of rAAV2 and rAAV2/3 variants to study vector transduction biology, prevalence of pathotoxicity, tissue/organ tropism, and bio- distribution profiles.
Mouse studies Candidate capsid variants are grouped based on tissue distribution, and prioritized by organs of interest. Groups of candidate variants are ted to clustered—indexing ( 6A), whereby multiple packaging plasmids expressing candidate capsid variants are mixed and expressed to e uniquely DNA barcoded transgenes by triple—transfection (e.g., F9 coagulation factor IX (FIX), to assess liver targeting and expression cy of secreted factors; EGFP, to assess bio—distribution and the extent of tissue—specific transduction via organ/tissue sectioning and comparative fluorescence microscopy; or Luciferase (Luc), to assess the quality of CNS and liver transduction via live animal imaging For studies that gauge the capacity of rAAV variants for liver—targeted transgene expression and ion, rAAV constructs comprising the thyroxine—binding in (TGB), a liver specific promoter, are designed. For studies that profile whole—animal vector transduction, constructs comprising the CMV—enhancer, chicken n promoter (CB6) regulatory cassette are designed.
Vectors encapsidating indexed transgenes are injected into adult and newborn mice by different routes of administration, and screened for secreted F.IX expression, EGFP expression, or Luc expression in h longitudinal studies to profile AAV t— mediated transgene expression. Routes of administration for the CNS/brain include peripheral intravascular (IV, to test transduction across the blood—brain barrier), intracerebroventricular (ICV), arenchymal, and hecal. stration for retina is performed via subretinal injection. In some embodiments, IV injections also target the liver.
Animals that exhibit unique transgene expression compared to control animals (e.g., transgenes delivered by AAVZ, AAV2/3, or AAVS) are sacrificed and harvested for organs.
Individual organs are assayed for the presence and abundance of barcoded transgenes by conventional PCR amplification of bulk DNA extracts or cDNA libraries containing transgene message, ed by Illumina sequencing to trace barcoded transgenes enriched in _ 66 _ each tissue. outlines the general design strategy for transgene indexing. The abundance and tissue/organ distribution of detectable barcoded transgenes reflects candidate rAAV variant tropism and uction efficacy of each group. Highly efficacious candidate groups with desirable vector properties are selected. Individual candidate ts from selected groups are used to e barcoded transgenes for a second round of screening for the purpose of identifying individual, highly cious variants. Clustered—indexing can be carried out iteratively in multiple rounds of hierarchical selection to reduce the workload.
Non-human primate (NHP) studies ate rAAV variants are screened for bio—distribution in non—human primates by a modality similar to the red—indexing ology outlined for mouse studies (). The transduction efficiencies to target organs via different routes of administration are re—assessed in NHPs to validate rAAV variant profiles observed in precursor mouse studies.
Immunogenicity, prevalence of neutralization dy in human populations, capacity for genotoxicity, and general aspects of pathogenicity are gauged alongside primary assessments, for example histopathology of multiple tissues and organs to scrutinize T—cell or neutrophil infiltrates, monitoring toxicity by ALT/AST activity, and analyzing inflammation by examination of histological sections, to determine uction profiles in non—human primate (NHP) animals.
Example 5: Isolation Of Novel AAV Capsid Sequences.
Additional AAV capsid sequences were ed. Using variant analysis pipelines developed from bioinformatic tools, an additional 263 previously undescribed, high— confidence AAV2 and AAV2/3 hybrid capsid sequence variants were identified. For purposes of comparison, wild—type AAV2 and AAV3 capsid amino acid ces are described in SEQ ID NOs: 869 and 870, respectively.
Table 8: Additional unique AAV2 and AAV2/3 hybrid variants (amino acid sequences) identified by SMRT sequencing and bioinformatics analyses.
Unique AAV2 variants _——— Size of Unique ts SEQ ID NOS Total unique SamP16 3011Ice DNA (kb) (33-) (33): variants (a.a.) 2-2kb _- 1726—1733 -_ L——verLwerTumor _ungTumor —_——— Unique AAV2/3 variants_——— Size of Unique variants Total unique Sample Source DNA (kb) (a.a.) variants (a.a.) Can—erBreast 1815—1832 1833—1849 22k]? 174 L——ver 966 _iverTumor 1967-1988 The corresponding DNA sequences are provided for all libraries. The nucleic acid sequences for the AAV2 capsid variants pond to SEQ ID NOs: 1989—2077. The nucleic acid sequences for the AAV2/3 capsid variants correspond to SEQ ID NOs: 2078—225 1.
This disclosure is not limited in its application to the details of construction and the arrangement of components set forth in this ption or illustrated in the drawings. The disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including, 6‘comprising," or g,:9 6Lcontaining,:9 6‘involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents f as well as additional items.
Having thus described l aspects of at least one embodiment of this disclosure, it is to be appreciated various alterations, modifications, and ements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the disclosure.
Accordingly, the foregoing description and drawings are by way of example only. _ 68 _
Claims (45)
1. l. A recombinant sion vector comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NO: I to 409, 435—868, or 988, or a fragment thereof that does not encode a peptide that is identical to a sequence of any one of SEQ ID NOs: 869, 870, or 871.
2. An isolated AAV capsid protein comprising an amino acid sequence selected 10 from the group consisting of: SEQ ID NOs: l to 409, 435—868 and 1726—1988, or fragment thereof.
3. An isolated AAV capsid protein sing a sequence selected from SEQ ID NOs: 1—409, 837—852, or 1726—1814, wherein an amino acid of the sequence that is not 15 identical to a corresponding amino acid of the sequence set forth as SEQ ID NO: 869 is replaced with a conservative substitution.
4. An isolated AAV capsid protein comprising a sequence selected from SEQ ID NOs: 8 or 1815—1988, wherein an amino acid of the sequence that is not cal to a 20 corresponding amino acid of the sequence set forth as SEQ ID NO: 869 or 870 is replaced with a conservative substitution.
5. An isolated AAV capsid n comprising a sequence selected from SEQ ID NOs: 629-836 or 853—868, wherein an amino acid of the sequence that is not identical to a 25 corresponding amino acid of the sequence set forth as SEQ ID NO: 871 is replaced with a conservative tution.
6. A peptide nt of the isolated AAV capsid protein of any one of claims 2 to 5 that is not identical to a sequence of any one of SEQ ID NOs: 869, 870, or 871.
7. An isolated AAV capsid protein comprising the peptide fragment of claim 6.
8. An recombinant expression vector comprising a c acid sequence encoding the isolated AAV capsid protein of any one of claims 2 to 5.
9. A composition sing the isolated AAV capsid protein of any one of claims 2 to 5.
10. A composition sing the isolated AAV capsid protein of any one of claims 2 to 5 and a pharmaceutically acceptable carrier.
11. A recombinant AAV (rAAV) comprising the isolated AAV capsid protein of any one of claims 2 to 5.
12. A composition comprising the recombinant rAAV of claim ll.
13. The composition of claim 12 further comprising a pharmaceutically acceptable carrier.
14. A host cell containing a nucleic acid that comprises a coding sequence of a 20 polypeptide selected from the group consisting of: SEQ ID NO: 1—409, 435—868, and 1726— 1988, that is operably linked to a er.
15. A composition comprising the host cell of claim 14 and a sterile cell culture medium.
16. A ition comprising the host cell of claim 15 and a cryopreservative.
17. A method for delivering a transgene to a subject comprising administering a rAAV of claim 11 to a subject, n the rAAV comprises at least 30 one transgene, and wherein the rAAV infects cells of a target tissue of the subject. WO 71831
18. A method for generating a somatic transgenic animal model comprising stering a recombinant rAAV of claim 11 to a non—human animal, wherein the rAAV comprises at least one transgene, and wherein the rAAV infects cells of a target tissue of the non—human animal.
19. The method of claim 17, wherein the at least one transgene is a protein coding gene.
20. The method of claim 17, wherein the at least one transgene encodes a small 10 interfering nucleic acid.
21. The method of claim 20, wherein the small interfering nucleic acid is a miRNA. 15
22. The method of claim 20, wherein the small interfering nucleic acid is a miRNA sponge or TuD RNA that inhibits the activity of at least one miRNA in the subject or animal.
23. The method of claim 22, wherein the miRNA is expressed in a cell of the 20 target tissue
24. The method of claim of claim 17, n the target tissue is liver, central nervous system (CNS), , gastrointestinal, respiratory, breast, pancreas, urinary tract, or uterine tissue.
25. The method of claim 18, wherein the transgene ses a transcript that comprises at least one binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than the target tissue, by hybridizing to the g site. 30
26. A method for generating a c transgenic animal model comprising administering a rAAV of claim 23 to a non—human animal, wherein the rAAV comprises at least one transgene, wherein the transgene expresses a transcript that comprises at least one _ 71 _ binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than a target tissue, by hybridizing to the binding site of the transcript.
27. The method of claim 26, wherein the transgene comprises a tissue specific promoter or inducible promoter.
28. The method of claim 27, wherein the tissue specific promoter is a liver— specific thyroxin binding globulin (TBG) promoter, an insulin promoter, a glucagon promoter, a somatostatin promoter, mucin—2 promoter, a pancreatic polypeptide (PPY) 10 promoter, a synapsin—l (Syn) promoter, a retinoschisin promoter, a K12 promoter, a CClO er, a tant protein C (SP—C) promoter, a PRCl promoter, a RRM2 promoter, uroplakin 2 (UPII) promoter, or a lactoferrin promoter.
29. The method of claim 17, wherein the rAAV is administered intravenously, 15 ermally, intraocularly, intrathecally, orally, intramuscularly, subcutaneously, asally, or by inhalation.
30. The method of claim 17, n the t is selected from a mouse, a rat, a rabbit, a dog, a cat, a sheep, a pig, and a non—human primate.
31. The method of claim 17, wherein the subject is a human.
32. A somatic transgenic animal model produced by the method of claim 18. 25
33. A kit for producing a rAAV, the kit comprising: a container housing an isolated nucleic acid encoding a polypeptide having a sequence of any one of SEQ ID NO: 1 to 409, 8, or 1726—1988.
34. The kit of claim 33 further comprising instructions for producing the rAAV.
35. The kit of claim 34 r comprising at least one container housing a recombinant AAV , wherein the recombinant AAV vector comprises a transgene.
36. A kit comprising: a container housing a recombinant AAV having an ed AAV capsid n of any one of claims 2 to 5.
37. The kit of claim 36, wherein the container is a syringe.
38. The isolated AAV capsid protein of any one of claims 2—5, wherein the capsid protein is a VPl capsid protein.
39. The isolated AAV capsid protein of any one of claims 2—5, wherein the capsid protein is a VP2 capsid protein.
40. The isolated capsid protein of any one of claims 2—5, wherein the capsid 15 protein is a VP3 capsid n.
41. A pseudotyped AAV comprising the capsid protein of any one of claims 2 to 5, or 7. 20
42. The recombinant expression vector of claim 1, wherein the nucleic acid encodes a V1 capsid protein.
43. The recombinant expression vector of claim 1, n the nucleic acid encodes a V2 capsid protein.
44. The recombinant sion vector of claim 1, wherein the nucleic acid encodes a V3 capsid protein.
45. A nucleic acid comprising a sequence selected from the group consisting of 30 SEQ ID NO: 410—434, 876—1718, and 1989—2251. _ 73
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/408,022 | 2016-10-13 | ||
US62/417,756 | 2016-11-04 | ||
US62/486,642 | 2017-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ792477A true NZ792477A (en) | 2022-09-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230374545A1 (en) | Aav capsid designs | |
US11542525B2 (en) | Recombinant AAV variants and uses thereof | |
US20230073187A1 (en) | Prostate targeting adeno-associated virus serotype vectors | |
US20200316221A1 (en) | Aav capsid designs | |
EP2954051B1 (en) | Modified aav8 capsid for gene transfer for retinal therapies | |
JP7303816B2 (en) | AAV vector | |
CN113121655A (en) | Ocular and muscle specific targeting type adeno-associated virus vector and application thereof | |
Pan et al. | AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart | |
WO2022222869A1 (en) | Recombinant adeno-associated virus and application thereof | |
WO2022026410A2 (en) | Compositions and methods for the treatment of niemann-pick type c1 disease | |
CN117247973B (en) | Nucleic acid construct for treating hereditary coagulation factor deficiency disease and application thereof | |
Moulay et al. | Polymers for improving the in vivo transduction efficiency of AAV2 vectors | |
NZ792477A (en) | Aav capsid designs | |
WO2009071679A1 (en) | Novel aav vector and uses thereof | |
CN115838725B (en) | Promoter sequence of specific promoter gene in mammal heart and application thereof | |
AU2024203491A1 (en) | AAV capsid designs | |
CN114686448A (en) | Purified adeno-associated virus with liver specific targeting and application thereof | |
CN114591921A (en) | Purification method and eluent of adeno-associated virus | |
JP2024502044A (en) | Sense suppressor transfer RNA compositions and related uses and functions | |
EA044901B1 (en) | DEVELOPMENT OF AAV CAPSIDS | |
CN115948403A (en) | Promoter sequence of specific promoter in mammal muscle and application thereof | |
CN118019757A (en) | KCNV2 Gene therapy | |
CN115244181A (en) | Novel use of aspirin compounds to increase nucleic acid expression |